[
  {
    "slug": "zolpidem",
    "name": "Zolpidem (Ambien)",
    "class": "Sleep Aid",
    "summary": "1 INDICATIONS AND USAGE Zolpidem Tartrate Tablets is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies ( 14 )].",
    "dose": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening.",
    "renal": "Zolpidem Tartrate Tablets is converted to inactive metabolites that are eliminated primarily by renal excretion.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Inform patients and their families about the benefits and risks of treatment with Zolpidem Tartrate Tablets.",
      "Inform patients of the availability of a Medication Guide and instruct them to read the Medication Guide prior to initiating treatment with Zolpidem Tartrate Tablets and with each prescription refill."
    ],
    "tags": [
      "Sleep Aid",
      "C-IV"
    ],
    "keywords": [
      "zolpidem",
      "ambien",
      "sleep",
      "aid",
      "c-iv"
    ]
  },
  {
    "slug": "amoxicillin",
    "name": "Amoxicillin (Amoxil)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis .",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium is administered at the start of a meal.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment: Dosage adjustment is recommended for severe renal impairment (GFR less than 30mL/min). ( 2.4 , 8.6 ) Revised 03/2024 8.1 Pregnancy Teratogenic Effects : Pregnancy Category B.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Administration Instructions Inform patients that Amoxicillin and Clavulanate Potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed.",
      "Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset.",
      "Allergic Reactions Counsel patients that Amoxicillin and Clavulanate Potassium contains a penicillin class drug product that can cause allergic reactions in some individuals."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "amoxicillin",
      "amoxil",
      "antibiotic"
    ]
  },
  {
    "slug": "amoxicillin-clavulanate",
    "name": "Amoxicillin + Clavulanate (Augmentin)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis .",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium is administered at the start of a meal.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment: Dosage adjustment is recommended for severe renal impairment (GFR less than 30mL/min). ( 2.4 , 8.6 ) Revised 03/2024 8.1 Pregnancy Teratogenic Effects : Pregnancy Category B.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Administration Instructions Inform patients that Amoxicillin and Clavulanate Potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed.",
      "Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset.",
      "Allergic Reactions Counsel patients that Amoxicillin and Clavulanate Potassium contains a penicillin class drug product that can cause allergic reactions in some individuals."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "amoxicillin",
      "clavulanate",
      "augmentin",
      "antibiotic"
    ]
  },
  {
    "slug": "metformin",
    "name": "Metformin (Glucophage)",
    "class": "Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ZITUVIMET is not recommended in patients with type 1 diabetes mellitus. ( 1 ) ZITUVIMET has not been studied in patients with a history of pancreatitis. ( 1 ) ZITUVIMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ZITUVIMET is not recommended in patients with type 1 diabetes mellitus.",
    "dose": "2 DOSAGE AND ADMINISTRATION Take ZITUVIMET orally twice daily with meals. ( 2.1 ) Individualize the dosage of ZITUVIMET on the basis of the patient's current regimen, effectiveness, and tolerability. ( 2.1 ) The maximum recommended daily dose is 100 mg of sitagliptin and 2,000 mg of metformin HCl. ( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of ZITUVIMET is 50 mg sitagliptin and 1,000 mg metformin HCl twice daily. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) ○ Do not use in patients with eGFR below 30 mL/min/1.73 m 2 ○ ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 .",
    "renal": "8 USE IN SPECIFIC POPULATIONS Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. ( 8.3 ) Geriatric Use: Assess renal function more frequently. ( 8.5 ) Hepatic Impairment: Avoid use in patients with hepatic impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Available data with ZITUVIMET and sitagliptin use in pregnant women are not sufficient to inform a ZITUVIMET-associated or sitagliptin-associated risk for major birth defects and miscarriage.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Lactic Acidosis Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development.",
      "Advise patients to discontinue ZITUVIMET immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "metformin",
      "glucophage",
      "antidiabetic"
    ]
  },
  {
    "slug": "furosemide",
    "name": "Furosemide (Lasix)",
    "class": "Diuretic/antihypertensive",
    "summary": "INDICATIONS AND USAGE Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide tablets are particularly useful when an agent with greater diuretic potential is desired.",
    "dose": "DOSAGE AND ADMINISTRATION Edema Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Adults: The usual initial dose of furosemide tablets is 20 to 80 mg given as a single dose.",
    "renal": "The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age).",
    "monitoring": "WARNING Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ).",
    "pearls": [
      "Information for Patients Patients receiving furosemide should be advised that they may experience symptoms from excessive fluid and/or electrolyte losses.",
      "The postural hypotension that sometimes occurs can usually be managed by getting up slowly.",
      "Potassium supplements and/or dietary measures may be needed to control or avoid hypokalemia."
    ],
    "tags": [
      "Diuretic",
      "Antihypertensive"
    ],
    "keywords": [
      "furosemide",
      "lasix",
      "diuretic",
      "antihypertensive"
    ]
  },
  {
    "slug": "atorvastatin",
    "name": "Atorvastatin (Lipitor)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).",
    "dose": "2 DOSAGE AND ADMINISTRATION Take orally once daily with or without food ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ).",
    "renal": "Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Myopathy and Rhabdomyolysis Advise patients that atorvastatin calcium may cause myopathy and rhabdomyolysis.",
      "Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.1) , Drug Interactions (7.1)] ."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "atorvastatin",
      "lipitor",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "metoprolol",
    "name": "Metoprolol (Lopressor)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer once daily with food or after a meal. Titrate at weekly or longer intervals as needed and tolerated. ( 2 ) Hypertension: Recommended starting dosage is 100 mg daily, in single or divided doses. ( 2.1 ) Angina Pectoris: Recommended starting dosage is 100 mg daily, given as two divided doses. ( 2.2 ) Myocardial Infarction: The starting dosage depends upon tolerance of intravenous metoprolol, see full prescribing information. ( 2.3 ) 2.1 Hypertension Individualize the dosage of metoprolol tartrate tablets.",
    "renal": "In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients to take metoprolol tartrate tablets regularly and continuously, as directed, preferably with or immediately following meals.",
      "If a dose is missed, the patient should take only the next scheduled dose (without doubling it).",
      "Patients should not interrupt or discontinue metoprolol tartrate tablets without consulting the physician."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "metoprolol",
      "lopressor",
      "antihypertensive"
    ]
  },
  {
    "slug": "hydrochlorothiazide-hctz",
    "name": "Hydrochlorothiazide (HCTZ) (Microzide)",
    "class": "Diuretic/antihypertensive",
    "summary": "Review prescribing info for Hydrochlorothiazide (HCTZ).",
    "dose": "See full prescribing information for dosing details.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Diuretic",
      "Antihypertensive"
    ],
    "keywords": [
      "hydrochlorothiazide",
      "(hctz)",
      "microzide",
      "diuretic",
      "antihypertensive"
    ]
  },
  {
    "slug": "esomeprazole",
    "name": "Esomeprazole (Nexium)",
    "class": "Antacid (PPI)",
    "summary": "Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect",
    "dose": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment • swallow 1 tablet with a glass of water before eating in the morning • take every day for 14 days • do not take more than 1 tablet a day • swallow whole. Do not crush or chew capsules. • do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) • you may repeat a 14-day course every 4 months • do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Allergy alert : Do not use if you are allergic to esomeprazole. Esomeprazole may cause severe skin reactions.",
    "pearls": [],
    "tags": [
      "Antacid"
    ],
    "keywords": [
      "esomeprazole",
      "nexium",
      "antacid",
      "(ppi)"
    ]
  },
  {
    "slug": "amlodipine",
    "name": "Amlodipine (Norvasc)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: •Hypertension ( 1.1 ) о Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. •Coronary Artery Disease ( 1.2 ) о Chronic Stable Angina о Vasospastic Angina (Prinzmetal's or Variant Angina) о Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION •Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. ( 2.1 ) о Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily. ( 2.1 ) •Pediatric starting dose: 2.5 mg to 5 mg once daily. ( 2.2 ) Important Limitation : Doses in excess of 5 mg daily have not been studied in pediatric patients. ( 2.2 ) 2.1 Adults The usual initial antihypertensive oral dose of amlodipine besylate tablet is 5 mg once daily and the maximum dose is 10 mg once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine besylate tablet to other antihypertensive therapy.",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "amlodipine",
      "norvasc",
      "antihypertensive"
    ]
  },
  {
    "slug": "oxycodone-apap",
    "name": "Oxycodone + APAP (Percocet)",
    "class": "Analgesic",
    "summary": "Oxycodone and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve oxycodone and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia",
    "dose": "Important Dosage and Administration Instructions Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS]. Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see WARNINGS].",
    "renal": "Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites.",
    "monitoring": "Addiction, Abuse, and Misuse Oxycodone and acetaminophen tablets contain oxycodone, a Schedule II controlled substance. As an opioid, oxycodone and acetaminophen tablets expose users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE].",
    "pearls": [],
    "tags": [
      "Analgesic",
      "C-II"
    ],
    "keywords": [
      "oxycodone",
      "apap",
      "percocet",
      "analgesic",
      "c-ii"
    ]
  },
  {
    "slug": "omeprazole",
    "name": "Omeprazole (Prilosec)",
    "class": "Antacid (PPI)",
    "summary": "Use(s) treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect",
    "dose": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Allergy alert: do not use if you are allergic to omeprazole omeprazole may cause severe skin reactions. Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away.",
    "pearls": [],
    "tags": [
      "Antacid"
    ],
    "keywords": [
      "omeprazole",
      "prilosec",
      "antacid",
      "(ppi)"
    ]
  },
  {
    "slug": "lisinopril",
    "name": "Lisinopril (Prinivil / Zestril)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "DOSAGE AND ADMINISTRATION Lisinopril monotherapy is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide monotherapy is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component.",
    "renal": "Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.",
    "monitoring": "WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including lisinopril and hydrochlorothiazide tablets) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including lisinopril.",
    "pearls": [
      "Information for Patients Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including lisinopril.",
      "Symptomatic Hypotension: Patients should be cautioned to report lightheadedness especially during the first few days of therapy.",
      "If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "lisinopril",
      "prinivil",
      "zestril",
      "antihypertensive"
    ]
  },
  {
    "slug": "levothyroxine",
    "name": "Levothyroxine (Synthroid)",
    "class": "Thyroid hormone replacement",
    "summary": "1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water. (2.1) Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. (2.2) See full prescribing information for dosing in specific patient populations. (2.3) Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4) 2.1 Important Administration Instructions Administer levothyroxine sodium tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging [see Adverse Reactions (6) ].",
    "renal": "The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Instruct patients to take levothyroxine sodium tablets as a single dose, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging.",
      "Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine.",
      "Instruct patients not to take levothyroxine sodium tablets within 4 hours of these agents."
    ],
    "tags": [
      "Thyroid Hormone Replacement"
    ],
    "keywords": [
      "levothyroxine",
      "synthroid",
      "thyroid",
      "hormone",
      "replacement"
    ]
  },
  {
    "slug": "atenolol",
    "name": "Atenolol (Tenormin)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Hypertension Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "DOSAGE AND ADMINISTRATION Hypertension The initial dose of atenolol is 50 mg given as one tablet a day either alone or added to diuretic therapy. The full effect of this dose will usually be seen within one to two weeks.",
    "renal": "Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.",
    "monitoring": "WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta-blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment.",
    "pearls": [
      "Information for Patients Hypoglycemia Inform patients or caregivers that there is a risk of hypoglycemia when atenolol is given to patients who are fasting or who are vomiting.",
      "Monitor for symptoms of hypoglycemia.",
      "General Patients already on a beta-blocker must be evaluated carefully before atenolol is administered."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "atenolol",
      "tenormin",
      "antihypertensive"
    ]
  },
  {
    "slug": "hydrocodone-apap",
    "name": "Hydrocodone + APAP (Vicodin)",
    "class": "Analgesic",
    "summary": "Hydrocodone Bitartrate and Acetaminophen Tablet is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at dosage or duration [see WARNINGS], reserve Hydrocodone Bitartrate and Acetaminophen Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not been tolerated, or are not expected to be tolerated, have not provided adequate analgesia, or are not expected to provide adequate analgesia Hydrocodone Bitartrate and Acetaminophen Tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.",
    "dose": "Important Dosage and Administration Instructions Hydrocodone Bitartrate and Acetaminophen Tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opiods and how to mitigate the associated risks. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS].",
    "renal": "Hydrocodone and its metabolites are eliminated primarily in the kidneys.",
    "monitoring": "Addiction, Abuse, and Misuse Hydrocodone Bitartrate and Acetaminophen Tablets contain hydrocodone, a Schedule II controlled substance. As an opioid, Hydrocodone Bitartrate and Acetaminophen Tablet exposes users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE].",
    "pearls": [],
    "tags": [
      "Analgesic",
      "C-II"
    ],
    "keywords": [
      "hydrocodone",
      "apap",
      "vicodin",
      "analgesic",
      "c-ii"
    ]
  },
  {
    "slug": "alprazolam",
    "name": "Alprazolam (Xanax)",
    "class": "Antianxiety",
    "summary": "1 INDICATIONS AND USAGE Alprazolam tablets are indicated for the: acute treatment of generalized anxiety disorder (GAD) in adults. treatment of panic disorder (PD), with or without agoraphobia in adults. Alprazolam is a benzodiazepine indicated for the: Acute treatment of generalized anxiety disorder in adults. ( 1 ) Treatment of panic disorder with or without agoraphobia in adults. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Generalized Anxiety Disorder : ( 2.1 ) Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).",
      "Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ].",
      "Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months."
    ],
    "tags": [
      "Antianxiety",
      "C-IV"
    ],
    "keywords": [
      "alprazolam",
      "xanax",
      "antianxiety",
      "c-iv"
    ]
  },
  {
    "slug": "azithromycin",
    "name": "Azithromycin (Zithromax)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: • Acute bacterial exacerbations of chronic bronchitis in adults ( 1.1 ) • Acute bacterial sinusitis in adults ( 1.1 ) • Uncomplicated skin and skin structure infections in adults ( 1.1 ) • Urethritis and cervicitis in adults ( 1.1 ) • Genital ulcer disease in men ( 1.1 ) • Acute otitis media in pediatric patients (6 months of age and older) ( 1.2 ) • Community-acquired pneumonia in adults and pediatric patients (6 months of age and older) ( 1.1 , 1.2 ) • Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) ( 1.1 , 1.2 ) Limitation of Use: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1.1 Adult Patients • Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . • Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis. or Streptococcus pneumoniae . • Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. • Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid).",
    "dose": "2 DOSAGE AND ADMINISTRATION • Adult Patients ( 2.1 ) Infection Recommended Dose/Duration of Therapy Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5. Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days.",
    "renal": "Specific Populations Patients with Renal Impairment Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "General Patient Counseling Azithromycin tablets can be taken with or without food.",
      "Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "azithromycin",
      "zithromax",
      "antibiotic"
    ]
  },
  {
    "slug": "simvastatin",
    "name": "Simvastatin (Zocor)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Ezetimibe and simvastatin tablets Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).",
    "dose": "2 DOSAGE AND ADMINISTRATION Important Dosage and Administration Information: ( 2.1 ) Take ezetimibe and simvastatin tablets orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily.",
    "renal": "Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Myopathy and Rhabdomyolysis Advise patients that ezetimibe and simvastatin tablets may cause myopathy and rhabdomyolysis.",
      "Inform patients taking the 80 mg daily dose of simvastatin that they are at an increased risk."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "simvastatin",
      "zocor",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "sertraline",
    "name": "Sertraline (Zoloft)",
    "class": "Antidepressant (SSRI)",
    "summary": "INDICATIONS AND USAGE Major Depressive Disorder – Sertraline hydrochloride is indicated for the treatment of major depressive disorder in adults. The efficacy of Sertraline hydrochloride in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ).",
    "dose": "DOSAGE AND ADMINISTRATION Initial Treatment Dosage for Adults Major Depressive Disorder –Sertraline hydrochloride treatment should be administered at a dose of 50 mg once daily. While a relationship between dose and effect has not been established for major depressive disorder, OCD, panic disorder, PTSD or social anxiety disorder, patients were dosed in a range of 50-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for the treatment of this indication.",
    "renal": "Renal Disease –Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination.",
    "monitoring": "WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.",
    "pearls": [
      "A patient Medication Guide about \"Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions\" is available for sertraline hydrochloride.",
      "The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.",
      "Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "sertraline",
      "zoloft",
      "antidepressant",
      "(ssri)"
    ]
  },
  {
    "slug": "ibuprofen",
    "name": "Ibuprofen (Advil)",
    "class": "Analgesic (NSAID)",
    "summary": "Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever",
    "dose": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: rash facial swelling asthma (wheezing) hives skin reddening shock blisters If an allergic reaction occurs, stop use and seek medical help right away.",
    "pearls": [],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "ibuprofen",
      "advil",
      "analgesic",
      "(nsaid)"
    ]
  },
  {
    "slug": "lorazepam",
    "name": "Lorazepam (Ativan)",
    "class": "Antianxiety",
    "summary": "INDICATIONS AND USAGE Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.",
    "dose": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.",
    "pearls": [
      "Information for Patients Advise the patient to read the FDA-approved patient labeling ( Error!",
      "Hyperlink reference not valid. ).",
      "Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see and )."
    ],
    "tags": [
      "Antianxiety",
      "C-IV"
    ],
    "keywords": [
      "lorazepam",
      "ativan",
      "antianxiety",
      "c-iv"
    ]
  },
  {
    "slug": "citalopram",
    "name": "Citalopram (Celexa)",
    "class": "Antidepressant (SSRI)",
    "summary": "1 INDICATIONS AND USAGE Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ] . Citalopram tablets are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ) .",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer once daily with or without food ( 2 ) . Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ).",
    "renal": "The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "QT Prolongation and Torsade de Pointes Advise patients to consult their health care provider immediately if they feel faint, lose consciousness, or have heart palpitations.",
      "Instruct patients to inform their health care provider that they are taking citalopram before taking any new medications [see Warnings and Precautions (5.2) , Drug Interactions (7) ] ."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "citalopram",
      "celexa",
      "antidepressant",
      "(ssri)"
    ]
  },
  {
    "slug": "ciprofloxacin",
    "name": "Ciprofloxacin (Cipro)",
    "class": "Antibiotic",
    "summary": "INDICATIONS AND USAGE Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.",
    "dose": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly.",
    "renal": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",
    "monitoring": "PRECAUTIONS General: As with other antibacterial preparations, prolonged use of ciprofloxacin may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.",
    "pearls": [
      "Information for patients: Do not touch dropper tip to any surface, as this may contaminate the solution."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "ciprofloxacin",
      "cipro",
      "antibiotic"
    ]
  },
  {
    "slug": "warfarin",
    "name": "Warfarin (Coumadin)",
    "class": "Anticoagulant",
    "summary": "1 INDICATIONS AND USAGE Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.",
    "dose": "2 DOSAGE AND ADMINISTRATION Individualize dosing regimen for each patient, and adjust based on INR response. ( 2.1 , 2.2 ) Knowledge of genotype can inform initial dose selection. ( 2.3 ) Monitoring: Obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determinations every 1 to 4 weeks. ( 2.4 ) Review conversion instructions from other anticoagulants. ( 2.8 ) 2.1 Individualized Dosing The dosage and administration of warfarin sodium tablets must be individualized for each patient according to the patient’s International Normalized Ratio (INR) response to the drug.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnant women with mechanical heart valves: Warfarin sodium may cause fetal harm; however, the benefits may outweigh the risks. ( 8.1 ) Lactation: Monitor breastfeeding infants for bruising or bleeding. ( 8.2 ) Renal Impairment: Instruct patients with renal impairment to frequently monitor their INR. ( 8.6 ) 8.1 Pregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [see Warnings and Precautions ( 5.7 )] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Instructions for Patients Advise patients to: Strictly adhere to the prescribed dosage schedule [see Dosage and Administration ( 2.1 )] .",
      "If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose of warfarin sodium the next day to make up for missed doses [see Dosage and Administration ( 2.6 )] ."
    ],
    "tags": [
      "Anticoagulant"
    ],
    "keywords": [
      "warfarin",
      "coumadin",
      "anticoagulant"
    ]
  },
  {
    "slug": "triamterene",
    "name": "Triamterene (Dyrenium)",
    "class": "Diuretic/antihypertensive",
    "summary": "INDICATIONS AND USAGE: This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.",
    "dose": "DOSAGE AND ADMINISTRATION: The usual dose of triamterene and hydrochlorothiazide tablets 37.5mg/25mg is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see WARNINGS ). The usual dose of triamterene and hydrochlorothiazide tablets 75mg/ 50 mg is one tablet daily, with appropriate monitoring of serum potassium (see WARNINGS ).",
    "renal": "It blocks the renal tubular absorption of sodium and chloride ions.",
    "monitoring": "WARNINGS: Hyperkalemia: Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-conserving diuretic combinations, including triamterene and hydrochlorothiazide. Hyperkalemia is more likely to occur in patients with renal impairment, diabetes (even without evidence of renal impairment), or elderly or severely ill patients.",
    "pearls": [
      "Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.",
      "Serum and urine electrolyte determinations are especially important and should be frequently performed when the patient is vomiting or receiving parenteral fluids.",
      "Any chloride deficit during thiazide therapy is generally mild and usually does not require any specific treatment except under extraordinary circumstances (as in liver disease or renal disease)."
    ],
    "tags": [
      "Diuretic",
      "Antihypertensive"
    ],
    "keywords": [
      "triamterene",
      "dyrenium",
      "diuretic",
      "antihypertensive"
    ]
  },
  {
    "slug": "cyclobenzaprine",
    "name": "Cyclobenzaprine (Flexeril)",
    "class": "Muscle relaxer",
    "summary": "INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.",
    "dose": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day.",
    "renal": "Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.",
    "monitoring": "WARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or (MAO) inhibitors. The concomitant use of cyclobenzaprine hydrochloride with MAO inhibitors is contraindicated (see CONTRAINDICATIONS ).",
    "pearls": [],
    "tags": [
      "Muscle Relaxer"
    ],
    "keywords": [
      "cyclobenzaprine",
      "flexeril",
      "muscle",
      "relaxer"
    ]
  },
  {
    "slug": "fluticasone",
    "name": "Fluticasone (Flonase)",
    "class": "Anti-inflammatory steroid",
    "summary": "Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing",
    "dose": "Directions read the Quick Start Guide for how to: prime the bottle use the spray clean the spray nozzle shake gently before each use use this product only once a day do not use more than directed ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER Week 1- use 2 sprays in each nostril once daily Week 2 through 6 months- use 1 or 2 sprays in each nostril once daily, as needed to treat your symptoms After 6 months of daily use – ask your doctor if you can keep using CHILDREN 4 TO 11 YEARS OF AGE the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Only for use in the nose. Do not spray into your eyes or mouth.",
    "pearls": [],
    "tags": [
      "Anti-inflammatory Steroid"
    ],
    "keywords": [
      "fluticasone",
      "flonase",
      "anti-inflammatory",
      "steroid"
    ]
  },
  {
    "slug": "cephalexin",
    "name": "Cephalexin (Keflex)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Cephalexin capsules are a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria: Respiratory tract infection ( 1.1 ) Otitis media ( 1.2 ) Skin and skin structure infections ( 1.3 ) Bone infections ( 1.4 ) Genitourinary tract infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Respiratory Tract Infections Cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes. 1.2 Otitis Media Cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis.",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults and patients at least 15 years of age The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered ( 2.1 ) Pediatric patients (over 1 year of age) Otitis media: 75 to 100 mg/kg in equally divided doses every 6 hours ( 2.2 ) All other indications: 25 to 50 mg/kg given in equally divided doses ( 2.2 ) In severe infections: 50 to 100 mg/kg may be administered in equally divided doses ( 2.2 ) Duration of therapy ranges from 7 to 14 days depending on the infection type and severity. ( 2 ) Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as creatinine clearance below 30 mL/min. ( 2.3 ) 2.1 Adults and Pediatric Patients at Least 15 Years of Age The usual dose of oral cephalexin capsules is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 to 14 days.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Renal Impairment: Monitor patients longer for toxicity and drug interactions due to delayed clearance. (8.6) 8.1 Pregnancy Risk Summary Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Allergic Reactions Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment.",
      "Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection.",
      "If severe watery or bloody diarrhea develops, advise patients to contact their healthcare provider."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "cephalexin",
      "keflex",
      "antibiotic"
    ]
  },
  {
    "slug": "clonazepam",
    "name": "Clonazepam (Klonopin)",
    "class": "Antianxiety",
    "summary": "INDICATIONS AND USAGE Seizure Disorders: Clonazepam tablets are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful.",
    "dose": "DOSAGE AND ADMINISTRATION Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.",
    "renal": "Pharmacokinetics in Demographic Subpopulations and in Disease States: Controlled studies examining the influence of gender and age on clonazepam pharmacokinetics have not been conducted, nor have the effects of renal or liver disease on clonazepam pharmacokinetics been studied.",
    "monitoring": "WARNINGS Risks from Concomitant Use With Opioids: Concomitant use of benzodiazepines, including clonazepam tablets, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids in patients for whom alternative treatment options are inadequate.",
    "pearls": [
      "Information for Patients: A clonazepam tablets Medication Guide must be given to the patient each time clonazepam tablets are dispensed, as required by law.",
      "Patients should be instructed to take clonazepam tablets only as prescribed.",
      "Physicians are advised to discuss the following issues with patients for whom they prescribe clonazepam tablets."
    ],
    "tags": [
      "Antianxiety",
      "C-IV"
    ],
    "keywords": [
      "clonazepam",
      "klonopin",
      "antianxiety",
      "c-iv"
    ]
  },
  {
    "slug": "escitalopram",
    "name": "Escitalopram (Lexapro)",
    "class": "Antidepressant (SSRI)",
    "summary": "1 INDICATIONS AND USAGE Escitalopram is indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.’s Lexapro (escitalopram) tablets and LEXAPRO (escitalopram) oral solution.",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. A fixed-dose trial of escitalopram demonstrated the effectiveness of both 10 mg and 20 mg of escitalopram, but failed to demonstrate a greater benefit of 20 mg over 10 mg [ see Clinical Studies (14.1) ].",
    "renal": "8.7 Renal Impairment Pharmacokinetics of escitalopram in patients with a creatinine clearance less than 20 mL/minute has not been evaluated.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid).",
      "Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [ see Warnings and Precautions (5.2) , Drug Interactions (7) ]."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "escitalopram",
      "lexapro",
      "antidepressant",
      "(ssri)"
    ]
  },
  {
    "slug": "gabapentin",
    "name": "Gabapentin (Neurontin)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin Capsules, USP are indicated for Postherpetic neuralgia in adults (1) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy (1)",
    "dose": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day).",
    "renal": "Since gabapentin is almost exclusively eliminated by renal excretion, the larger treatment effect observed in patients ≥75 years may be a consequence of increased gabapentin exposure for a given dose that results from an age-related decrease in renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Administrative Information Inform patients that Gabapentin is taken orally with or without food.",
      "Other drugs with sedative properties may increase these symptoms."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "gabapentin",
      "neurontin",
      "anticonvulsant"
    ]
  },
  {
    "slug": "clopidogrel",
    "name": "Clopidogrel (Plavix)",
    "class": "Anticoagulant",
    "summary": "1 INDICATIONS AND USAGE Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) – For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization.",
    "dose": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) – Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. – Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose. ( 2.2 ) 2.1 Acute Coronary Syndrome In patients who need an antiplatelet effect within hours, initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily.",
    "renal": "8.6 Renal Impairment Experience is limited in patients with severe and moderate renal impairment [see Clinical Pharmacology (12.2) ].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients to read FDA approved patient labeling ( Medication Guide ).",
      "Discontinuation Advise patients not to discontinue clopidogrel without first discussing it with the healthcare provider who prescribed it [see Warnings and Precautions (5.3) ] .",
      "Invasive Procedures Advise patients to inform physicians and dentists that they are taking clopidogrel before any surgery or dental procedure [see Warnings and Precautions (5.2 , 5.3) ] ."
    ],
    "tags": [
      "Anticoagulant"
    ],
    "keywords": [
      "clopidogrel",
      "plavix",
      "anticoagulant"
    ]
  },
  {
    "slug": "pravastatin",
    "name": "Pravastatin (Pravachol)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. (2.2) Significant renal impairment: the recommended starting dose is pravastatin 10 mg once daily. (2.3) Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. (2.4) Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. (2.4) 2.1 General Dosing Information The patient should be placed on a standard cholesterol-lowering diet before receiving Pravastatin Sodium and should continue on this diet during treatment with Pravastatin Sodium [see NCEP Treatment Guidelines for details on dietary therapy].",
    "renal": "After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Liver Enzymes It is recommended that liver enzyme tests be performed before the initiation of Pravastatin Sodium, and thereafter when clinically indicated.",
      "Lactation Advise women not to breastfeed during treatment with Pravastatin Sodium [see Contraindications (4.4) , Use in Specific Populations (8.2) ].",
      "Manufactured by: Appco Pharma LLC Piscataway, NJ 08854 Manufactured for: Biocon Pharma Inc., 485 US Highway 1 S Suite B305, Iselin NJ 08830-3009 USA Revised: 10/2020"
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "pravastatin",
      "pravachol",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "albuterol",
    "name": "Albuterol (ProAir / Ventolin / Proventil)",
    "class": "Bronchodilator",
    "summary": "1 INDICATIONS AND USAGE Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.",
    "dose": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. For some patients, 1 inhalation every 4 hours may be sufficient. ( 2.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation 15 to 30 minutes before exercise. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Frequency of Use Inform patients that the action of Albuterol Sulfate HFA should last up to 4 to 6 hours.",
      "Do not use Albuterol Sulfate HFA more frequently than recommended."
    ],
    "tags": [
      "Bronchodilator"
    ],
    "keywords": [
      "albuterol",
      "proair",
      "ventolin",
      "proventil",
      "bronchodilator"
    ]
  },
  {
    "slug": "fluoxetine",
    "name": "Fluoxetine (Prozac)",
    "class": "Antidepressant (SSRI)",
    "summary": "1 INDICATIONS AND USAGE Fluoxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult — Initiate fluoxetine 20 mg/day orally in the morning. Consider a dose increase after several weeks if insufficient clinical improvement is observed.",
    "renal": "The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See the FDA-approved Medication Guide .",
      "Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking fluoxetine as monotherapy or in combination with olanzapine.",
      "When using fluoxetine and olanzapine in combination, also refer to the Patient Counseling Information section of the package insert for Symbyax."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "fluoxetine",
      "prozac",
      "antidepressant",
      "(ssri)"
    ]
  },
  {
    "slug": "sulfamethoxazole-trimethoprim",
    "name": "Sulfamethoxazole + Trimethoprim (Septra)",
    "class": "Antibiotic combination",
    "summary": "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.",
    "dose": "DOSAGE AND ADMINISTRATION Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children Adults: The usual adult dosage in the treatment of urinary tract infections is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet or 2 sulfamethoxazole and trimethoprim tablets every 12 hours for 10 to 14 days.",
    "renal": "However, patients with severely impaired renal function exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see DOSAGE AND ADMINISTRATION section).",
    "monitoring": "WARNINGS Embryofetal Toxicity Some epidemiologic studies suggest that exposure to sulfamethoxazole/trimethoprim during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If sulfamethoxazole/trimethoprim is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus.",
    "pearls": [],
    "tags": [
      "Antibiotic Combination"
    ],
    "keywords": [
      "sulfamethoxazole",
      "trimethoprim",
      "septra",
      "antibiotic",
      "combination"
    ]
  },
  {
    "slug": "montelukast",
    "name": "Montelukast (Singulair)",
    "class": "Anti-asthmatic",
    "summary": "1. INDICATIONS AND USAGE Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: • Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older , and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3).",
    "dose": "2. DOSAGE AND ADMINISTRATION Administration (by indications): • Asthma (2.1):Once daily in the evening for patients 2 years and older. • Acute prevention of EIB (2.2): One tablet at least 2 hours before exercise for patients 15 years of age and older. • Seasonal allergic rhinitis (2.3): Once daily for patients 2 years and older. • Perennial allergic rhinitis (2.3): Once daily for patients 2 years and older.",
    "renal": "8.7 Renal Insufficiency No dosage adjustment is recommended in patients with renal insufficiency [see Clinical Pharmacology (12.3)].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17.",
      "They should have appropriate short-acting inhaled β-agonist medication available to treat asthma exacerbations.",
      "Patients who have exacerbations of asthma after exercise should be instructed to have available for rescue a short-acting inhaled β-agonist."
    ],
    "tags": [
      "Anti-asthmatic"
    ],
    "keywords": [
      "montelukast",
      "singulair",
      "anti-asthmatic"
    ]
  },
  {
    "slug": "prednisone",
    "name": "Prednisone (Sterapred)",
    "class": "Anti-inflammatory steroid",
    "summary": "INDICATIONS Prednisone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2.",
    "dose": "DOSAGE AND ADMINISTRATION The initial dosage of prednisone may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use.",
    "pearls": [
      "General Precautions Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage.",
      "This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.",
      "Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently."
    ],
    "tags": [
      "Anti-inflammatory Steroid"
    ],
    "keywords": [
      "prednisone",
      "sterapred",
      "anti-inflammatory",
      "steroid"
    ]
  },
  {
    "slug": "tramadol",
    "name": "Tramadol (Ultram)",
    "class": "Analgesic (narcotic-like)",
    "summary": "1 INDICATIONS AND USAGE Tramadol hydrochloride extended-release tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosages or duration, and persist over the course of therapy, [see Warnings and Precautions (5.1)], reserve opioid analgesics, including tramadol hydrochloride extended-release tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Tramadol hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic.",
    "dose": "2 DOSAGE AND ADMINISTRATION Tramadol hydrochloride extended-release tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks. (2.1) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of tramadol hydrochloride extended-release tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. (2.1, 5) Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. (2.1, 5.1) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with tramadol hydrochloride extended-release tablets.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. ( 8.1 ) Lactation: Breastfeeding not recommended. ( 8.2 ) Severe Hepatic or Renal Impairment: Use not recommended. ( 8.6 , 8.7 ) 8.1 Pregnancy Risk Summary Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.4)] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines.",
      "Instruct patients not to share tramadol hydrochloride extended-release tablets with others and to take steps to protect tramadol hydrochloride extended-release tablets from theft or misuse."
    ],
    "tags": [
      "Analgesic",
      "C-IV"
    ],
    "keywords": [
      "tramadol",
      "ultram",
      "analgesic",
      "(narcotic-like)",
      "c-iv"
    ]
  },
  {
    "slug": "fluticasone-salmeterol",
    "name": "Fluticasone + Salmeterol (Advair)",
    "class": "Steroid + bronchodilator",
    "summary": "Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing",
    "dose": "Directions read the Quick Start Guide for how to: prime the bottle use the spray clean the spray nozzle shake gently before each use use this product only once a day do not use more than directed ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER Week 1- use 2 sprays in each nostril once daily Week 2 through 6 months- use 1 or 2 sprays in each nostril once daily, as needed to treat your symptoms After 6 months of daily use – ask your doctor if you can keep using CHILDREN 4 TO 11 YEARS OF AGE the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Only for use in the nose. Do not spray into your eyes or mouth.",
    "pearls": [],
    "tags": [
      "Steroid",
      "Bronchodilator"
    ],
    "keywords": [
      "fluticasone",
      "salmeterol",
      "advair",
      "steroid",
      "bronchodilator"
    ]
  },
  {
    "slug": "naproxen",
    "name": "Naproxen (Aleve)",
    "class": "Analgesic (NSAID)",
    "summary": "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: • rheumatoid arthritis • osteoarthritis • ankylosing spondylitis • Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: • tendonitis • bursitis • acute gout the management of: • pain • primary dysmenorrhea Naproxen tablets and naproxen sodium tablets are non-steroidal anti-inflammatory drugs indicated for: the relief of the signs and symptoms of: • rheumatoid arthritis • osteoarthritis • ankylosing spondylitis • polyarticular juvenile idiopathic arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: • tendonitis • bursitis • acute gout the management of: • pain • primary dysmenorrhea",
    "dose": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen tablets 250 mg (one-half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one-half tablet) 550 mg twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/ day for up to 6 months.",
    "renal": "Consider withdrawal of naproxen tablets and naproxen sodium tablets in women who have difficulties conceiving. ( 8.3 ) Renal Impairment : Naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance <30 mL/min). ( 8.7 ) 8.1 Pregnancy Risk Summary Use of NSAIDs, including naproxen tablets and naproxen sodium tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.",
      "Inform patients, families, or their caregivers of the following information before initiating therapy with naproxen tablets or naproxen sodium tablets and periodically during the course of ongoing therapy.",
      "Gastrointestinal Bleeding, Ulceration, and Perforation Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider."
    ],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "naproxen",
      "aleve",
      "analgesic",
      "(nsaid)"
    ]
  },
  {
    "slug": "cetirizine",
    "name": "Cetirizine (Zyrtec)",
    "class": "Antihistamine (H1)",
    "summary": "Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat",
    "dose": "Directions may be taken with or without water chew or crush tablets completely before swallowing children 2 to under 6 years of age Chew and swallow 1 tablet (2.5 mg) once daily; If needed, dose can be increased to a maximum of 2 tablets (5 mg) once daily or 1 tablet (2.5 mg) every 12 hours. Do not give more than 2 tablets (5 mg) in 24 hours. adults and children 6 years and over Chew and swallow 2 tablets (5 mg) or 4 tablets (10 mg) once daily depending upon severity of symptoms; do not take more than 4 tablets (10 mg) in 24 hours. adults 65 years and over Chew and swallow 2 tablets (5 mg) once daily; do not take more than 2 tablets (5 mg) in 24 hours. children under 2 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Do not use if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine. Ask a doctor before use if you have liver or kidney disease.",
    "pearls": [],
    "tags": [
      "Antihistamine"
    ],
    "keywords": [
      "cetirizine",
      "zyrtec",
      "antihistamine",
      "(h1)"
    ]
  },
  {
    "slug": "carvedilol",
    "name": "Carvedilol (Coreg)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Take with food. Individualize dosage and monitor during up-titration. ( 2 ) Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks.",
    "renal": "In hypertensive patients with normal renal function, therapeutic doses of carvedilol tablets decreased renal vascular resistance with no change in glomerular filtration rate or renal plasma flow.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Patients taking carvedilol tablets should be advised of the following: Patients should take carvedilol tablets with food.",
      "Patients should not interrupt or discontinue using carvedilol tablets without a physician's advice."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "carvedilol",
      "coreg",
      "antihypertensive"
    ]
  },
  {
    "slug": "rosuvastatin",
    "name": "Rosuvastatin (Crestor)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Rosuvastatin tablets is indicated: To reduce the risk major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.",
    "dose": "2 DOSAGE AND ADMINISTRATION Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults : Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2) Pediatric Patients with HoFH : Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients : Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis) : Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for rosuvastatin tablets dosage and administration modifications due to drug interactions. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food.",
    "renal": "Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Myopathy and Rhabdomyolysis Advise patients that rosuvastatin may cause myopathy and rhabdomyolysis.",
      "Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "rosuvastatin",
      "crestor",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "duloxetine",
    "name": "Duloxetine (Cymbalta)",
    "class": "Antidepressant",
    "summary": "1 INDICATIONS AND USAGE Duloxetine delayed-release capsules is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatric patients 13 years of age and older Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older ( 1 ) Chronic musculoskeletal pain in adults ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Take Duloxetine delayed-release capsules once daily, with or without food. Swallow whole; do not crush, chew, or open capsule ( 2.1 ) Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 40 mg/day to 60 mg/day Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD ( 2.3 ) Adults 60 mg/day 60 mg/day (once daily) 120 mg/day Geriatric 30 mg/day 60 mg/day (once daily) 120 mg/day Pediatrics (7 to 17 years of age) 30 mg/day 30 to 60 mg/day (once daily) 120 mg/day DPNP ( 2.4 ) 60 mg/day 60 mg/day (once daily) 60 mg/day FM ( 2.5 ) Adults and Pediatrics (13 to 17 years of age) 30 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain ( 2.6 ) 30 mg/day 60 mg/day (once daily) 60 mg/day Discontinuing Duloxetine delayed-release capsules: Gradually reduce dosage to avoid discontinuation symptoms ( 2.8 , 5.7 ) 2.1 Important Administration Instructions Administer Duloxetine delayed-release capsules orally (with or without meals) and swallow whole.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy : Third trimester use may increase risk for symptoms of poor adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, irritability) in the neonate ( 8.1 ) Hepatic Impairment : Avoid use in patients with chronic liver disease or cirrhosis ( 5.14 ) Renal Impairment : Avoid use in patients with severe renal impairment, GFR <30 mL/minute ( 5.14 ) 8.1 Pregnancy Risk Summary Data from a postmarketing retrospective cohort study indicate that use of duloxetine in the month before delivery may be associated with an increased risk of postpartum hemorrhage.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Hepatotoxicity — Inform patients that severe liver problems, sometimes fatal, have been reported in patients treated with Duloxetine delayed-release capsules.",
      "Instruct patients to talk to their healthcare provider if they develop itching, right upper belly pain, dark urine, or yellow skin/eyes while taking Duloxetine delayed-release capsules, which may be signs of liver problems."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "duloxetine",
      "cymbalta",
      "antidepressant"
    ]
  },
  {
    "slug": "trazodone",
    "name": "Trazodone (Desyrel)",
    "class": "Antidepressant",
    "summary": "1 INDICATIONS AND USAGE Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) ( 1 ). Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.",
    "dose": "2 DOSAGE AND ADMINISTRATION Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days.",
    "renal": "8.6 Renal Impairment Trazodone has not been studied in patients with renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Dosage and Administration Advise patients that trazodone hydrochloride tablets should be taken shortly after a meal or light snack.",
      "Advise patients regarding the importance of following dosage titration instructions [see Dosage and Administration ( 2 )] ."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "trazodone",
      "desyrel",
      "antidepressant"
    ]
  },
  {
    "slug": "fluconazole",
    "name": "Fluconazole (Diflucan)",
    "class": "Antifungal",
    "summary": "INDICATIONS AND USAGE Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis.",
    "dose": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. Multiple Dose SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF FLUCONAZOLE IS THE SAME FOR ORAL AND INTRAVENOUS ADMINISTRATION.",
    "renal": "A single oral 150 mg dose of fluconazole administered to 14 patients penetrated into vaginal fluid, resulting in fluid: plasma ratios ranging from 0.36 to 0.71 over the first 72 hours following dosing. * Relative to concurrent concentrations in plasma in subjects with normal renal function. † Independent of degree of meningeal inflammation.",
    "monitoring": "WARNINGS (1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions.",
    "pearls": [
      "General Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram.",
      "Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (Ikr).",
      "Most of these reports involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications that may have been contributory."
    ],
    "tags": [
      "Antifungal"
    ],
    "keywords": [
      "fluconazole",
      "diflucan",
      "antifungal"
    ]
  },
  {
    "slug": "valsartan",
    "name": "Valsartan (Diovan)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. The target maintenance dose is 97 mg/103mg orally twice daily. ( 2.2 ) Adjust adult doses every 2 to 4 weeks to the target maintenance dose, as tolerated by the patient. ( 2.2 ) For pediatric patients, see the Full Prescribing Information for recommended dosage, titrations, preparation and administration instructions. ( 2.3 , 2.4 , 2.5 ) Reduce starting dose to half the usually recommended starting dosage for: patients not currently taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents. ( 2.6 ) patients with severe renal impairment. ( 2.7 ) patients with moderate hepatic impairment. ( 2.8 ) 2.1 General Considerations ENTRESTO is contraindicated with concomitant use of an angiotensin-converting enzyme (ACE) inhibitor.",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death ( see Clinical Considerations ).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Pregnancy: Advise female patients of childbearing age about the consequences of exposure to ENTRESTO during pregnancy.",
      "Discuss treatment options with women planning to become pregnant."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "valsartan",
      "diovan",
      "antihypertensive"
    ]
  },
  {
    "slug": "venlafaxine",
    "name": "Venlafaxine (Effexor)",
    "class": "Antidepressant",
    "summary": "INDICATIONS AND USAGE Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).",
    "dose": "DOSAGE AND ADMINISTRATION Initial Treatment The recommended starting dose for venlafaxine tablets is 75 mg/day, administered in two or three divided doses, taken with food. Depending on tolerability and the need for further clinical effect, the dose may be increased to 150 mg/day.",
    "renal": "Renal elimination of venlafaxine and its metabolites is the primary route of excretion.",
    "monitoring": "WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.",
    "pearls": [
      "A patient Medication Guide about \"Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions\" is available for venlafaxine tablets.",
      "The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.",
      "Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "venlafaxine",
      "effexor",
      "antidepressant"
    ]
  },
  {
    "slug": "amitriptyline",
    "name": "Amitriptyline (Elavil)",
    "class": "Antidepressant",
    "summary": "INDICATIONS AND USAGE For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states.",
    "dose": "DOSAGE AND ADMINISTRATION Oral Dosage Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerance. Initial Dosage for Adults For outpatients, 75 mg of amitriptyline hydrochloride a day in divided doses is usually satisfactory.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.",
    "pearls": [
      "A patient Medication Guide about \"Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions\" is available for amitriptyline hydrochloride.",
      "The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.",
      "Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "amitriptyline",
      "elavil",
      "antidepressant"
    ]
  },
  {
    "slug": "alendronate",
    "name": "Alendronate (Fosamax)",
    "class": "Bone strengthener",
    "summary": "1 INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.3 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet 70 mg is indicated for the treatment of osteoporosis in postmenopausal women.",
    "dose": "2 DOSAGE AND ADMINISTRATION 70 mg BINOSTO effervescent tablet once weekly. ( 2.1 , 2.2 ) Instruct patients to: ( 2.3 ) Dissolve one tablet of BINOSTO in approximately half a glass of plain room temperature water (4 oz). Wait at least 5 minutes after the effervescence stops, stir the solution for approximately 10 seconds and consume contents.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: Discontinue when pregnancy is recognized. ( 8.1 ) BINOSTO is not indicated for use in pediatric patients. ( 8.4 ) BINOSTO is not recommended in patients with renal impairment (creatinine clearance less than 35 mL/min). ( 5.6 , 8.6 ) 8.1 Pregnancy Risk Summary Available data on the use of BINOSTO in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Medication Guide) .",
      "Instruct patients to read the Medication Guide before starting therapy with BINOSTO and to reread it each time the prescription is renewed.",
      "17.1 Osteoporosis Recommendations, Including Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D, if daily dietary intake is inadequate."
    ],
    "tags": [
      "Bone Strengthener"
    ],
    "keywords": [
      "alendronate",
      "fosamax",
      "bone",
      "strengthener"
    ]
  },
  {
    "slug": "potassium-chloride",
    "name": "Potassium Chloride (Klor-Con)",
    "class": "Electrolyte",
    "summary": "1 INDICATIONS AND USAGE Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chloride Extended-Release Tablets are a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosages accordingly (2.1) If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation (2.1) Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. (2.1) Treatment of hypokalemia : Doses range from 40 to 100 mEq/day in divided doses.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Cirrhosis: Initiate therapy at the low end of the dosing range (8.6) Renal Impairment: Initiate therapy at the low end of the dosing range (8.7) 8.1 Pregnancy Risk Summary There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets.",
      "Inform patients that the wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool.",
      "Advise patients seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed."
    ],
    "tags": [
      "Electrolyte"
    ],
    "keywords": [
      "potassium",
      "chloride",
      "klor-con",
      "electrolyte"
    ]
  },
  {
    "slug": "lovastatin",
    "name": "Lovastatin (Mevacor)",
    "class": "Cholesterol lowering",
    "summary": "INDICATIONS AND USAGE Therapy with Lovastatin Tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.",
    "dose": "DOSAGE AND ADMINISTRATION The patient should be placed on a standard cholesterol-lowering diet before receiving lovastatin tablets and should continue on this diet during treatment with lovastatin tablets (see NCEP Treatment Guidelines for details on dietary therapy). Lovastatin tablets should be given with meals.",
    "renal": "In a study of patients with severe renal insufficiency (creatinine clearance 10 to 30 mL/min), the plasma concentrations of total inhibitors after a single dose of lovastatin were approximately two-fold higher than those in healthy volunteers.",
    "monitoring": "WARNINGS Myopathy/Rhabdomyolysis Lovastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred.",
    "pearls": [
      "Patients should also be advised to inform other physicians prescribing a new medication that they are taking lovastatin.",
      "It is recommended that liver enzymes be checked before starting therapy, and if signs or symptoms of liver injury occur.",
      "All patients treated with lovastatin should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "lovastatin",
      "mevacor",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "meloxicam",
    "name": "Meloxicam (Mobic)",
    "class": "Analgesic (NSAID.)",
    "summary": "1 INDICATIONS AND USAGE Meloxicam tablet USP is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg ( 1.3 ) 1.1 Osteoarthritis (OA Meloxicam tablets USP are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies ( 14.1 )] . 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets USP are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies ( 14.1 )] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children ≥60 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions ( 5 )] .",
    "renal": "Consider withdrawal of meloxicam in women who have difficulties conceiving ( 8.3 ) 8.1 Pregnancy Risk Summary Use of NSAIDs, including meloxicam, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.",
      "Inform patients, families or their caregivers of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.",
      "Gastrointestinal Bleeding, Ulceration, and Perforation Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their healthcare provider."
    ],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "meloxicam",
      "mobic",
      "analgesic",
      "(nsaid.)"
    ]
  },
  {
    "slug": "paroxetine",
    "name": "Paroxetine (Paxil)",
    "class": "Antidepressant (SSRI)",
    "summary": "1 INDICATIONS AND USAGE Paroxetine tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Obsessive compulsive disorder (OCD) Panic disorder (PD) Social anxiety disorder (SAD) Generalized anxiety disorder (GAD) Posttraumatic stress disorder (PTSD) Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of ( 1 ): Major Depressive Disorder (MDD) Obsessive Compulsive Disorder (OCD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Generalized Anxiety Disorder (GAD) Posttraumatic Stress Disorder (PTSD)",
    "dose": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. ( 2.3 ) Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. ( 2.4 ) When discontinuing paroxetine tablets, reduce dosage gradually. ( 2.6 , 5.7 ) 2.1 Administration Information Administer paroxetine tablets as a single daily dose in the morning, with or without food.",
    "renal": "8.6 Renal and Hepatic Impairment Increased plasma concentrations of paroxetine occur in patients with renal and hepatic impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "John's Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid).",
      "Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )]."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "paroxetine",
      "paxil",
      "antidepressant",
      "(ssri)"
    ]
  },
  {
    "slug": "diazepam",
    "name": "Diazepam (Valium)",
    "class": "Antianxiety",
    "summary": "INDICATIONS AND USAGE Diazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.",
    "dose": "DOSAGE AND ADMINISTRATION Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepiones, including diazepam tablets, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.",
    "pearls": [
      "Information for Patients Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).",
      "Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see WARNINGS: Risks from Concomitant Use with Opioids and PRECAUTIONS: Drug Interactions ).",
      "Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months."
    ],
    "tags": [
      "Antianxiety",
      "C-IV"
    ],
    "keywords": [
      "diazepam",
      "valium",
      "antianxiety",
      "c-iv"
    ]
  },
  {
    "slug": "doxycycline",
    "name": "Doxycycline (Vibramycin)",
    "class": "Antibiotic",
    "summary": "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.",
    "dose": "DOSAGE AND ADMINISTRATION The usual dosage and frequency of administration of doxycycline differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.",
    "renal": "Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min.).",
    "monitoring": "WARNINGS The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses.",
    "pearls": [
      "General As with other antibacterial drugs, use of doxycycline may result in overgrowth of nonsusceptible organisms, including fungi.",
      "If superinfection occurs, doxycycline should be discontinued and appropriate therapy instituted.",
      "Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy, when indicated."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "doxycycline",
      "vibramycin",
      "antibiotic"
    ]
  },
  {
    "slug": "prazosin",
    "name": "Prazosin (Minipress)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "DOSAGE AND ADMINISTRATION The dose of prazosin hydrochloride capsules should be adjusted according to the patient’s individual blood pressure response. The following is a guide to its administration: Initial Dose 1 mg two or three times a day (see WARNINGS. ) Maintenance Dose Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses.",
    "renal": "The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and glomerular filtration rate.",
    "monitoring": "WARNINGS As with all alpha-blockers, prazosin hydrochloride may cause syncope with sudden loss of consciousness. In most cases, this is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe tachycardia with heart rates of 120 to 160 beats per minute.",
    "pearls": [
      "Information for Patients: Dizziness or drowsiness may occur after the first dose of this medicine.",
      "Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased.",
      "Dizziness, lightheadedness, or fainting may occur, especially when rising from a lying or sitting position."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "prazosin",
      "minipress",
      "antihypertensive"
    ]
  },
  {
    "slug": "nebivolol",
    "name": "Nebivolol (Bystolic)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [ see Clinical Studies ( 14.1 ) ].",
    "dose": "2 DOSAGE AND ADMINISTRATION Can be taken with and without food. Individualize to the needs of the patient and monitor during up-titration. ( 2 ) Hypertension: Most patients start at 5 mg once daily.",
    "renal": "Renal Disease The apparent clearance of nebivolol was unchanged following a single 5 mg dose of nebivolol tablets in patients with mild renal impairment (ClCr 50 to 80 mL/min, n=7), and it was reduced negligibly in patients with moderate (ClCr 30 to 50 mL/min, n=9), but clearance was reduced by 53% in patients with severe renal impairment (ClCr <30 mL/min, n=5).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information). • Patient Advice Advise patients to take nebivolol tablets regularly and continuously, as directed.",
      "Nebivolol tablets can be taken with or without food.",
      "If a dose is missed, take the next scheduled dose only (without doubling it)."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "nebivolol",
      "bystolic",
      "antihypertensive"
    ]
  },
  {
    "slug": "pioglitazone",
    "name": "Pioglitazone (Actos)",
    "class": "Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . Important Limitations of Use Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin.",
    "dose": "2 DOSAGE AND ADMINISTRATION Initiate pioglitazone tablets at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. (2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (2.1) Obtain liver tests before starting pioglitazone tablets.",
    "renal": "Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-Approved Patient Labeling (Medication Guide).",
      "It is important to instruct patients to adhere to dietary instructions and to have blood glucose and glycosylated hemoglobin tested regularly.",
      "During periods of stress such as fever, trauma, infection, or surgery, medication requirements may change and patients should be reminded to seek medical advice promptly."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "pioglitazone",
      "actos",
      "antidiabetic"
    ]
  },
  {
    "slug": "clonidine",
    "name": "Clonidine (Catapres)",
    "class": "Antihypertensive/sleep aid",
    "summary": "INDICATIONS AND USAGE Clonidine hydrochloride tablets are indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents.",
    "dose": "DOSAGE AND ADMINISTRATION Adults: The dose of clonidine hydrochloride tablets must be adjusted according to the patient’s individual blood pressure response. The following is a general guide to its administration.",
    "renal": "This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure.",
    "monitoring": "WARNINGS Withdrawal Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.",
    "pearls": [
      "Information for Patients Patients should be cautioned against interruption of clonidine hydrochloride tablets therapy without their physician’s advice.",
      "Since patients may experience a possible sedative effect, dizziness, or accommodation disorder with use of clonidine, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery.",
      "Also, inform patients that this sedative effect may be increased by concomitant use of alcohol, barbiturates, or other sedating drugs."
    ],
    "tags": [
      "Antihypertensive",
      "Sleep Aid"
    ],
    "keywords": [
      "clonidine",
      "catapres",
      "antihypertensive",
      "sleep",
      "aid"
    ]
  },
  {
    "slug": "celecoxib",
    "name": "Celecoxib (Celebrex)",
    "class": "Analgesic (NSAID.)",
    "summary": "1. INDICATIONS AND USAGE Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Acute Pain (AP) ( 1.5 ) Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis For the management of the signs and symptoms of OA [ see Clinical Studies (14.1) ].",
    "dose": "2. DOSAGE AND ADMINISTRATION Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) JRA: 50 mg twice daily in patients 10 kg to 25 kg.",
    "renal": "Consider withdrawal of celecoxib in women who have difficulties conceiving. ( 8.3 ) 8.1 Pregnancy Risk Summary Use of NSAIDs, including celecoxib, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17.",
      "PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.",
      "Inform patients, families, or their caregivers of the following information before initiating therapy with celecoxib and periodically during the course of ongoing therapy."
    ],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "celecoxib",
      "celebrex",
      "analgesic",
      "(nsaid.)"
    ]
  },
  {
    "slug": "tamsulosin",
    "name": "Tamsulosin (Flomax)",
    "class": "Reduces enlarged prostate",
    "summary": "1 INDICATIONS AND USAGE Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)]. Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension.",
    "dose": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day.",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Pediatric Use: Not indicated for use in pediatric populations ( 8.4 , 12.3 ) • Geriatric Use: No overall differences in efficacy or safety vs. younger patients, but greater sensitivity of some older adults cannot be ruled out ( 8.5 , 12.3 ) • Renal Impairment: Has not been studied in patients with end-stage renal disease ( 8.6 , 12.3 ) • Hepatic Impairment: Has not been studied in patients with severe hepatic impairment ( 8.7 , 12.3 ) 8.1 Pregnancy Risk Summary Tamsulosin hydrochloride is not indicated for use in women.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Drug Interactions Advise the patient that tamsulosin hydrochloride capsules should not be used in combination with strong inhibitors of CYP3A4 [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].",
      "Priapism Advise the patient about the possibility of priapism as a result of treatment with tamsulosin hydrochloride capsules and other similar medications."
    ],
    "tags": [
      "Reduces Enlarged Prostate"
    ],
    "keywords": [
      "tamsulosin",
      "flomax",
      "reduces",
      "enlarged",
      "prostate"
    ]
  },
  {
    "slug": "insulin-glargine",
    "name": "Insulin Glargine (Lantus)",
    "class": "Insulin",
    "summary": "1 INDICATIONS AND USAGE BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.",
    "dose": "2 DOSAGE AND ADMINISTRATION Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, prior insulin use. ( 2.2 , 2.3 , 2.4 ) Administer subcutaneously once daily at any time of day, but at the same time every day. ( 2.2 ) Rotate injection sites into the abdominal area, thigh, or deltoid to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) Closely monitor glucose when converting to BASAGLAR and during initial weeks thereafter. ( 2.2 ) Do not dilute or mix with any other insulin or solution. ( 2.1 ) 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions ( 5.4 )] . Visually inspect BASAGLAR prefilled pens for particulate matter and discoloration prior to administration.",
    "renal": "8.6 Renal Impairment The effect of renal impairment on the pharmacokinetics of BASAGLAR has not been studied.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Hyperglycemia or Hypoglycemia Inform patients that hypoglycemia is the most common adverse reaction with insulin.",
      "Inform patients of the symptoms of hypoglycemia."
    ],
    "tags": [
      "Insulin"
    ],
    "keywords": [
      "insulin",
      "glargine",
      "lantus"
    ]
  },
  {
    "slug": "levofloxacin",
    "name": "Levofloxacin (Levaquin)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS & USAGE Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated (1, 12.4). • Pneumonia: Nosocomial (1.1) and Community Acquired (1.2, 1.3) • Skin and Skin Structure Infections (SSSI): Complicated (1.4) and Uncomplicated (1.5) • Chronic bacterial prostatitis (1.6) • Inhalational Anthrax, Post-Exposure in adult and pediatric patients (1.7) • Plague in adult and pediatric patients (1.8) • Urinary Tract Infections (UTI): Complicated (1.9, 1.10) and Uncomplicated (1.12) • Acute Pyelonephritis (1.11) • Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) • Acute Bacterial Sinusitis (1.14) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.15). 1.1 Nosocomial Pneumonia Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae.",
    "dose": "2 DOSAGE & ADMINISTRATION • Administer Levofloxacin Tablets to pediatric patients weighing 30 kg and greater only (2.1, 2.2). • Levofloxacin Tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg (2.2).",
    "renal": "The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Serious Adverse Reactions Advise patients to stop taking levofloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.",
      "Symptoms may be irreversible."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "levofloxacin",
      "levaquin",
      "antibiotic"
    ]
  },
  {
    "slug": "methylprednisolone",
    "name": "Methylprednisolone (Medrol)",
    "class": "Anti-inflammatory steroid",
    "summary": "1 INDICATIONS AND USAGE Bupivacaine Hydrochloride Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of Bupivacaine Hydrochloride Injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see Dosage and Administration (2.2) ].",
    "dose": "2 DOSAGE AND ADMINISTRATION Not for intrathecal use. ( 2.1 ) Avoid use of solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia. ( 2.1 , 5.4 ) Three mL of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) is recommended for use as a test dose prior to caudal and lumbar epidural blocks when clinical conditions permit. ( 2.4 ) See full prescribing information for: Recommended concentrations and dosages of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection according to type of block. ( 2.2 ) Additional dosage and administration information pertaining to use in epidural anesthesia, test dose for caudal and lumbar epidural blocks, use in dentistry, and use in ophthalmic surgery. ( 2.3 , 2.4 , 2.5 , 2.6 ) 2.1 Important Dosage and Administration Information Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is not for intrathecal use. Avoid use of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia [see Warnings and Precautions (5.4) ] .",
    "renal": "This product is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "WARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke.",
    "pearls": [
      "Methemoglobinemia Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly.",
      "Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly.",
      "General This product, like many other corticosteroids, is sensitive to heat."
    ],
    "tags": [
      "Anti-inflammatory Steroid"
    ],
    "keywords": [
      "methylprednisolone",
      "medrol",
      "anti-inflammatory",
      "steroid"
    ]
  },
  {
    "slug": "oxycodone",
    "name": "Oxycodone (Oxycontin)",
    "class": "Analgesic",
    "summary": "1 INDICATIONS AND USAGE Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1)] , reserve opioid analgesics, including oxycodone hydrochloride tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.",
    "dose": "2 DOSAGE AND ADMINISTRATION Oxycodone hydrochloride tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. (2.1) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of oxycodone hydrochloride for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. (2.1, 5) Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic.",
    "renal": "In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Analgesic",
      "C-II"
    ],
    "keywords": [
      "oxycodone",
      "oxycontin",
      "analgesic",
      "c-ii"
    ]
  },
  {
    "slug": "promethazine",
    "name": "Promethazine (Phenergan)",
    "class": "Antinausea/anti-emetic",
    "summary": "INDICATIONS AND USAGE Promethazine HCl Suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis.",
    "dose": "DOSAGE AND ADMINISTRATION Promethazine HCl Suppositories are contraindicated for children under 2 years of age (see WARNINGS - Black Box Warning and Use in Pediatric Patients ). Promethazine HCl Suppositories are for rectal administration only.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS PROMETHAZINE HCl SUPPOSITORIES SHOULD NOT BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL FOR FATAL RESPIRATORY DEPRESSION. POSTMARKETING CASES OF RESPIRATORY DEPRESSION, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE HCl SUPPOSITORIES IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE.",
    "pearls": [
      "Pediatric patients should be supervised to avoid potential harm in bike riding or other hazardous activities.",
      "Patients should be advised to report any involuntary muscle movements.",
      "Avoid prolonged exposure to the sun."
    ],
    "tags": [
      "Antinausea",
      "Anti-emetic"
    ],
    "keywords": [
      "promethazine",
      "phenergan",
      "antinausea",
      "anti-emetic"
    ]
  },
  {
    "slug": "lansoprazole",
    "name": "Lansoprazole (Prevacid)",
    "class": "Antacid (PPI)",
    "summary": "1 INDICATIONS AND USAGE Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Maintenance of healed duodenal ulcers in adults ( 1.3 ) Treatment of active benign gastric ulcer in adults ( 1.4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults ( 1.5 ) Risk reduction of NSAID-associated gastric ulcer in adults ( 1.6 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) Maintenance of healing of EE in adults ( 1.9 ) Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES) in adults ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 )]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: lansoprazole/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori .",
    "dose": "2 DOSAGE AND ADMINISTRATION Recommended Dosage: See full prescribing information for complete dosing information for lansoprazole delayed-release capsules by indication and age group and dosage adjustment in patients with severe hepatic impairment. ( 2.1 , 2.2 , 2.3 ) Administration Instructions ( 2.4 ) Lansoprazole delayed-release capsules Should be swallowed whole. See full prescribing information for alternative administration options 2.1 Recommended Adult Dosage by Indication Indication Recommended Dose Frequency Duodenal Ulcers Short-Term Treatment 15 mg Once daily for 4 weeks Maintenance of Healed 15 mg Once daily Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence* Triple Therapy: Lansoprazole 30 mg Twice daily for 10 or 14 days Amoxicillin 1 gram Twice daily for 10 or 14 days Clarithromycin 500 mg Twice daily for 10 or 14 days Dual Therapy: Lansoprazole 30 mg Three times daily for 14 days Amoxicillin 1 gram Three times daily for 14 days Benign Gastric Ulcer Short-Term Treatment 30 mg Once daily for up to 8 weeks NSAID-associated Gastric Ulcer Healing 30 mg Once daily for 8 weeks † Risk Reduction 15 mg Once daily for up to 12 weeks † Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD 15 mg Once daily for up to 8 weeks Short-Term Treatment of Erosive Esophagitis 30 mg Once daily for up to 8 weeks ‡ Maintenance of Healing of Erosive Esophagitis 15 mg Once daily # Pathological Hypersecretory Conditions including Zollinger-Ellison Syndrome 60 mg Once daily ¶ * Please refer to the amoxicillin and clarithromycin full prescribing information CONTRAINDICATIONS and WARNINGS and PRECAUTIONS sections, and for information regarding dosing in elderly and renally-impaired patients. † Controlled studies did not extend beyond indicated duration. ‡ For patients who do not heal with lansoprazole for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment.",
    "renal": "Other Effects No systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).",
      "Advise patients to: Acute Tubulointerstitial Nephritis To call their healthcare provider if they experience signs and/or symptoms associated with acute tubulointerstitial nephritis [see Warnings and Precautions ( 5.2 )] .",
      "Clostridium difficile -Associated Diarrhea To immediately call their healthcare provider if they experience diarrhea that does not improve [see Warnings and Precautions ( 5.3 )] ."
    ],
    "tags": [
      "Antacid"
    ],
    "keywords": [
      "lansoprazole",
      "prevacid",
      "antacid",
      "(ppi)"
    ]
  },
  {
    "slug": "azilsartan",
    "name": "Azilsartan (Edarbi)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy.",
    "dose": "2 DOSAGE AND ADMINISTRATION Starting dose is 40/12.5 mg once daily ( 2.1 ) Edarbyclor may be used to provide additional blood pressure lowering for patients not adequately controlled on azilsartan medoxomil 80 mg or chlorthalidone 25 mg ( 2.1 ) Dose may be increased to 40/25 mg after 2 to 4 weeks as needed to achieve blood pressure goals ( 2.1 ) Maximal dose is 40/25 mg ( 2.1 ) May be administered with other antihypertensive agents ( 2.1 ) Edarbyclor may be administered with or without food ( 2.1 ) Replace volume in volume-depleted patients prior to use ( 2.2 ) 2.1 Dosing Information The recommended starting dose of Edarbyclor is 40/12.5 mg taken orally once daily. Most of the antihypertensive effect is apparent within 1 to 2 weeks.",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death ( see Clinical Considerations ).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) .",
      "Tell patients that if they miss a dose, they should take it later in the same day, but not to double the dose on the following day.",
      "Pregnancy Tell female patients of childbearing potential about the consequences of exposure to Edarbyclor during pregnancy."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "azilsartan",
      "edarbi",
      "antihypertensive"
    ]
  },
  {
    "slug": "quetiapine",
    "name": "Quetiapine (Seroquel)",
    "class": "Antipsychotic",
    "summary": "1 INDICATIONS & USAGE Quetiapine is an atypical antipsychotic indicated for the treatment of: Schizophrenia ( 1.1 ) Bipolar I disorder manic episodes ( 1.2 ) Bipolar disorder, depressive episodes ( 1.2 ) 1.1 Schizophrenia Quetiapine is indicated for the treatment of schizophrenia. The efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years).",
    "dose": "2 DOSAGE & ADMINISTRATION · Quetiapine tablets, USP can be taken with or without food ( 2.1 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults (2.2) 25 mg twice daily 150 to 750 mg/day 750 mg/day Schizophrenia-Adolescents (13 to 17 years) (2.2) 25 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Adults Monotherapy or as an adjunct to lithium or divalproex (2.2) 50 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy (2.2) 25 mg twice daily 400 to 600 mg/day 600 mg/day Bipolar Depression-Adults (2.2) 50 mg once daily at bedtime 300 mg/day 300 mg/day Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration and careful monitoring during the initial dosing period in the elderly ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (25 mg/day) and slower titration may be needed ( 2.4 , 8.7 , 12.3 ) 2.1 Important Administration Instructions Quetiapine tablets, USP can be taken with or without food. 2.2 Recommended Dosing The recommended initial dose, titration, dose range and maximum quetiapine dose for each approved indication is displayed in Table 1.",
    "renal": "8.6 Renal Impairment Clinical experience with quetiapine in patients with renal impairment is limited [see Clinical Pharmacology (12.3) ].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking quetiapine.",
      "Quetiapine is not approved for elderly patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] ."
    ],
    "tags": [
      "Antipsychotic"
    ],
    "keywords": [
      "quetiapine",
      "seroquel",
      "antipsychotic"
    ]
  },
  {
    "slug": "carisoprodol",
    "name": "Carisoprodol (Soma)",
    "class": "Muscle relaxer",
    "summary": "1 INDICATIONS AND USAGE Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [ see Dosage and Administration (2) ].",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended dose of carisoprodol is 350 mg three times a day and at bedtime. The recommended maximum duration of carisoprodol use is up to two or three weeks.",
    "renal": "8.6 Renal Impairment The safety and pharmacokinetics of carisoprodol in patients with renal impairment have not been evaluated.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Patients should be advised to contact their physician if they experience any adverse reactions to carisoprodol.",
      "Sedation Advise patients that carisoprodol may cause drowsiness and/or dizziness, and has been associated with motor vehicle accidents.",
      "Patients should be advised to avoid taking carisoprodol before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [ see Warnings and Precautions (5.1) ]."
    ],
    "tags": [
      "Muscle Relaxer",
      "C-IV"
    ],
    "keywords": [
      "carisoprodol",
      "soma",
      "muscle",
      "relaxer",
      "c-iv"
    ]
  },
  {
    "slug": "fenofibrate",
    "name": "Fenofibrate (Tricor)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 160 mg once daily ( 2.2 ). Severe hypertriglyceridemia: Initial dose of 54 to 160 mg once daily.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Determine dose selection based on renal function ( 8.5 ).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Manufactured for: Lupin Pharmaceuticals, Inc.",
      "Baltimore, Maryland 21202 United States.",
      "MADE IN INDIA."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "fenofibrate",
      "tricor",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "codeine-apap",
    "name": "Codeine + Apap (Tylenol 3)",
    "class": "Analgesic",
    "summary": "INDICATIONS AND USAGE Acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (see WARNINGS ), reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) · Have not provided adequate analgesia, or are not expected to provide adequate analgesia, · Have not been tolerated, or are not expected to be tolerated.",
    "dose": "DOSAGE AND ADMINISTRATION Important Dosage and Administration Instructions Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse (see WARNINGS ).",
    "renal": "It is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen, and kidney.",
    "monitoring": "WARNINGS Addiction, Abuse, and Misuse Acetaminophen and codeine phosphate tablets contain codeine. Codeine in combination with acetaminophen, is a Schedule III controlled substance.",
    "pearls": [
      "Information for Patients/Caregivers Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Inform patients that leaving acetaminophen and codeine phosphate tablets unsecured can pose a deadly risk to others in the home.",
      "Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly."
    ],
    "tags": [
      "Analgesic",
      "C-III"
    ],
    "keywords": [
      "codeine",
      "apap",
      "tylenol",
      "3",
      "analgesic",
      "c-iii"
    ]
  },
  {
    "slug": "enalapril",
    "name": "Enalapril (Vasotec)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.",
    "dose": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with enalapril maleate to reduce the likelihood of hypotension (see WARNINGS, Hypotension ).",
    "renal": "Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.",
    "monitoring": "WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including enalapril maleate) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate.",
    "pearls": [
      "Information for Patients Angioedema Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin-converting enzyme inhibitors, including enalapril.",
      "Hypotension Patients should be cautioned to report lightheadedness, especially during the first few days of therapy.",
      "If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "enalapril",
      "vasotec",
      "antihypertensive"
    ]
  },
  {
    "slug": "sildenafil",
    "name": "Sildenafil (Viagra)",
    "class": "Erectile dysfunction",
    "summary": "1 INDICATIONS AND USAGE Sildenafil tablets are indicated for the treatment of erectile dysfunction. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED)",
    "dose": "2 DOSAGE AND ADMINISTRATION For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Geriatric use: Consider a starting dose of 25 mg ( 2.5 , 8.5 ) Severe renal impairment: Consider a starting dose of 25 mg ( 2.5 , 8.6 ) Hepatic impairment: Consider a starting dose of 25 mg ( 2.5 , 8.7 ) 8.1 Pregnancy Risk Summary Sildenafil is not indicated for use in females.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Guanylate Cyclase (GC) Stimulators Physicians should discuss with patients the contraindication of sildenafil with use of guanylate cyclase stimulators such as riociguat [ see Contraindications (4.3) ].",
      "Concomitant Use with Drugs Which Lower Blood Pressure Physicians should advise patients of the potential for sildenafil to augment the blood pressure lowering effect of alpha-blockers and anti-hypertensive medications.",
      "Concomitant administration of sildenafil and an alpha - blocker may lead to symptomatic hypotension in some patients."
    ],
    "tags": [
      "Erectile Dysfunction"
    ],
    "keywords": [
      "sildenafil",
      "viagra",
      "erectile",
      "dysfunction"
    ]
  },
  {
    "slug": "dexmethylphenidate",
    "name": "Dexmethylphenidate (Focalin)",
    "class": "ADHD",
    "summary": "1 INDICATIONS AND USAGE AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )].",
    "dose": "2 DOSAGE AND ADMINISTRATION Pediatric Patients 6 to 12 years : Recommended starting dosage is 39.2 mg/7.8 mg orally once daily in the morning. Dosage may be increased to 52.3 mg/10.4 mg daily or decreased to 26.1 mg/5.2 mg daily after one week.",
    "renal": "Renal Impairment There is no experience with the use of AZSTARYS in patients with renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Advise patients to store AZSTARYS in a safe place, preferably locked, and instruct patients to not give AZSTARYS to anyone else.",
      "Risk to Patients with Serious Cardiac Disease Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with AZSTARYS use."
    ],
    "tags": [
      "ADHD",
      "C-II"
    ],
    "keywords": [
      "dexmethylphenidate",
      "focalin",
      "adhd",
      "c-ii"
    ]
  },
  {
    "slug": "ethinyl-estradiol-drospirenone",
    "name": "Ethinyl Estradiol + Drospirenone (Yaz)",
    "class": "Birth control",
    "summary": "1 INDICATIONS AND USAGE Iclevia TM (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. Iclevia is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day for 91 days. (2.1) Take tablets in the order directed on the Extended-Cycle Wallet. (2.2) 2.1 How to Start and Take Iclevia Iclevia is dispensed in an Extended-Cycle Wallet [see How Supplied/Storage and Handling (16) ]. Iclevia should be started on a Sunday (see Table 1).",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Cigarette Smoking Cigarette smoking increases the risk of serious cardiovascular events from COC use.",
      "Women who are over 35 years old and smoke should not use Iclevia [see Boxed Warning and Warnings and Precautions (5.1) ]."
    ],
    "tags": [
      "Birth Control"
    ],
    "keywords": [
      "ethinyl",
      "estradiol",
      "drospirenone",
      "yaz",
      "birth",
      "control"
    ]
  },
  {
    "slug": "allopurinol",
    "name": "Allopurinol (Zyloprim)",
    "class": "Antigout",
    "summary": "1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia. Allopurinol tablets are a xanthine oxidase inhibitor indicated for the management of: Adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) ( 1 ) Adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels ( 1 ) Adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes ( 1 ) Limitations of Use Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Gout : Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. ( 2.1 , 2.2 ) Patients with normal kidney function: Initial dosage is 100 mg orally daily.",
    "renal": "A case report published in 2011 described the outcome of a full-term pregnancy in a 35-year-old woman who had recurrent kidney stones since age 18 who took allopurinol throughout the pregnancy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Administration Advise patients to take allopurinol tablets after meals to minimize gastric irritation.",
      "If a single dose of allopurinol tablets is occasionally forgotten, there is no need to double the dose at the next scheduled time.",
      "Skin Rash and Hypersensitivity Inform patients that allopurinol tablets may increase the risk of serious and sometimes fatal dermatologic reactions."
    ],
    "tags": [
      "Antigout"
    ],
    "keywords": [
      "allopurinol",
      "zyloprim",
      "antigout"
    ]
  },
  {
    "slug": "spironolactone",
    "name": "Spironolactone (Aldactone)",
    "class": "Diuretic/antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION Heart Failure: Initiate treatment at 25 mg once daily ( 2.2 ). Hypertension: Initiate treatment at 25 mg to 100 mg daily in either single or divided doses ( 2.3 ).",
    "renal": "8.5 Geriatric Use Spironolactone is substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Patients who receive spironolactone should be advised to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes.",
      "This product’s label may have been updated.",
      "For current full prescribing information, please visit www.amneal.com."
    ],
    "tags": [
      "Diuretic",
      "Antihypertensive"
    ],
    "keywords": [
      "spironolactone",
      "aldactone",
      "diuretic",
      "antihypertensive"
    ]
  },
  {
    "slug": "ramipril",
    "name": "Ramipril (Altace)",
    "class": "Antihypertensive",
    "summary": "1. INDICATIONS AND USAGE • Ramipril capsules USP are indicated for the treatment of hypertension.",
    "dose": "2. DOSAGE AND ADMINISTRATION • Hypertension: Initial dose is 2.5 mg to 20 mg once daily.",
    "renal": "8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17.",
      "PATIENT COUNSELING INFORMATION 17.1 Angioedema Angioedema, including laryngeal edema, can occur rarely with treatment with ACE inhibitors, especially following the first dose.",
      "Advise patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "ramipril",
      "altace",
      "antihypertensive"
    ]
  },
  {
    "slug": "glimepiride",
    "name": "Glimepiride (Amaryl)",
    "class": "Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "dose": "2 DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response.",
    "renal": "Geriatric or Renally Impaired Patients: At risk for hypoglycemia with glimepiride.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Hypoglycemia Explain the symptoms and treatment of hypoglycemia as well as conditions that predispose to hypoglycemia.",
      "Hypersensitivity Reactions Inform patients that hypersensitivity reactions may occur with glimepiride and that if a reaction occurs to seek medical treatment and discontinue glimepiride [see Warnings and Precautions (5.2) ].",
      "Pregnancy Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1) ]."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "glimepiride",
      "amaryl",
      "antidiabetic"
    ]
  },
  {
    "slug": "methylphenidate",
    "name": "Methylphenidate (Concerta)",
    "class": "ADHD",
    "summary": "1 INDICATIONS AND USAGE Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), in pediatric patients 6 to 12 years of age [see Clinical Studies ( 14 )] . Methylphenidate hydrochloride extended-release capsules are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer orally once daily in the morning. ( 2.2 ) Capsules may be swallowed whole, or opened and the entire contents sprinkled on applesauce. ( 2.2 ) Should not be crushed, chewed, or divided. ( 2.2 ) Patients new to methylphenidate: Start at 20 mg daily, titrating the dose weekly in 10-mg increments. Doses above 60 mg daily are not recommended. ( 2.3 ) For patients currently using methylphenidate hydrochloride tablets or methylphenidate hydrochloride extended-release tablets: Dosage is based on current dose regimen. ( 2.4 ) If switching from other methylphenidate products, discontinue treatment and titrate with methylphenidate hydrochloride extended-release capsules. ( 2.4 ) 2.1 Pretreatment Screening Prior to initiating treatment with central nervous system (CNS) stimulants, including methylphenidate hydrochloride extended-release capsules, assess for the presence of cardiac disease (i.e., perform a careful history including family history of sudden death or ventricular arrhythmia, and physical examination) [see Warnings and Precautions ( 5.2 )] .",
    "renal": "Patient s with Renal Impairment Methylphenidate hydrochloride extended-release capsules have not been studied in renally-impaired patients.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Controlled Substance Status/High Potential for Abuse and Dependence Advise patients that methylphenidate hydrochloride extended-release capsules are a controlled substance, and they can be abused and lead to dependence.",
      "Instruct patients that they should not give methylphenidate hydrochloride extended-release capsules to anyone else."
    ],
    "tags": [
      "ADHD",
      "C-II"
    ],
    "keywords": [
      "methylphenidate",
      "concerta",
      "adhd",
      "c-ii"
    ]
  },
  {
    "slug": "losartan",
    "name": "Losartan (Cozaar)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.",
    "dose": "2 DOSAGE AND ADMINISTRATION Hypertension • Usual adult dose: 50 mg once daily. (2.1) • Usual pediatric starting dose: 0.7 mg per kg once daily (up to 50 mg). (2.1) Hypertensive Patients with Left Ventricular Hypertrophy • Usual starting dose: 50 mg once daily. (2.2) • Add hydrochlorothiazide 12.5 mg and/or increase losartan potassium to 100 mg followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. (2.2 , 14.2) Nephropathy in Type 2 Diabetic Patients • Usual dose: 50 mg once daily. (2.3) • Increase dose to 100 mg once daily if further blood pressure response is needed. (2.3) 2.1 Hypertension Adult Hypertension The usual starting dose of losartan potassium tablets is 50 mg once daily. The dosage can be increased to a maximum dose of 100 mg once daily as needed to control blood pressure [see Clinical Studies (14.1) ].",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ).",
      "Pregnancy Advise female patients of childbearing age about the consequences of exposure to losartan potassium during pregnancy.",
      "Discuss treatment options with women planning to become pregnant."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "losartan",
      "cozaar",
      "antihypertensive"
    ]
  },
  {
    "slug": "levocetirizine",
    "name": "Levocetirizine (Xyzal)",
    "class": "Antihistamine",
    "summary": "Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat",
    "dose": "Directions adults 65 years of age and older ask a doctor adults and children 12-64 years of age take 1 tablet (5 mg) once daily in the evening do not take more than 1 tablet (5 mg) in 24 hours 1/2 tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms children 6-11 years of age take 1/2 tablet (2.5 mg) once daily in the evening do not take more than 1/2 tablet (2.5 mg) in 24 hours children under 6 years of age do not use consumers with kidney disease do not use",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine Ask a doctor before use if you have ever had trouble urinating or emptying your bladder When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery Stop use and ask doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. Seek medical help right away.",
    "pearls": [],
    "tags": [
      "Antihistamine"
    ],
    "keywords": [
      "levocetirizine",
      "xyzal",
      "antihistamine"
    ]
  },
  {
    "slug": "folic-acid",
    "name": "Folic Acid (Folvite)",
    "class": "Mineral supplement",
    "summary": "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia. Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid.",
    "dose": "DOSAGE AND ADMINISTRATION: Adults (persons over 12 years of age), One (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Mineral Supplement"
    ],
    "keywords": [
      "folic",
      "acid",
      "folvite",
      "mineral",
      "supplement"
    ]
  },
  {
    "slug": "isosorbide-mononitrate",
    "name": "Isosorbide Mononitrate (Imdur)",
    "class": "Anti-angina (chest pain)",
    "summary": "INDICATIONS AND USAGE Isosorbide mononitrate extended-release tablets, USP are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.",
    "dose": "DOSAGE AND ADMINISTRATION The recommended starting dose of isosorbide mononitrate extended-release tablets is 30 mg (given as a single 30 mg tablet or as 1/2 of a 60 mg tablet) or 60 mg (given as a single tablet) once daily. After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily.",
    "renal": "Renal clearance accounts for only about 4% of total body clearance.",
    "monitoring": "WARNINGS Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension. The time course and dose dependence of this interaction have not been studied.",
    "pearls": [],
    "tags": [
      "Anti-angina"
    ],
    "keywords": [
      "isosorbide",
      "mononitrate",
      "imdur",
      "anti-angina",
      "(chest",
      "pain)"
    ]
  },
  {
    "slug": "digoxin",
    "name": "Digoxin (Lanoxin)",
    "class": "Treats heart failure/arrhythmia",
    "summary": "1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.",
    "dose": "2 DOSAGE & ADMINISTRATION Digoxin dose is based on patient-specific factors (age, lean body weight, renal function, etc.). See full prescribing information.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnant patients: It is unknown whether use during pregnancy can cause fetal harm. ( 8.1 ) Pediatric patients: Newborn infants display variability in tolerance to digoxin. ( 8.4 ) Geriatric patients: Consider renal function in dosage selection, and carefully monitor for side effects. ( 8.5 ) Renal impairment: Digoxin is excreted by the kidneys.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients that many drugs can interact with digoxin.",
      "Instruct patients to inform their doctor and pharmacist if they are taking any over the counter medications, including herbal medication, or are started on a new prescription.",
      "Advise parents or caregivers that the symptoms of having too high digoxin doses may be difficult to recognize in infants and pediatric patients."
    ],
    "tags": [
      "Treats Heart Failure",
      "Arrhythmia"
    ],
    "keywords": [
      "digoxin",
      "lanoxin",
      "treats",
      "heart",
      "failure",
      "arrhythmia"
    ]
  },
  {
    "slug": "pregabalin",
    "name": "Pregabalin (Lyrica)",
    "class": "Anticonvulsant/Antinerve pain",
    "summary": "1 INDICATIONS AND USAGE Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pregabalin capsules are indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1 ) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1) Fibromyalgia ( 1) Neuropathic pain associated with spinal cord injury (1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week.",
    "renal": "Pregabalin is known to be substantially excreted by the kidney, and the risk of toxic reactions to pregabalin may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Angioedema Advise patients that pregabalin capsules may cause angioedema, with swelling of the face, mouth (lip, gum, tongue) and neck (larynx and pharynx) that can lead to life-threatening respiratory compromise.",
      "Instruct patients to discontinue pregabalin capsules and immediately seek medical care if they experience these symptoms [see Warnings and Precautions (5.1) ] ."
    ],
    "tags": [
      "Anticonvulsant",
      "Antinerve Pain",
      "C-V"
    ],
    "keywords": [
      "pregabalin",
      "lyrica",
      "anticonvulsant",
      "antinerve",
      "pain",
      "c-v"
    ]
  },
  {
    "slug": "triamcinolone",
    "name": "Triamcinolone (Nasacort)",
    "class": "Anti-inflammatory steroid",
    "summary": "INDICATIONS & USAGE Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.",
    "dose": "DOSAGE & ADMINISTRATION Apply a thin film of Triamcinolone Acetonide Ointment 0.025% to the affected area two to four times daily. Apply a thin film of the 0.1% or the 0.5% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily.",
    "renal": "Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.",
    "monitoring": "PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.",
    "pearls": [
      "Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1.",
      "This medication is to be used as directed by the physician.",
      "It is for external use only."
    ],
    "tags": [
      "Anti-inflammatory Steroid"
    ],
    "keywords": [
      "triamcinolone",
      "nasacort",
      "anti-inflammatory",
      "steroid"
    ]
  },
  {
    "slug": "desvenlafaxine",
    "name": "Desvenlafaxine (Pristiq)",
    "class": "Antidepressant",
    "summary": "1 INDICATIONS AND USAGE PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION • Recommended dose: 50 mg once daily with or without food ( 2.1 ). • There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). • The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). • Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). • Take tablets whole; do not divide, crush, chew, or dissolve ( 2.1 ). • Moderate renal impairment: Maximum dose 50 mg per day ( 2.2 ). • Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day ( 2.2 ). • Moderate to severe hepatic impairment: Maximum dose 100 mg per day ( 2.3 ). 2.1 General Instructions for Use The recommended dose for PRISTIQ is 50 mg once daily, with or without food.",
    "renal": "For elderly patients, possible reduced renal clearance of PRISTIQ should be considered when determining dose [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) ] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Concomitant Medication Advise patients taking PRISTIQ not to use concomitantly other products containing desvenlafaxine or venlafaxine.",
      "Healthcare professionals should instruct patients not to take PRISTIQ with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping PRISTIQ before starting an MAOI [see Contraindications (4) ] ."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "desvenlafaxine",
      "pristiq",
      "antidepressant"
    ]
  },
  {
    "slug": "cefdinir",
    "name": "Cefdinir (Omnicef)",
    "class": "Antibiotic",
    "summary": "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.",
    "dose": "DOSAGE AND ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing.",
    "renal": "Cefdinir Capsules Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300 and 600 mg oral doses of cefdinir to adult subjects are presented in the following table: Mean (±SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Capsules to Adult Subjects Dose C max (mcg/mL) t max (hr) AUC (mcg•hr/mL) 300 mg 1.6 (0.55) 2.9 (0.89) 7.05 (2.17) 600 mg 2.87 (1.01) 3 (0.66) 11.1 (3.87) Cefdinir Suspension Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7 and 14 mg/kg oral doses of cefdinir to pediatric subjects (age 6 months to 12 years) are presented in the following table: Mean (±SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Suspension to Pediatric Subjects Dose C max (mcg/mL) t max (hr) AUC (mcg•hr/mL) 7 mg/kg 2.3 (0.65) 2.2 (0.6) 8.31 (2.5) 14 mg/kg 3.86 (0.62) 1.8 (0.4) 13.4 (2.64) Multiple Dosing Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.",
    "monitoring": "WARNINGS BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.",
    "pearls": [
      "Information for Patients Patients should be counseled that antibacterial drugs including cefdinir should only be used to treat bacterial infections.",
      "They do not treat viral infections (e.g., the common cold).",
      "When cefdinir is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "cefdinir",
      "omnicef",
      "antibiotic"
    ]
  },
  {
    "slug": "insulin-glulisine",
    "name": "Insulin Glulisine (Apidra)",
    "class": "Insulin - Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important administration instructions. ( 2.1 , 2.2 ) Individualize and adjust the dosage of APIDRA based on route of administration, individual's metabolic needs, blood glucose monitoring results, and glycemic control goal. ( 2.3 ) Dosage adjustments may be needed when switching from another insulin, with changes in physical activity, changes in concomitant medications, changes in meal patterns, changes in renal or hepatic function or during acute illness. ( 2.3 ) Subcutaneous Injection: ( 2.2 ) Inject within 15 minutes before a meal or within 20 minutes after starting a meal into the abdomen, thigh, or upper arm. Rotate injection sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.",
    "renal": "8.6 Renal Impairment Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent APIDRA dose adjustment and more frequent blood glucose monitoring [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Never Share an APIDRA SoloStar Pen or Syringe or Needle between Patients Advise patients that they must never share an APIDRA SoloStar pen with another person, even if the needle is changed.",
      "Advise patients using APIDRA vials not to reuse or share needles or syringes with another person."
    ],
    "tags": [
      "Insulin - Antidiabetic"
    ],
    "keywords": [
      "insulin",
      "glulisine",
      "apidra",
      "-",
      "antidiabetic"
    ]
  },
  {
    "slug": "rivaroxaban",
    "name": "Rivaroxaban (Xarelto)",
    "class": "Anticoagulant",
    "summary": "1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ].",
    "dose": "2 DOSAGE AND ADMINISTRATION Nonvalvular Atrial Fibrillation : 15 or 20 mg, once daily with food ( 2.1 ) Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment ( 2.1 ) Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment ( 2.1 ) Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food ( 2.1 ) Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding : 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days ( 2.1 ) CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75–100 mg) once daily ( 2.1 ) Pediatric Patients: See dosing recommendations in the Full Prescribing Information ( 2.2 ) 2.1 Recommended Dosage in Adults Table 1: Recommended Dosage in Adults Indication Renal Considerations Calculate CrCl based on actual weight. [See Warnings and Precautions (5.4) and Use in Specific Populations (8.6)] Dosage Food/Timing See Clinical Pharmacology (12.3) Reduction in Risk of Stroke in Nonvalvular Atrial Fibrillation CrCl >50 mL/min 20 mg once daily Take with evening meal CrCl ≤50 mL/min Patients with CrCl <30 mL/min were not studied, but administration of XARELTO is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Use in Specific Populations (8.6)] 15 mg once daily Take with evening meal Treatment of DVT and/or PE CrCl ≥15 mL/min 15 mg twice daily ▼ after 21 days, transition to ▼ 20 mg once daily Take with food, at the same time each day CrCl <15 mL/min Avoid Use Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE CrCl ≥15 mL/min 10 mg once daily, after at least 6 months of standard anticoagulant treatment Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of DVT Following: Hip Replacement Surgery See Dosage and Administration (2.4) CrCl ≥15 mL/min 10 mg once daily for 35 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use Knee Replacement Surgery CrCl ≥15 mL/min 10 mg once daily for 12 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding CrCl ≥15 mL/min 10 mg once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days Take with or without food CrCl <15 mL/min Avoid Use Reduction of Risk of Major Cardiovascular Events (CV Death, MI, and Stroke) in CAD No dose adjustment needed based on CrCl 2.5 mg twice daily , plus aspirin (75–100 mg) once daily Take with or without food Reduction of Risk of Major Thrombotic Vascular Events in PAD, Including Patients after Lower Extremity Revascularization due to Symptomatic PAD No dose adjustment needed based on CrCl 2.5 mg twice daily , plus aspirin (75–100 mg) once daily. When starting therapy after a successful lower extremity revascularization procedure, initiate once hemostasis has been established.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Renal impairment: Avoid or adjust dose ( 8.6 ) Hepatic impairment: Avoid use in Child-Pugh B and C hepatic impairment or hepatic disease associated with coagulopathy ( 8.7 ) 8.1 Pregnancy Risk Summary The limited available data on XARELTO in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION For the tablets, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).",
      "For the suspension, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).",
      "Instructions for Patient Use Advise patients to take XARELTO only as directed."
    ],
    "tags": [
      "Anticoagulant"
    ],
    "keywords": [
      "rivaroxaban",
      "xarelto",
      "anticoagulant"
    ]
  },
  {
    "slug": "temazepam",
    "name": "Temazepam (Restoril)",
    "class": "Sleep aid",
    "summary": "INDICATIONS AND USAGE Temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days).",
    "dose": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including temazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.",
    "pearls": [],
    "tags": [
      "Sleep Aid",
      "C-IV"
    ],
    "keywords": [
      "temazepam",
      "restoril",
      "sleep",
      "aid",
      "c-iv"
    ]
  },
  {
    "slug": "oseltamivir",
    "name": "Oseltamivir (Tamiflu)",
    "class": "Antiviral (Flu)",
    "summary": "1 INDICATIONS AND USAGE Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza A and B in patients 1 year and older.",
    "dose": "2 DOSAGE AND ADMINISTRATION Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days ( 2.2 ) Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days ( 2.2 ) Pediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days ( 2.2 ) Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg twice daily for 5 days ( 2.4 ) Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once daily for 5 days ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ( 2.4 ) ESRD patients on CAPD: Reduce to a single 30 mg dose immediately ( 2.4 ) Prophylaxis of influenza Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days ( 2.3 ) Community outbreak: 75 mg once daily for up to 6 weeks ( 2.3 ) Pediatric patients 1 to 12 years of age: Based on weight once daily for 10 days ( 2.3 ) Community outbreak: Based on weight once daily for up to 6 weeks ( 2.3 ) Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg once daily ( 2.4 ) Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once every other day ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after alternate hemodialysis cycles for the recommended duration of prophylaxis ( 2.4 ) ESRD patients on CAPD: Reduce to 30 mg immediately and then 30 mg once weekly for the recommended duration of prophylaxis ( 2.4 ) 2.1 Dosage and Administration Overview Administer oseltamivir phosphate for oral suspension for the treatment of influenza in patients 2 weeks of age or older [see Dosage and Administration (2.2) ] or for prophylaxis of influenza in patients 1 year and older [see Dosage and Administration (2.3) ] using: Oseltamivir phosphate for oral suspension (supplied as a powder).",
    "renal": "8.6 Renal Impairment Patients with renal impairment had higher blood levels of oseltamivir carboxylate compared to patients with normal renal function which may increase the risk of oseltamivir phosphate -associated adverse reactions.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Serious Skin/Hypersensitivity Reactions Advise patients and/or caregivers of the risk of severe allergic reactions (including anaphylaxis) or serious skin reactions.",
      "Instruct patients and/or caregiver to stop oseltamivir phosphate for oral suspension and seek immediate medical attention if an allergic-like reaction occurs or is suspected [ see Warnings and Precautions (5.1) ] ."
    ],
    "tags": [
      "Antiviral"
    ],
    "keywords": [
      "oseltamivir",
      "tamiflu",
      "antiviral",
      "(flu)"
    ]
  },
  {
    "slug": "valacyclovir",
    "name": "Valacyclovir (Valtrex)",
    "class": "Antiviral",
    "summary": "1 INDICATIONS AND USAGE Valacyclovir hydrochloride is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients. 1.1 Adult Patients Cold Sores (Herpes Labialis) Valacyclovir tablets are indicated for treatment of cold sores (herpes labialis).",
    "dose": "2 DOSAGE AND ADMINISTRATION Valacyclovir tablets may be given without regard to meals. Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate [see Dosage and Administration (2.3) ] .",
    "renal": "Elderly patients are more likely to have reduced renal function and require dose reduction.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ).",
      "Importance of Adequate Hydration Patients should be advised to maintain adequate hydration.",
      "Missed Dose Instruct patients that if they miss a dose of valacyclovir hydrochloride, to take it as soon as they remember."
    ],
    "tags": [
      "Antiviral"
    ],
    "keywords": [
      "valacyclovir",
      "valtrex",
      "antiviral"
    ]
  },
  {
    "slug": "labetalol",
    "name": "Labetalol (Trandate)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Labetalol hydrochloride tablets USP are indicated in the management of hypertension. Labetalol hydrochloride tablets USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.",
    "dose": "DOSAGE AND ADMINISTRATION DOSAGE MUST BE INDIVIDUALIZED. The recommended initial dosage is 100 mg twice daily whether used alone or added to a diuretic regimen.",
    "renal": "Doses of labetalol hydrochloride that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal renal function.",
    "monitoring": "WARNINGS Hepatic Injury Severe hepatocellular injury, confirmed by rechallenge in at least one case, occurs rarely with labetalol therapy. The hepatic injury is usually reversible, but hepatic necrosis and death have been reported.",
    "pearls": [],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "labetalol",
      "trandate",
      "antihypertensive"
    ]
  },
  {
    "slug": "ezetimibe",
    "name": "Ezetimibe (Zetia)",
    "class": "Cholesterol lowering",
    "summary": "1 INDICATIONS AND USAGE Ezetimibe and simvastatin tablets Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).",
    "dose": "2 DOSAGE AND ADMINISTRATION Important Dosage and Administration Information: ( 2.1 ) Take ezetimibe and simvastatin tablets orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily.",
    "renal": "Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Myopathy and Rhabdomyolysis Advise patients that ezetimibe and simvastatin tablets may cause myopathy and rhabdomyolysis.",
      "Inform patients taking the 80 mg daily dose of simvastatin that they are at an increased risk."
    ],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "ezetimibe",
      "zetia",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "aripiprazole",
    "name": "Aripiprazole (Abilify)",
    "class": "Antipsychotic",
    "summary": "1 INDICATIONS AND USAGE Aripiprazole is indicated for the treatment of: • Schizophrenia • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: • Schizophrenia (14.1) • Irritability Associated with Autistic Disorder (14.4) • Treatment of Tourette’s disorder (14.5)",
    "dose": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia – adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia – adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder – pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette’s disorder – (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients ≥50 kg 2 mg/day 10 mg/day 20 mg/day •Oral formulations: Administer once daily without regard to meals (2) •Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 or 15 mg/day were not more effective than 10 or 15 mg/day.",
    "renal": "At all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide).",
      "Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.",
      "Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms."
    ],
    "tags": [
      "Antipsychotic"
    ],
    "keywords": [
      "aripiprazole",
      "abilify",
      "antipsychotic"
    ]
  },
  {
    "slug": "amphetamine-dextroamphetamine",
    "name": "Amphetamine + Dextroamphetamine (Adderall)",
    "class": "ADHD",
    "summary": "INDICATIONS AND USAGE Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin.",
    "dose": "DOSAGE AND ADMINISTRATION Regardless of indication, amphetamine should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of resulting insomnia.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Abuse, Misuse, and Addiction Amphetamine sulfate tablets have a high potential for abuse and misuse. The use of amphetamine sulfate tablets exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction.",
    "pearls": [
      "Information for Patients Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).",
      "Advise patients to store amphetamine sulfate tablets in a safe place, preferably locked, and instruct patients to not give amphetamine sulfate tablets to anyone else.",
      "Risks to Patients with Serious Cardiac Disease Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with amphetamine sulfate tablets use."
    ],
    "tags": [
      "ADHD",
      "C-II"
    ],
    "keywords": [
      "amphetamine",
      "dextroamphetamine",
      "adderall",
      "adhd",
      "c-ii"
    ]
  },
  {
    "slug": "phentermine",
    "name": "Phentermine (Adipex)",
    "class": "Appetite suppressant",
    "summary": "1 INDICATIONS AND USAGE Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m 2 , or ≥ 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights.",
    "dose": "2 DOSAGE AND ADMINISTRATION Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2.1) Late evening administration should be avoided (risk of insomnia). (2.1) Phentermine hydrochloride tablets can be taken with or without food. (2.1) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) (2.2) 2.1 Exogenous Obesity Dosage should be individualized to obtain an adequate response with the lowest effective dose. The usual adult dose is one tablet (37.5 mg) daily, as prescribed by the physician, administered before breakfast or 1 to 2 hours after breakfast.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. ( 4 , 8.3 ) Pediatric use: Safety and effectiveness not established. ( 8.4 ) Geriatric use: Due to substantial renal excretion, use with caution. ( 8.5 ) Renal Impairment: Avoid use in patients with eGFR less than 15 mL/min/1.73m 2 or end-stage renal disease requiring dialysis. (8.6) 8.1 Pregnancy Pregnancy Category X Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Patients must be instructed on how much phentermine to take, and when and how to take it [ see Dosage and Administration (2) ].",
      "Advise pregnant women and nursing mothers not to use phentermine [ see Use in Specific Populations (8.1 , 8.3) ].",
      "Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action."
    ],
    "tags": [
      "Appetite Suppressant",
      "C-IV"
    ],
    "keywords": [
      "phentermine",
      "adipex",
      "appetite",
      "suppressant",
      "c-iv"
    ]
  },
  {
    "slug": "donepezil",
    "name": "Donepezil (Aricept)",
    "class": "Anti-Alzheimer's",
    "summary": "1 INDICATIONS AND USAGE Donepezil hydrochloride tablet is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease ( 1 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION Mild to Moderate Alzheimer's Disease: 5 mg to 10 mg once daily ( 2.1 ) Moderate to Severe Alzheimer's Disease: 10 mg to 23 mg once daily ( 2.2 ) 2.1 Dosing in Mild to Moderate Alzheimer’s Disease The recommended starting dosage of donepezil hydrochloride tablet is 5 mg administered once per day in the evening, just prior to retiring. The maximum recommended dosage of donepezil hydrochloride tablets in patients with mild to moderate Alzheimer's disease is 10 mg per day.",
    "renal": "Renal Disease In a study of 11 patients with moderate to severe renal impairment (Cl C < 18 mL/min/1.73 m 2 ) the clearance of donepezil hydrochloride did not differ from 11 age- and sex-matched healthy subjects.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Instruct patients and caregivers to take donepezil hydrochloride only once per day, as prescribed.",
      "Instruct patients and caregivers that donepezil hydrochloride can be taken with or without food."
    ],
    "tags": [
      "Anti-Alzheimer's"
    ],
    "keywords": [
      "donepezil",
      "aricept",
      "anti-alzheimer's"
    ]
  },
  {
    "slug": "olmesartan",
    "name": "Olmesartan (Benicar)",
    "class": "Antihypertensive (ARB)",
    "summary": "1 INDICATIONS AND USAGE Olmesartan medoxomil and hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] .",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of olmesartan medoxomil and hydrochlorothiazide is 40/12.5 mg once daily in patients whose blood pressure is not adequately controlled with olmesartan monotherapy. Dose can be titrated up to 40 /25 mg if necessary.",
    "renal": "8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity, and death.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Pregnancy: Advisefemale patients of childbearing age about the consequences of exposure to olmesartan medoxomil and hydrochlorothiazide during pregnancy.",
      "Discuss treatment options with women planning to become pregnant.",
      "Tell patients to report pregnancies to their physicians as soon as possible [see Use in Specific Populations (8.1) ] ."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "olmesartan",
      "benicar",
      "antihypertensive",
      "(arb)"
    ]
  },
  {
    "slug": "diclofenac",
    "name": "Diclofenac (Cataflam)",
    "class": "Analgesic (NSAID.)",
    "summary": "Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. If no pain relief in 7 days, stop use.",
    "dose": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings For external use only Allergy alert: Diclofenac may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: hives asthma (wheezing) skin reddening blisters facial swelling shock rash If an allergic reaction occurs, stop use and seek medical help right away.",
    "pearls": [],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "diclofenac",
      "cataflam",
      "analgesic",
      "(nsaid.)"
    ]
  },
  {
    "slug": "lisinopril-hctz",
    "name": "Lisinopril + HCTZ (Zestoretic)",
    "class": "Antihypertensive + diuretic",
    "summary": "Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "Lisinopril monotherapy is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide monotherapy is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component.",
    "renal": "Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.",
    "monitoring": "General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including lisinopril and hydrochlorothiazide tablets) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including lisinopril.",
    "pearls": [],
    "tags": [
      "Antihypertensive",
      "Diuretic"
    ],
    "keywords": [
      "lisinopril",
      "hctz",
      "zestoretic",
      "antihypertensive",
      "diuretic"
    ]
  },
  {
    "slug": "clindamycin",
    "name": "Clindamycin (Cleocin)",
    "class": "Antimicrobial",
    "summary": "INDICATIONS AND USAGE Clindamycin phosphate topical lotion is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).",
    "dose": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface.",
    "pearls": [
      "General Clindamycin phosphate should be prescribed with caution in atopic individuals."
    ],
    "tags": [
      "Antimicrobial"
    ],
    "keywords": [
      "clindamycin",
      "cleocin",
      "antimicrobial"
    ]
  },
  {
    "slug": "metronidazole",
    "name": "Metronidazole (Flagyl)",
    "class": "Antimicrobial",
    "summary": "INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).",
    "dose": "DOSAGE AND ADMINISTRATION Trichomoniasis: In the Female: One-day treatment − two grams of metronidazole tablets, given either as a single dose or in two divided doses of one gram each, given in the same day. Seven-day course of treatment − 250 mg three times daily for seven consecutive days.",
    "renal": "Renal clearance of metronidazole is approximately 10 mL/min/1.73 m 2 .",
    "monitoring": "WARNINGS Central and Peripheral Nervous System Effects Encephalopathy and peripheral neuropathy: Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported with metronidazole. Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria.",
    "pearls": [
      "Treatment of Bacterial and Parasitic Infections Patients should be counseled that metronidazole should only be used to treat bacterial and parasitic infections.",
      "Metronidazole does not treat viral infections ( e.g., the common cold).",
      "When metronidazole is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed."
    ],
    "tags": [
      "Antimicrobial"
    ],
    "keywords": [
      "metronidazole",
      "flagyl",
      "antimicrobial"
    ]
  },
  {
    "slug": "glipizide",
    "name": "Glipizide (Glucotrol)",
    "class": "Antidiabetic",
    "summary": "INDICATIONS AND USAGE Glipizide Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "dose": "DOSAGE AND ADMINISTRATION There is no fixed dosage regimen for the management of diabetes mellitus with glipizide or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patient’s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.",
    "pearls": [
      "Information for Patients Patients should be informed of the potential risks and advantages of glipizide and of alternative modes of therapy.",
      "They should also be informed about the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.",
      "The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "glipizide",
      "glucotrol",
      "antidiabetic"
    ]
  },
  {
    "slug": "lamotrigine",
    "name": "Lamotrigine (Lamictal)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Lamotrigine orally disintegrating tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older : partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine in the acute treatment of mood episodes has not been established.",
    "dose": "2 DOSAGE AND ADMINISTRATION Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. Lamotrigine Starter Kits and Lamotrigine Orally Disintegrating Tablets Patient Titration Kits are available for the first 5 weeks of treatment. ( 2.1 , 16 ) Do not restart lamotrigine orally disintegrating tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy : Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. ( 2.2 ) Conversion to monotherapy—See Table 4. ( 2.3 ) Bipolar disorder : See Tables 5 and 6. ( 2.4 ) 2.1 General Dosing Considerations Rash There are suggestions, yet to be proven, that the risk of severe, potentially life-threatening rash may be increased by (1) coadministration of lamotrigine with valproate, (2) exceeding the recommended initial dose of lamotrigine, or (3) exceeding the recommended dose escalation for lamotrigine.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data may cause fetal harm. ( 8.1 ) Hepatic impairment: Dosage adjustments required in patients with moderate and severe liver impairment. ( 2.1 , 8.6 ) Renal impairment: Reduced maintenance doses may be effective for patients with significant renal impairment. ( 2.1 , 8.7 ) 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, including lamotrigine, during pregnancy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Multiorgan Hypersensitivity Reactions, Blood Dyscrasias, and Organ Failure Inform patients that multiorgan hypersensitivity reactions and acute multiorgan failure may occur with lamotrigine.",
      "Isolated organ failure or isolated blood dyscrasias without evidence of multiorgan hypersensitivity may also occur."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "lamotrigine",
      "lamictal",
      "anticonvulsant"
    ]
  },
  {
    "slug": "gemfibrozil",
    "name": "Gemfibrozil (Lopid)",
    "class": "Cholesterol lowering",
    "summary": "INDICATIONS AND USAGE Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.",
    "dose": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS 1. Because of chemical, pharmacological, and clinical similarities between gemfibrozil and clofibrate, the adverse findings with clofibrate in two large clinical studies may also apply to gemfibrozil.",
    "pearls": [],
    "tags": [
      "Cholesterol Lowering"
    ],
    "keywords": [
      "gemfibrozil",
      "lopid",
      "cholesterol",
      "lowering"
    ]
  },
  {
    "slug": "benazepril",
    "name": "Benazepril (Lotensin)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "2 DOSAGE AND ADMINISTRATION • Adult Patients: Initiate with 10 mg once daily (or 5 mg if patient is on diuretic). Titrate to 40 mg daily based on blood pressure response. ( 2.1 ) • Pediatric patients age 6 years and above with glomerular filtration rate (GFR) >30 mL/min/1.73 m 2 : Initiate with 0.2 mg/kg once daily.",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Pregnancy : Tell female patients of childbearing age about the consequences of exposure to benazepril hydrochloride during pregnancy.",
      "Discuss treatment options with women planning to become pregnant.",
      "Instruct patients to report pregnancies to their physicians as soon as possible."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "benazepril",
      "lotensin",
      "antihypertensive"
    ]
  },
  {
    "slug": "ethinyl-estradiol-norgestimate",
    "name": "Ethinyl Estradiol + Norgestimate (Ortho Tri Cyclen)",
    "class": "Birth Control",
    "summary": "1 INDICATIONS AND USAGE Iclevia TM (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. Iclevia is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day for 91 days. (2.1) Take tablets in the order directed on the Extended-Cycle Wallet. (2.2) 2.1 How to Start and Take Iclevia Iclevia is dispensed in an Extended-Cycle Wallet [see How Supplied/Storage and Handling (16) ]. Iclevia should be started on a Sunday (see Table 1).",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Cigarette Smoking Cigarette smoking increases the risk of serious cardiovascular events from COC use.",
      "Women who are over 35 years old and smoke should not use Iclevia [see Boxed Warning and Warnings and Precautions (5.1) ]."
    ],
    "tags": [
      "Birth Control"
    ],
    "keywords": [
      "ethinyl",
      "estradiol",
      "norgestimate",
      "ortho",
      "tri",
      "cyclen",
      "birth",
      "control"
    ]
  },
  {
    "slug": "metoclopramide",
    "name": "Metoclopramide (Reglan)",
    "class": "GI motility stimulant",
    "summary": "INDICATIONS AND USAGE The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration.",
    "dose": "DOSAGE AND ADMINISTRATION Therapy with metoclopramide oral solution should not exceed 12 weeks in duration. For the Relief of Symptomatic Gastroesophageal Reflux Administer from 10 mg to 15 mg metoclopramide orally up to 4 times daily 30 minutes before each meal and at bedtime, depending upon symptoms being treated and clinical response (see CLINICAL PHARMACOLOGY and INDICATIONS AND USAGE ).",
    "renal": "The average elimination half-life in individuals with normal renal function is 5 to 6 hours.",
    "monitoring": "WARNINGS Mental depression has occurred in patients with and without prior history of depression. Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.",
    "pearls": [
      "Information for Patients The use of metoclopramide oral solution is recommended for adults only.",
      "Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle.",
      "The ambulatory patient should be cautioned accordingly."
    ],
    "tags": [
      "GI Motility Stimulant"
    ],
    "keywords": [
      "metoclopramide",
      "reglan",
      "gi",
      "motility",
      "stimulant"
    ]
  },
  {
    "slug": "risperidone",
    "name": "Risperidone (Risperdal)",
    "class": "Antipsychotic",
    "summary": "1 INDICATIONS AND USAGE Risperidone tablets are an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia Risperidone tablets are indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Table 1. Recommended Daily Dosage by Indication Initial Dose Titration (Increments) Target Dose Effective Dose Range Schizophrenia: adults ( 2.1 ) 2 mg 1 to 2 mg 4 to 8 mg 4 to 16 mg Schizophrenia: adolescents ( 2.2 ) 0.5 mg 0.5 to 1 mg 3 mg 1 to 6 mg Bipolar mania: adults ( 2.2 ) 2 to 3 mg 1 mg 1 to 6 mg 1 to 6 mg Bipolar mania: children and adolescents ( 2.2 ) 0.5 mg 0.5 to 1 mg 1 to 2.5 mg 1 to 6 mg Irritability in autistic disorder ( 2.3 ) 0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg) 0.5 mg Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg) After Day 4, at intervals of > 2 weeks: 0.25 mg (body weight less than 20 kg) 0.5 mg (body weight greater than or equal to 20 kg) 0.5 mg: (body weight less than 20 kg) 1 mg: (body weight greater than or equal to 20 kg) 0.5 to 3 mg Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily.",
    "renal": "In general, a lower starting dose is recommended for an elderly patient, reflecting a decreased pharmacokinetic clearance in the elderly, as well as a greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) and Dosage & Administration (2.4 , 2.5) ] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Physicians are advised to discuss the following issues with patients for whom they prescribe risperidone tablets.",
      "Neuroleptic Malignant Syndrome (NMS) Counsel patients about a potentially fatal adverse reaction, Neuroleptic Malignant Syndrome (NMS), that has been reported in association with administration of antipsychotic drugs.",
      "Tardive Dyskinesia Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur [see Warnings and Precautions ( 5.4 )] ."
    ],
    "tags": [
      "Antipsychotic"
    ],
    "keywords": [
      "risperidone",
      "risperdal",
      "antipsychotic"
    ]
  },
  {
    "slug": "tiotropium",
    "name": "Tiotropium (Spiriva)",
    "class": "Reduces mucus secretion/bronchodilator",
    "summary": "1 INDICATIONS AND USAGE STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) 1.1 Maintenance Treatment of COPD STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use STIOLTO RESPIMAT is not indicated to treat acute deteriorations of COPD [see Warnings and Precautions (5.2) ].",
    "dose": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. Two inhalations of STIOLTO RESPIMAT once-daily at the same time of day. ( 2 ) 2.1 Recommended Dosage The recommended dosage of STIOLTO RESPIMAT is two inhalations once-daily at the same time of the day.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Patients with moderate to severe renal impairment should be monitored closely for potential anticholinergic side effects. ( 2 , 8.7 ) 8.1 Pregnancy Risk Summary There are no adequate and well-controlled clinical studies with STIOLTO RESPIMAT or its individual components, tiotropium bromide and olodaterol, in pregnant women to inform of drug-associated risk of adverse pregnancy-related outcomes.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Serious Asthma-Related Events Inform patients that LABA, such as STIOLTO RESPIMAT, when used as monotherapy [without an inhaled corticosteroid], increase the risk of serious asthma-related events, including asthma-related death.",
      "STIOLTO RESPIMAT is not indicated for the treatment of asthma."
    ],
    "tags": [
      "Reduces Mucus Secretion",
      "Bronchodilator"
    ],
    "keywords": [
      "tiotropium",
      "spiriva",
      "reduces",
      "mucus",
      "secretion",
      "bronchodilator"
    ]
  },
  {
    "slug": "verapamil",
    "name": "Verapamil (Verelan)",
    "class": "Anti-arrhythmia",
    "summary": "INDICATIONS AND USAGE Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2.",
    "dose": "DOSAGE AND ADMINISTRATION The dose of verapamil must be individualized by titration. The usefulness and safety of dosages exceeding 480 mg/day have not been established; therefore, this daily dosage should not be exceeded.",
    "renal": "Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.",
    "monitoring": "WARNINGS Heart failure: Verapamil has a negative inotropic effect, which in most patients is compensated by its afterload reduction (decreased systemic vascular resistance) properties without a net impairment of ventricular performance. In clinical experience with 4,954 patients, 87 (1.8%) developed congestive heart failure or pulmonary edema.",
    "pearls": [
      "General Use in patients with impaired hepatic function: Since verapamil is highly metabolized by the liver, it should be administered cautiously to patients with impaired hepatic function.",
      "Severe liver dysfunction prolongs the elimination half-life of verapamil to about 14 to 16 hours; hence, approximately 30% of the dose given to patients with normal liver function should be administered to these patients.",
      "Careful monitoring for abnormal prolongation of the PR interval or other signs of excessive pharmacologic effects (see OVERDOSAGE ) should be carried out."
    ],
    "tags": [
      "Anti-arrhythmia"
    ],
    "keywords": [
      "verapamil",
      "verelan",
      "anti-arrhythmia"
    ]
  },
  {
    "slug": "hydroxyzine",
    "name": "Hydroxyzine (Vistaril)",
    "class": "Antihistamine",
    "summary": "INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.",
    "dose": "DOSAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 mg to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.",
    "pearls": [],
    "tags": [
      "Antihistamine"
    ],
    "keywords": [
      "hydroxyzine",
      "vistaril",
      "antihistamine"
    ]
  },
  {
    "slug": "meclizine",
    "name": "Meclizine (Antivert)",
    "class": "Antivertigo",
    "summary": "Uses For the prevention and treatment of nausea, vomiting or dizziness associated with motion sickness. For other uses consult your doctor",
    "dose": "Directions take dose one hour before travel starts tablets can be chewed or swallowed whole with water adults & children 12 years and over: take 1-2 tablets once daily children under 12 years: ask a doctor",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Ask a doctor before use if you have glaucoma a breathing problem such as emphysema or chronic bronchitis trouble urinating due to an elarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product you may get drowsy avoid alcoholic drinks alcohol, sedatives and tranquilizers may increse drowsiness be careful when driving a moor vehicle or operating machinery",
    "pearls": [],
    "tags": [
      "Antivertigo"
    ],
    "keywords": [
      "meclizine",
      "antivert",
      "antivertigo"
    ]
  },
  {
    "slug": "buspirone",
    "name": "Buspirone (BuSpar)",
    "class": "Antianxiety",
    "summary": "INDICATIONS AND USAGE Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.",
    "dose": "DOSAGE AND ADMINISTRATION The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed.",
    "renal": "Renal Impairment After multiple-dose administration of buspirone to renally impaired (Cl cr =10-70 mL/min/1.73 m 2 ) patients, steady state AUC of buspirone increased 4-fold compared with healthy (Cl cr ≥80 mL/min/1.73 m 2 ) subjects (see PRECAUTIONS ).",
    "monitoring": "WARNINGS The administration of buspirone hydrochloride tablets to a patient taking a monoamine oxidase inhibitor (MAOI) may pose a hazard. There have been reports of the occurrence of elevated blood pressure when buspirone hydrochloride has been added to a regimen including an MAOI.",
    "pearls": [
      "Information for Patients To assure safe and effective use of buspirone hydrochloride tablets, the following information and instructions should be given to patients: 1.",
      "Do not take a monoamine oxidase inhibitor (MAOI).",
      "Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid."
    ],
    "tags": [
      "Antianxiety"
    ],
    "keywords": [
      "buspirone",
      "buspar",
      "antianxiety"
    ]
  },
  {
    "slug": "diltiazem",
    "name": "Diltiazem (Cardizem)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.",
    "dose": "DOSAGE AND ADMINISTRATION Patients controlled on diltiazem alone or in combination with other medications may be switched to diltiazem hydrochloride extended-release capsules, USP at the nearest equivalent total daily dose. Higher doses of diltiazem hydrochloride extended-release capsules, USP may be needed in some patients.",
    "renal": "Diltiazem hydrochloride extended-release capsules reduce the renal and peripheral effects of angiotensin II.",
    "monitoring": "WARNINGS Cardiac Conduction : Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3290 patients or 0.40%).",
    "pearls": [],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "diltiazem",
      "cardizem",
      "antihypertensive"
    ]
  },
  {
    "slug": "doxazosin",
    "name": "Doxazosin (Cardura)",
    "class": "Reduces enlarged prostate",
    "summary": "1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION • For the treatment of BPH: Initiate therapy at 1 mg once daily. Dose may be titrated at 1 to 2 week intervals, up to 8 mg once daily.( 2.2 ) • For the treatment hypertension: Initiate therapy at 1 mg once daily.",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Advise patients to report symptoms to their healthcare provider.",
      "Priapism Advise patients of the possibility of priapism and to seek immediate medical attention if symptoms occur."
    ],
    "tags": [
      "Reduces Enlarged Prostate"
    ],
    "keywords": [
      "doxazosin",
      "cardura",
      "reduces",
      "enlarged",
      "prostate"
    ]
  },
  {
    "slug": "divalproex",
    "name": "Divalproex (Depakote)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Divalproex sodium extended-release tablets are indicated for: • Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) • Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Divalproex sodium extended-release tablets are a valproate and are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood.",
    "dose": "2 DOSAGE AND ADMINISTRATION Divalproex sodium extended-release tablets are an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed. • Divalproex sodium extended-release tablets are intended for once-a-day oral administration.",
    "renal": "Higher than expected free fractions occur in the elderly, in hyperlipidemic patients, and in patients with hepatic and renal diseases.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).",
      "Pancreatitis Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly [see Warnings and Precautions (5.5) ].",
      "Advise women to use effective contraception while taking valproate."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "divalproex",
      "depakote",
      "anticonvulsant"
    ]
  },
  {
    "slug": "tolterodine",
    "name": "Tolterodine (Detrol)",
    "class": "Urinary antispasmodic",
    "summary": "1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies (14) ] . Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION • 4 mg capsules taken orally once daily with water and swallowed whole. ( 2.1 ) • 2 mg capsules taken orally once daily with water and swallowed whole in the presence of: o mild to moderate hepatic impairment (Child-Pugh class A or B) ( 2.2 ) o severe renal impairment [Creatinine Clearance (CCr) 10-30 mL/min] ( 2.2 ) o drugs that are potent CYP3A4 inhibitors. ( 2.2 ) • Tolterodine tartrate extended-release capsules are not recommended for use in patients with CCr <10 mL/min. ( 2.2 ) • Tolterodine tartrate extended-release capsules are not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). ( 2.2 ) 2.1 Dosing Information The recommended dose of tolterodine tartrate extended-release capsules is 4 mg once daily with water and swallowed whole. The dose may be lowered to 2 mg daily based on individual response and tolerability; however, limited efficacy data are available for tolterodine tartrate extended-release capsules 2 mg [see Clinical Studies (14) ] .",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Renal Impairment: Tolterodine tartrate extended-release capsules are not recommended for use in patients with CCr <10 mL/min.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ).",
      "Antimuscarinic Effects Inform patients that antimuscarinic agents such as tolterodine tartrate extended-release capsules may have side effects including blurred vision, dizziness, or drowsiness.",
      "Advise patients not to drive, operate machinery, or do other potentially dangerous activities until they know how tolterodine tartrate extended-release capsules affects them."
    ],
    "tags": [
      "Urinary Antispasmodic"
    ],
    "keywords": [
      "tolterodine",
      "detrol",
      "urinary",
      "antispasmodic"
    ]
  },
  {
    "slug": "nitrofurantoin",
    "name": "Nitrofurantoin (Furadantin)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS & USAGE Nitrofurantoin is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli , Enterococcus species, Staphylococcus aureus , Klebsiella species and Enterobacter species. Limitations of Use Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)].",
    "dose": "2 DOSAGE & ADMINISTRATION Adult Patients: 50 mg to 100 mg four times a day -the lower dosage level is recommended for uncomplicated urinary tract infections. (2.2) Pediatric Patients: 5 mg/kg to 7 mg/kg of body weight per 24 hours, given in four divided doses (contraindicated under one month of age). (2.3) 2.1 Recommended Dosage and Administration in Adult Patients The recommended dosage is 50 mg to 100 mg of nitrofurantoin four times a day. For long-term suppressive therapy in adults, a reduction of dosage to 50 mg to 100 mg at bedtime may be adequate .",
    "renal": "Patients with Renal Impairment The reported urinary recoveries of nitrofurantoin after a single 100 mg oral dose and 100 mg four times a day in patients with varying renal function showed approximate linear relationship between the amount of nitrofurantoin recovered and creatinine clearance.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "nitrofurantoin",
      "furadantin",
      "antibiotic"
    ]
  },
  {
    "slug": "losartan-hctz",
    "name": "Losartan + HCTZ (Hyzaar)",
    "class": "Antihypertensive + diuretic",
    "summary": "1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.",
    "dose": "2 DOSAGE AND ADMINISTRATION Hypertension • Usual adult dose: 50 mg once daily. (2.1) • Usual pediatric starting dose: 0.7 mg per kg once daily (up to 50 mg). (2.1) Hypertensive Patients with Left Ventricular Hypertrophy • Usual starting dose: 50 mg once daily. (2.2) • Add hydrochlorothiazide 12.5 mg and/or increase losartan potassium to 100 mg followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. (2.2 , 14.2) Nephropathy in Type 2 Diabetic Patients • Usual dose: 50 mg once daily. (2.3) • Increase dose to 100 mg once daily if further blood pressure response is needed. (2.3) 2.1 Hypertension Adult Hypertension The usual starting dose of losartan potassium tablets is 50 mg once daily. The dosage can be increased to a maximum dose of 100 mg once daily as needed to control blood pressure [see Clinical Studies (14.1) ].",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ).",
      "Pregnancy Advise female patients of childbearing age about the consequences of exposure to losartan potassium during pregnancy.",
      "Discuss treatment options with women planning to become pregnant."
    ],
    "tags": [
      "Antihypertensive",
      "Diuretic"
    ],
    "keywords": [
      "losartan",
      "hctz",
      "hyzaar",
      "antihypertensive",
      "diuretic"
    ]
  },
  {
    "slug": "propranolol",
    "name": "Propranolol (Inderal)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic.",
    "dose": "DOSAGE AND ADMINISTRATION General Because of the variable bioavailability of propranolol, the dose should be individualized based on response. Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic.",
    "renal": "Factors that may contribute to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain.",
    "monitoring": "WARNINGS Angina Pectoris There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks and the patient should be cautioned against interruption or cessation of therapy without the physician’s advice.",
    "pearls": [
      "General Propranolol should be used with caution in patients with impaired hepatic or renal function.",
      "Propranolol is not indicated for the treatment of hypertensive emergencies.",
      "Beta-adrenergic receptor blockade can cause reduction of intraocular pressure."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "propranolol",
      "inderal",
      "antihypertensive"
    ]
  },
  {
    "slug": "sitagliptin",
    "name": "Sitagliptin (Januvia)",
    "class": "Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ZITUVIMET is not recommended in patients with type 1 diabetes mellitus. ( 1 ) ZITUVIMET has not been studied in patients with a history of pancreatitis. ( 1 ) ZITUVIMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ZITUVIMET is not recommended in patients with type 1 diabetes mellitus.",
    "dose": "2 DOSAGE AND ADMINISTRATION Take ZITUVIMET orally twice daily with meals. ( 2.1 ) Individualize the dosage of ZITUVIMET on the basis of the patient's current regimen, effectiveness, and tolerability. ( 2.1 ) The maximum recommended daily dose is 100 mg of sitagliptin and 2,000 mg of metformin HCl. ( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of ZITUVIMET is 50 mg sitagliptin and 1,000 mg metformin HCl twice daily. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) ○ Do not use in patients with eGFR below 30 mL/min/1.73 m 2 ○ ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 .",
    "renal": "8 USE IN SPECIFIC POPULATIONS Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. ( 8.3 ) Geriatric Use: Assess renal function more frequently. ( 8.5 ) Hepatic Impairment: Avoid use in patients with hepatic impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Available data with ZITUVIMET and sitagliptin use in pregnant women are not sufficient to inform a ZITUVIMET-associated or sitagliptin-associated risk for major birth defects and miscarriage.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Lactic Acidosis Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development.",
      "Advise patients to discontinue ZITUVIMET immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "sitagliptin",
      "januvia",
      "antidiabetic"
    ]
  },
  {
    "slug": "pramipexole",
    "name": "Pramipexole (Mirapex)",
    "class": "Anti-tremor (Parkinson's disease)",
    "summary": "1 INDICATIONS AND USAGE Pramipexole dihydrochloride extended-release tablets are indicated for the treatment of Parkinson's disease. Pramipexole dihydrochloride extended-release tablet is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease (PD) (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION Pramipexole dihydrochloride extended-release tablets are taken once daily, with or without food (2.1) Tablets must be swallowed whole and must not be chewed, crushed, or divided (2.1) Starting dose is 0.375 mg given once daily (2.2) Dose may be increased gradually, not more frequently than every 5 to 7 days, first to 0.75 mg per day and then by 0.75 mg increments up to a maximum recommended dose of 4.5 mg per day. Assess therapeutic response and tolerability at a minimal interval of 5 days or longer after each dose increment. (2.2) Patients may be switched overnight from immediate-release pramipexole tablets to extended-release pramipexole tablets at the same daily dose.",
    "renal": "8.5 Geriatric Use Pramipexole total oral clearance is approximately 30% lower in subjects older than 65 years compared with younger subjects, because of a decline in pramipexole renal clearance due to an age-related reduction in renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Dosing Instructions Instruct patients to take pramipexole dihydrochloride extended-release tablets only as prescribed.",
      "If a dose is missed, pramipexole dihydrochloride extended-release tablets should be taken as soon as possible, but no later than 12 hours after the regularly scheduled time."
    ],
    "tags": [
      "Anti-tremor"
    ],
    "keywords": [
      "pramipexole",
      "mirapex",
      "anti-tremor",
      "(parkinson's",
      "disease)"
    ]
  },
  {
    "slug": "apixaban",
    "name": "Apixaban (Eliquis)",
    "class": "Anticoagulant",
    "summary": "1 INDICATIONS & USAGE Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.",
    "dose": "2 DOSAGE & ADMINISTRATION Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily. ( 2.1 ) In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. ( 2.1 ) Prophylaxis of DVT following hip or knee replacement surgery: The recommended dose is 2.5 mg orally twice daily. ( 2.1 ) Treatment of DVT and PE: The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily. ( 2.1 ) Reduction in the risk of recurrent DVT and PE following initial therapy: The recommended dose is 2.5 mg taken orally twice daily. ( 2.1 ) 2.1 Recommended Dose Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The recommended dose of apixaban tablets for most patients is 5 mg taken orally twice daily. The recommended dose of apixaban tablets is 2.5 mg twice daily in patients with at least two of the following characteristics: • age greater than or equal to 80 years • body weight less than or equal to 60 kg • serum creatinine greater than or equal to 1.5 mg/dL Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery The recommended dose of apixaban tablets is 2.5 mg taken orally twice daily.",
    "renal": "8.6 Renal Impairment Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The recommended dose is 2.5 mg twice daily in patients with at least two of the following characteristics [see Dosage and Administration ( 2.1 )]: • age greater than or equal to 80 years • body weight less than or equal to 60 kg • serum creatinine greater than or equal to 1.5 mg/dL Patients with End-Stage Renal Disease on Dialysis Clinical efficacy and safety studies with apixaban did not enroll patients with end-stage renal disease (ESRD) on dialysis.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients to read the FDA-approved patient labeling (Medication Guide).",
      "Advise patients of the following: Not to discontinue apixaban without talking to their physician first.",
      "That it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with apixaban ."
    ],
    "tags": [
      "Anticoagulant"
    ],
    "keywords": [
      "apixaban",
      "eliquis",
      "anticoagulant"
    ]
  },
  {
    "slug": "mirtazapine",
    "name": "Mirtazapine (Remeron)",
    "class": "Antidepressant",
    "summary": "1 INDICATIONS AND USAGE Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ]. Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION • Starting dose: 15 mg once daily; may increase up to maximum recommended dose of 45 mg once daily. ( 2.1 ) • Administer orally once daily, preferably in the evening prior to sleep. ( 2.1 ) • Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.13 ) 2.1 Recommended Dosage The recommended starting dose of mirtazapine tablets is 15 mg once daily, administered orally, preferably in the evening prior to sleep. If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day.",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Pregnancy : Use only if clearly needed. ( 8.1 ) • Nursing Mothers: Caution should be exercised when administered to a nursing woman. ( 8.3 ) • Geriatric Use : Use with caution in elderly patients. ( 5.11 , 5.14 , 8.5 ) • Renal impairment: Dosage decrease may be needed in patients with moderate to severe renal impairment. ( 8.6 ) • Hepatic impairment : Dosage decrease may be needed in patients with hepatic impairment. ( 8.6 ) 8.1 Pregnancy Reproduction studies in pregnant rats and rabbits at doses up to 100 mg/kg and 40 mg/kg, respectively [20 and 17 times the maximum recommended human dose (MRHD) on an mg/m 2 basis, respectively], have revealed no evidence of teratogenic effects.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Error!",
      "Hyperlink reference not valid. ).",
      "John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid)."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "mirtazapine",
      "remeron",
      "antidepressant"
    ]
  },
  {
    "slug": "guaifenesin",
    "name": "Guaifenesin (Robitussin)",
    "class": "Anti-mucus (expectorant)",
    "summary": "Uses Uses: temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes.",
    "dose": "Directions Do not give more than 6 doses in any 24 hours period  shake well before use  measure only with dosing cup provided  keep dosing cup with product  mL = milliliter Age Dose Children 6 to under 12 years of age 5 mL every 4 hours Children 4 to under 6 years of age 2.5 mL every 4 hours Children under 4 years of age Do not use",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings Do not use in child who is taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional condition, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your child’s prescription drug contains an MAOI, ask a doctor or pharmacist before giving this product.",
    "pearls": [],
    "tags": [
      "Anti-mucus"
    ],
    "keywords": [
      "guaifenesin",
      "robitussin",
      "anti-mucus",
      "(expectorant)"
    ]
  },
  {
    "slug": "buprenorphine-naloxone",
    "name": "Buprenorphine + Naloxone (Suboxone)",
    "class": "Opioid Recovery",
    "summary": "1 INDICATIONS AND USAGE Buprenorphine sublingual tablet is indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablet should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer buprenorphine sublingual tablet sublingually as a single daily dose. (2.1) Strongly consider prescribing naloxone at the time buprenorphine sublingual tablet is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. (2.2) To avoid precipitating withdrawal, induction with buprenorphine sublingual tablet should be undertaken when objective and clear signs of withdrawal are evident. (2.3) Buprenorphine and naloxone sublingual film or buprenorphine and naloxone sublingual tablet is generally initiated after two days of buprenorphine sublingual tablet titration. (2.4) Administer buprenorphine sublingual tablets as directed in the Full Prescribing Information. (2.3, 2.4, 2.5) Buprenorphine sublingual tablet must be administered whole. Do not cut, chew, or swallow buprenorphine sublingual tablets. (2.5) When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. (2.9) 2.1 Important Dosage and Administration Instructions Buprenorphine sublingual tablet is administered sublingually as a single daily dose.",
    "renal": "Due to possible decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in geriatric patients, the decision to prescribe buprenorphine sublingual tablets should be made cautiously in individuals 65 years of age or older and these patients should be monitored for signs and symptoms of toxicity or overdose.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise patients to read the FDA-approved patient labeling (Medication Guide).",
      "Inform patients that leaving buprenorphine sublingual tablets unsecured can pose a deadly risk to others in the home.",
      "Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly."
    ],
    "tags": [
      "Opioid Recovery",
      "C-III"
    ],
    "keywords": [
      "buprenorphine",
      "naloxone",
      "suboxone",
      "opioid",
      "recovery",
      "c-iii"
    ]
  },
  {
    "slug": "topiramate",
    "name": "Topiramate (Topamax)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older (1.1); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy Topiramate tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older.",
    "dose": "2 DOSAGE AND ADMINISTRATION Topiramate tablets initial dose, titration, and recommended maintenance dose varies by indication and age group. See Full Prescribing Information for recommended dosage, and dosing considerations in patients with renal impairment, geriatric patients, and patients undergoing hemodialysis ( 2.1 , 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) 2.1 Dosing in Monotherapy Epilepsy Adults and Pediatric Patients 10 Years of Age and Older The recommended dose for topiramate tablets monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses.",
    "renal": "Topiramate resulted in an increased incidence of patients with increased creatinine (any topiramate dose 5%, placebo 0%), BUN (any topiramate dose 3%, placebo 0%), and protein (any topiramate dose 34%, placebo 6%), and an increased incidence of decreased potassium (any topiramate dose 7%, placebo 0%).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Eye Disorders Instruct patients taking topiramate to seek immediate medical attention if they experience blurred vision, visual disturbances, or periorbital pain [see Warnings and Precautions ( 5.1 , 5.2 )] .",
      "Oligohidrosis and Hyperthermia Closely monitor topiramate-treated patients, especially pediatric patients, for evidence of decreased sweating and increased body temperature, especially in hot weather."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "topiramate",
      "topamax",
      "anticonvulsant"
    ]
  },
  {
    "slug": "lisdexamfetamine",
    "name": "Lisdexamfetamine (Vyvanse)",
    "class": "ADHD",
    "summary": "1 INDICATIONS AND USAGE Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1) ] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2) ] . Lisdexamfetamine dimesylate capsules are a central nervous system (CNS) stimulant indicated for the treatment of ( 1 ): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use : The use of lisdexamfetamine dimesylate capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ) Lisdexamfetamine dimesylate capsules are not indicated for weight loss.",
    "dose": "2 DOSAGE AND ADMINISTRATION Indicated Population Initial Dose Titration Schedule Recommended Dose Maximum Dose ADHD (Adults and pediatric patients 6 years and older) ( 2.2 ) 30 mg every morning 10 mg or 20 mg weekly 30 mg to 70 mg per day 70 mg per day BED (Adults) ( 2.3 ) 30 mg every morning 20 mg weekly 50 mg to 70 mg per day 70 mg per day Prior to treatment, assess for presence of cardiac disease ( 2.4 ) Severe renal impairment: Maximum dose is 50 mg/day ( 2.5 ) End stage renal disease (ESRD): Maximum dose is 30 mg/day ( 2.5 ) 2.1 Pretreatment Screening Prior to treating patients with lisdexamfetamine dimesylate capsules, assess: for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2) ] . the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating lisdexamfetamine dimesylate capsules [see Warnings and Precautions (5.8) ] 2.2 General Instructions for Use Take lisdexamfetamine dimesylate capsules orally in the morning with or without food; avoid afternoon doses because of the potential for insomnia. Lisdexamfetamine dimesylate capsules may be administered in one of the following ways: Information for lisdexamfetamine dimesylate capsules: Swallow lisdexamfetamine dimesylate capsules whole, or Open capsules, empty and mix the entire contents with yogurt, water, or orange juice.",
    "renal": "In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Advise patients to store lisdexamfetamine dimesylate capsules in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate capsules to anyone else.",
      "Risks to Patients with Serious Cardiac Disease Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with lisdexamfetamine dimesylate capsules use."
    ],
    "tags": [
      "ADHD",
      "C-II"
    ],
    "keywords": [
      "lisdexamfetamine",
      "vyvanse",
      "adhd",
      "c-ii"
    ]
  },
  {
    "slug": "bupropion",
    "name": "Bupropion (Wellbutrin)",
    "class": "Antidepressant",
    "summary": "1 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) (1.1) prevention of seasonal affective disorder (SAD) ( 1.2) 1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD.",
    "dose": "2 DOSAGE AND ADMINISTRATION General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder Initiate treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) Starting dose: 150 mg once daily.",
    "renal": "Bupropion is extensively metabolized in the liver to active metabolites, which are further metabolized and excreted by the kidneys.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Advise families and caregivers of patients to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.",
      "Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms."
    ],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "bupropion",
      "wellbutrin",
      "antidepressant"
    ]
  },
  {
    "slug": "latanoprost",
    "name": "Latanoprost (Xalatan)",
    "class": "Antiglaucoma",
    "summary": "1 INDICATIONS AND USAGE Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal.",
    "renal": "Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Potential for Pigmentation Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent.",
      "Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of latanoprost ophthalmic solution [see Warnings and Precautions (5.1) ] .",
      "Potential for Eyelash Changes Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with latanoprost ophthalmic solution."
    ],
    "tags": [
      "Antiglaucoma"
    ],
    "keywords": [
      "latanoprost",
      "xalatan",
      "antiglaucoma"
    ]
  },
  {
    "slug": "acyclovir",
    "name": "Acyclovir (Zovirax)",
    "class": "Antiviral",
    "summary": "INDICATIONS AND USAGE Herpes Zoster Infections : Acyclovir is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes : Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.",
    "dose": "DOSAGE AND ADMINISTRATION Acute Treatment of Herpes Zoster : 800 mg every 4 hours orally, 5 times daily for 7 to 10 days. Genital Herpes : Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days.",
    "renal": "Special Populations: Adults with Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function.",
    "monitoring": "WARNINGS Acyclovir capsules are intended for oral ingestion only. Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS: Observed During Clinical Practice and OVERDOSAGE ).",
    "pearls": [
      "Patients should be advised to maintain adequate hydration.",
      "Herpes Zoster : There are no data on treatment initiated more than 72 hours after onset of the zoster rash.",
      "Patients should be advised to initiate treatment as soon as possible after a diagnosis of herpes zoster."
    ],
    "tags": [
      "Antiviral"
    ],
    "keywords": [
      "acyclovir",
      "zovirax",
      "antiviral"
    ]
  },
  {
    "slug": "quinapril",
    "name": "Quinapril (Accupril)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Hypertension Quinapril tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.",
    "dose": "DOSAGE AND ADMINISTRATION Hypertension Monotherapy: The recommended initial dosage of quinapril in patients not on diuretics is 10 or 20 mg once daily. Dosage should be adjusted according to blood pressure response measured at peak (2–6 hours after dosing) and trough (predosing).",
    "renal": "Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.",
    "monitoring": "WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue quinapril as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because ACE inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including quinapril) may be subject to a variety of adverse reactions, some of them serious.",
    "pearls": [
      "Pediatric Use Neonates with a history of in utero exposure to quinapril : If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.",
      "Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.",
      "Removal of quinapril, which crosses the placenta, from the neonatal circulation is not significantly accelerated by these means."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "quinapril",
      "accupril",
      "antihypertensive"
    ]
  },
  {
    "slug": "rabeprazole",
    "name": "Rabeprazole (Aciphex)",
    "class": "Antacid (PPI)",
    "summary": "1 INDICATIONS AND USAGE Rabeprazole sodium delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication Recommended Dosage ( 2 ) Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily for 4 to 8 weeks Maintenance of Healing of Erosive or Ulcerative GERD* studied for 12 months 20 mg once daily* Symptomatic GERD in Adults 20 mg once daily for 4 weeks Healing of Duodenal Ulcers 20 mg once daily after morning meal for up to 4 weeks Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Three Drug Regimen: Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1,000 mg Clarithromycin 500 mg All three medications should be taken twice daily with morning and evening meals for 7 days. Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs Symptomatic GERD in Adolescents 12 Years of Age and Older 20 mg once daily for up to 8 weeks Administration Instructions ( 2 ) : Swallow rabeprazole sodium delayed-release tablets whole.",
    "renal": "Other Effects In humans treated with rabeprazole sodium delayed-release tablets for up to one year, no systemic effects have been observed on the central nervous, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Clostridium difficile -Associated Diarrhea Advise the patient or caregiver to immediately call the patient's healthcare provider if they experience diarrhea that does not improve [see Warnings and Precautions ( 5.4 )].",
      "Bone Fracture Advise the patient or caregiver to report any fractures, especially of the hip, wrist or spine, to the patient's healthcare provider [see Warnings and Precautions ( 5.5 )]."
    ],
    "tags": [
      "Antacid"
    ],
    "keywords": [
      "rabeprazole",
      "aciphex",
      "antacid",
      "(ppi)"
    ]
  },
  {
    "slug": "irbesartan",
    "name": "Irbesartan (Avapro)",
    "class": "Antihypertensive",
    "summary": "1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication Dose Hypertension ( 2.2 ) 150 to 300 mg once daily Diabetic Nephropathy ( 2.3 ) 300 mg once daily 2.1 General Considerations Irbesartan tablets may be administered with other antihypertensive agents and with or without food. 2.2 Hypertension The recommended initial dose of irbesartan tablets is 150 mg once daily.",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death [see Clinical Considerations] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Pregnancy Advise female patients of childbearing age about the consequences of exposure to irbesartan tablets during pregnancy.",
      "Discuss treatment options with women planning to become pregnant.",
      "Patients should be asked to report pregnancies to their physicians as soon as possible."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "irbesartan",
      "avapro",
      "antihypertensive"
    ]
  },
  {
    "slug": "mupirocin",
    "name": "Mupirocin (Bactroban)",
    "class": "Topical antibacterial",
    "summary": "1 INDICATIONS AND USAGE Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes) . Mupirocin cream is an RNA synthetase inhibitor antibacterial indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes . ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION For Topical Use Only. Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days.",
    "renal": "Excretion : Monic acid is predominantly eliminated by renal excretion.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Advise the patient to administer mupirocin cream as follows: Use mupirocin cream only as directed by the healthcare provider.",
      "It is for external use only."
    ],
    "tags": [
      "Topical Antibacterial"
    ],
    "keywords": [
      "mupirocin",
      "bactroban",
      "topical",
      "antibacterial"
    ]
  },
  {
    "slug": "ibandronate",
    "name": "Ibandronate (Boniva)",
    "class": "Bone strengthener",
    "summary": "1 INDICATIONS AND USAGE Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. ( 1.1 ). Limitations of Use The optimal duration of use has not been determined.",
    "dose": "2 DOSAGE AND ADMINISTRATION Take one 150 mg tablet once monthly on the same day each month ( 2.1 ) Instruct patient to: ( 2.2 ) Swallow whole tablet with 6 to 8 oz of plain water only, at least 60 minutes before the first food, beverage, or medication of day. Avoid lying down for at least 60 minutes after taking ibandronate sodium tablets.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Ibandronate sodium tablets are not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min). ( 5.6 , 8.6 ) 8.1 Pregnancy Risk Summary Ibandronate sodium tablets is not indicated for use in women of reproductive potential.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Patients should not lie down for 60 minutes after taking ibandronate sodium tablets.",
      "Patients should not eat, drink anything except for water, or take other medications for 60 minutes after taking ibandronate sodium tablets.",
      "Plain water is the only drink that should be taken with ibandronate sodium tablets."
    ],
    "tags": [
      "Bone Strengthener"
    ],
    "keywords": [
      "ibandronate",
      "boniva",
      "bone",
      "strengthener"
    ]
  },
  {
    "slug": "albuterol-ipratropium",
    "name": "Albuterol + Ipratropium (Combivent)",
    "class": "Bronchodilator/anti-mucus",
    "summary": "1 INDICATIONS AND USAGE Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.",
    "dose": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. For some patients, 1 inhalation every 4 hours may be sufficient. ( 2.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation 15 to 30 minutes before exercise. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Frequency of Use Inform patients that the action of Albuterol Sulfate HFA should last up to 4 to 6 hours.",
      "Do not use Albuterol Sulfate HFA more frequently than recommended."
    ],
    "tags": [
      "Bronchodilator",
      "Anti-mucus"
    ],
    "keywords": [
      "albuterol",
      "ipratropium",
      "combivent",
      "bronchodilator",
      "anti-mucus"
    ]
  },
  {
    "slug": "fentanyl-transdermal-patch",
    "name": "Fentanyl Transdermal Patch (Duragesic)",
    "class": "Analgesic",
    "summary": "Review prescribing info for Fentanyl Transdermal Patch.",
    "dose": "See full prescribing information for dosing details.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Analgesic",
      "C-II"
    ],
    "keywords": [
      "fentanyl",
      "transdermal",
      "patch",
      "duragesic",
      "analgesic",
      "c-ii"
    ]
  },
  {
    "slug": "mirabegron",
    "name": "Mirabegron (Myrbetriq)",
    "class": "Overactive bladder",
    "summary": "1 INDICATIONS AND USAGE Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Extended-Release Tablets Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Pediatric use information is approved for Astellas Pharma Global Development, Inc.'s MYRBETRIQ (mirabegron extended-release tablets).",
    "dose": "2 DOSAGE AND ADMINISTRATION Mirabegron extended-release tablets and mirabegron for extended-release oral suspension are two different products and they are not substitutable on a milligram-per-milligram basis. Select the recommended product (mirabegron extended-release tablets or mirabegron for extended-release oral suspension) based on the indication.",
    "renal": "8.6 Renal Impairment Mirabegron extended-release tablets have not been studied in patients with End-Stage Renal Disease (eGFR <15 mL/min/1.73 m 2 ) or patients requiring hemodialysis and, therefore, is not recommended for use in these patient populations.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information).",
      "Increases in Blood Pressure Inform patients and/or their caregivers that mirabegron extended-release tablets may increase blood pressure.",
      "Advise patients, especially patients with hypertension, to periodically monitor their blood pressure and report increased measurement to their health care provider [see Warnings and Precautions ( 5.1 )]."
    ],
    "tags": [
      "Overactive Bladder"
    ],
    "keywords": [
      "mirabegron",
      "myrbetriq",
      "overactive",
      "bladder"
    ]
  },
  {
    "slug": "butalbital-apap-caffeine",
    "name": "Butalbital/apap/caffeine (Fioricet)",
    "class": "Antimigraine",
    "summary": "INDICATIONS AND USAGE Fioricet is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable.",
    "dose": "DOSAGE AND ADMINISTRATION 1 or 2 capsules every 4 hours as needed. Total daily dosage should not exceed 6 capsules.",
    "renal": "Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites.",
    "monitoring": "WARNINGS Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.",
    "pearls": [
      "Information for Patients This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.",
      "Such tasks should be avoided while taking this product.",
      "Alcohol and other CNS depressants may produce an additive CNS depression when taken with this combination product, and should be avoided."
    ],
    "tags": [
      "Antimigraine"
    ],
    "keywords": [
      "butalbital",
      "apap",
      "caffeine",
      "fioricet",
      "antimigraine"
    ]
  },
  {
    "slug": "polyethylene-glycol",
    "name": "Polyethylene Glycol (Glycolax)",
    "class": "Laxative",
    "summary": "Uses for protection against further irritation for temporary relief of burning and irritation due to dryness of the eye",
    "dose": "Directions instill 1 to 2 drops in the affected eye(s) as needed",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Warnings For external use only Do not use this product if solution changes color or becomes cloudy When using this product to avoid contamination, do not touch tip of container to any surface. Replace cap after using. remove contact lenses before using Stop use and ask a doctor if you experience eye pain changes in vision continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours If pregnant or breast-feeding, ask a health professional before use.",
    "pearls": [],
    "tags": [
      "Laxative"
    ],
    "keywords": [
      "polyethylene",
      "glycol",
      "glycolax",
      "laxative"
    ]
  },
  {
    "slug": "terazosin",
    "name": "Terazosin (Hytrin)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules.",
    "dose": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. Benign Prostatic Hyperplasia Initial Dose : 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose.",
    "renal": "Impaired renal function had no significant effect on the elimination of terazosin, and dosage adjustment of terazosin to compensate for the drug removal during hemodialysis (approximately 10%) does not appear to be necessary.",
    "monitoring": "WARNINGS Syncope and “First-dose” Effect Terazosin capsules, like other alpha-adrenergic blocking agents, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy. A similar effect can be anticipated if therapy is interrupted for several days and then restarted.",
    "pearls": [
      "They should be cautioned to avoid situations where injury could result should syncope occur during initiation of terazosin therapy.",
      "They should also be advised of the need to sit or lie down when symptoms of lowered blood pressure occur, although these symptoms are not always orthostatic, and to be careful when rising from a sitting or lying position.",
      "If dizziness, lightheadedness, or palpitations are bothersome they should be reported to the physician, so that dose adjustment can be considered."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "terazosin",
      "hytrin",
      "antihypertensive"
    ]
  },
  {
    "slug": "sumatriptan",
    "name": "Sumatriptan (Imitrex)",
    "class": "Antimigraine",
    "summary": "1 INDICATIONS AND USAGE Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: • Use only if a clear diagnosis of migraine or cluster headache has been established.",
    "dose": "2 DOSAGE AND ADMINISTRATION • For subcutaneous use only (2.1) • Acute treatment of migraine: single dose of 1 to 6 mg (2.1) • Acute treatment of cluster headache: single dose of 6 mg (2.1) • Maximum dose in a 24-hour period: 12 mg, separate doses by at least 1 hour (2.1) • Patients receiving doses other than 4 or 6 mg: Use the 6-mg single-dose vial (2.3) 2.1 Dosing Information The maximum single recommended adult dose of Sumatriptan injection, USP for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the treatment of migraine, if side effects are dose limiting, lower doses (1 mg to 5 mg) may be used [see Clinical Studies (14.1)].",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Apprise patients of the importance of this follow-up [see Warnings and Precautions (5.1, 5.2, 5.4, 5.5, 5.8)].",
      "Hypersensitivity Reactions Inform patients that anaphylactic reactions have occurred in patients receiving sumatriptan injection."
    ],
    "tags": [
      "Antimigraine"
    ],
    "keywords": [
      "sumatriptan",
      "imitrex",
      "antimigraine"
    ]
  },
  {
    "slug": "guanfacine",
    "name": "Guanfacine (Tenex)",
    "class": "Antihypertensive and attention deficit hyperactivity disorder (ADHD)",
    "summary": "1 INDICATIONS AND USAGE Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)] . Guanfacine extended-release tablets are a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications (1, 14).",
    "dose": "2 DOSAGE AND ADMINISTRATION Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability (2.2). Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week (2.2).",
    "renal": "8.6 Renal Impairment It may be necessary to reduce the dosage in patients with significant impairment of renal function [see Clinical Pharmacology (12.3)] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Dosing and Administration Instruct patients to swallow guanfacine extended-release tablets whole with water, milk or other liquid.",
      "Tablets should not be crushed, chewed or broken prior to administration because this may increase the rate of release of the active drug ."
    ],
    "tags": [
      "Antihypertensive",
      "Attention Deficit Hyperactivity Disorder"
    ],
    "keywords": [
      "guanfacine",
      "tenex",
      "antihypertensive",
      "and",
      "attention",
      "deficit",
      "hyperactivity",
      "disorder",
      "(adhd)"
    ]
  },
  {
    "slug": "carbamazepine",
    "name": "Carbamazepine (Tegretol)",
    "class": "Anticonvulsant",
    "summary": "INDICATIONS AND USAGE Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1.",
    "dose": "DOSAGE AND ADMINISTRATION (SEE TABLE BELOW) Carbamazepine suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs (see PRECAUTIONS, Drug Interactions). Because the extent to which this occurs with other liquid medications is not known, Carbamazepine suspension should not be administered simultaneously with other liquid medications or diluents.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "carbamazepine",
      "tegretol",
      "anticonvulsant"
    ]
  },
  {
    "slug": "methimazole",
    "name": "Methimazole (Tapazole)",
    "class": "Anti thyroid hormone",
    "summary": "INDICATIONS AND USAGE",
    "dose": "DOSAGE AND ADMINISTRATION",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS First Trimester Use of Methimazole and Congenital Malformations Methimazole crosses the placental membranes and can cause fetal harm when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole in the first trimester of pregnancy.",
    "pearls": [
      "Information for Patients Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy.",
      "Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole tablets.",
      "Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis (see WARNINGS and ADVERSE REACTIONS )."
    ],
    "tags": [
      "Anti Thyroid Hormone"
    ],
    "keywords": [
      "methimazole",
      "tapazole",
      "anti",
      "thyroid",
      "hormone"
    ]
  },
  {
    "slug": "famotidine",
    "name": "Famotidine (Pepcid)",
    "class": "Antacid",
    "summary": "1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence.",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication Recommended Dosage ( 2.1 ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily • See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1 , 2.2 ) Administration ( 2.3 ): • Take once daily before bedtime or twice daily in the morning and before bedtime with or without food. 2.1 Recommended Dosage Table 1 shows the recommended dosage of famotidine 20 mg and 40 mg tablets in adult and pediatric patients weighing 40 kg and greater with normal renal function.",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Geriatric Use: Use the lowest effective dose for an elderly patient and monitor renal function. ( 2.2 , 5.1 , 8.5 ) • Renal Impairment: Risk of CNS adverse reactions and QT prolongation in patients with moderate and severe renal impairment; reduce the dosage. ( 2.2 , 8.6 ) 8.1 Pregnancy Risk Summary Available data with H 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Report symptoms immediately to a healthcare provider.",
      "QT Prolongation Advise patients with moderate and severe renal impairment of the risk of QT interval prolongation [see Use in Specific Populations ( 8.6 )].",
      "Report new cardiac symptoms, such as palpitations, fainting and dizziness or lightheadedness immediately to a healthcare provider."
    ],
    "tags": [
      "Antacid"
    ],
    "keywords": [
      "famotidine",
      "pepcid",
      "antacid"
    ]
  },
  {
    "slug": "nifedipine",
    "name": "Nifedipine (Procardia)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm.",
    "dose": "DOSAGE AND ADMINISTRATION Dosage must be adjusted according to each patient's needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily.",
    "renal": "Thus, the pharmacokinetics of nifedipine are not significantly influenced by the degree of renal impairment.",
    "monitoring": "WARNINGS Excessive Hypotension Although in most angina patients the hypotensive effect of nifedipine is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.",
    "pearls": [
      "Information for Patients Nifedipine Extended-release Tablets should be swallowed whole.",
      "Do not chew, divide or crush tablets.",
      "Do not be concerned if you occasionally notice in your stool something that looks like a tablet."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "nifedipine",
      "procardia",
      "antihypertensive"
    ]
  },
  {
    "slug": "finasteride",
    "name": "Finasteride (Proscar)",
    "class": "Reduces enlarged prostate",
    "summary": "1 INDICATIONS & USAGE Finasteride tablets USP are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY. Efficacy in bitemporal recession has not been established.",
    "dose": "2 DOSAGE & ADMINISTRATION Finasteride tablets USP may be administered with or without meals. The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily.",
    "renal": "8.7 Renal Impairment No dosage adjustment is necessary in patients with renal impairment [ see Clinical Pharmacology (12.3) ].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Finasteride tablets USP are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.",
      "17.3 Additional Instructions Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain or nipple discharge.",
      "Breast changes including breast enlargement, tenderness and neoplasm have been reported [ see Adverse Reactions (6.1) ]."
    ],
    "tags": [
      "Reduces Enlarged Prostate"
    ],
    "keywords": [
      "finasteride",
      "proscar",
      "reduces",
      "enlarged",
      "prostate"
    ]
  },
  {
    "slug": "methotrexate",
    "name": "Methotrexate (Rheumatrex)",
    "class": "Antirheumatic",
    "summary": "1 INDICATIONS AND USAGE Methotrexate tablets are a diydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen (1.1) • Treatment of adults with mycosis fungoides (1.1) • Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen (1.1) • Treatment of adults with rheumatoid arthritis (1.2) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) (1.3) • Treatment of adults with severe psoriasis (1.4) 1.1 Neoplastic Diseases Methotrexate tablets are indicated for the: • treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen • treatment of adults with mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen • treatment of adults with relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen 1.2 Rheumatoid Arthritis Methotrexate tablets are indicated for the treatment of adults with rheumatoid arthritis. 1.3 Polyarticular Juvenile Idiopathic Arthritis Methotrexate tablets are indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA).",
    "dose": "2 DOSAGE AND ADMINISTRATION • Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths. (2.1, 5.9) • Verify pregnancy status in females of reproductive potential before starting methotrexate tablets. (4, 5.1) • ALL: The recommended dosage is 20 mg/m 2 orally once weekly as a part of a combination chemotherapy maintenance regimen. (2.2) • Mycosis fungoides: The recommended dosage is 25 to 75 mg orally once weekly as monotherapy; 10 mg/m 2 orally twice weekly as part of combination chemotherapy. (2.2) • Relapsed or refractory non-Hodgkin lymphoma: The recommended dosage is 2.5 mg orally two to four times per week as part of metronomic combination chemotherapy. (2.2) • Rheumatoid Arthritis: The recommended starting dosage is 7.5 mg orally once weekly; adjust dose to achieve an optimal response. (2.3) • pJIA: The recommended starting dosage is 10 mg/m 2 orally once weekly; adjust dose to achieve an optimal response. (2.4) • Psoriasis: The recommended dosage is 10 to 25 mg orally once weekly until adequate response is achieved. (2.5) 2.1 Important Dosage and Safety Information Verify pregnancy status in females of reproductive potential before starting methotrexate tablets [see Contraindications (4), Warnings and Precautions (5.1)]. Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths [see Warnings and Precautions (5.9)].",
    "renal": "8.6 Renal Impairment Methotrexate elimination is reduced in patients with renal impairment [see Clinical Pharmacology (12.3)] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Advise females of reproductive potential to use effective contraception during treatment with methotrexate tablets and for 6 months after the final dose [see Use in Specific Populations (8.3)] .",
      "Advise males of reproductive potential to use effective contraception during treatment with methotrexate tablets and for 3 months after the final dose [see Use in Specific Populations (8.3)] ."
    ],
    "tags": [
      "Antirheumatic"
    ],
    "keywords": [
      "methotrexate",
      "rheumatrex",
      "antirheumatic"
    ]
  },
  {
    "slug": "benzonatate",
    "name": "Benzonatate (Tessalon Perles)",
    "class": "Cough suppressant",
    "summary": "INDICATIONS AND USAGE Benzonatate Capsule is indicated for the symptomatic relief of cough.",
    "dose": "DOSAGE AND ADMINISTRATION Adults and Children over 10 years of age Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.",
    "pearls": [
      "Information for Patients Swallow Benzonatate Capsules whole.",
      "Do not break, chew, dissolve, cut, or crush Benzonatate Capsules.",
      "Release of Benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur."
    ],
    "tags": [
      "Cough Suppressant"
    ],
    "keywords": [
      "benzonatate",
      "tessalon",
      "perles",
      "cough",
      "suppressant"
    ]
  },
  {
    "slug": "risedronate",
    "name": "Risedronate (Actonel)",
    "class": "Bone strengthener",
    "summary": "1 INDICATIONS AND USAGE Risedronate sodium delayed-release tablets are bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal osteoporosis (1.1) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (1.2).",
    "dose": "2 DOSAGE AND ADMINISTRATION One 35 mg delayed-release tablet once-a-week (2.1) Instruct patients to: • Take risedronate sodium delayed-release tablets in the morning immediately following breakfast with at least 4 ounces of plain water (2.2) • Avoid lying down for 30 minutes after taking risedronate sodium delayed-release tablets (2.2) • Take supplemental calcium and vitamin D if dietary intake is inadequate (2.3) 2.1 Treatment of Postmenopausal Osteoporosis [ see Indications and Usage (1.1) ] The recommended regimen is: • one 35 mg delayed-release tablet orally, taken once-a-week [see Indications and Usage (1.1)] 2.2 Important Administration Instructions Instruct patients to do the following: • Take risedronate sodium delayed-release tablets in the morning immediately following breakfast. Risedronate sodium delayed-release tablets should be taken immediately following breakfast and not under fasting conditions because of a higher risk of abdominal pain if taken before breakfast when fasting. • Swallow risedronate sodium delayed-release tablets whole while in an upright position and with at least 4 ounces of plain water to facilitate delivery to the stomach.",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Pregnancy: Discontinue when pregnancy is recognized (8.1) • Risedronate sodium is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min) (5.6, 8.6, 12.3) • Risedronate sodium is not indicated for use in pediatric patients (8.4) 8.1 Pregnancy Risk Summary Available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Instruct patients to pay particular attention to the dosing instructions as clinical benefits may be compromised by failure to take the drug according to instructions.",
      "Instruct patients to take risedronate sodium delayed-release tablets in the morning, while in an upright position (sitting or standing) with at least 4 ounces of plain water immediately following breakfast.",
      "Risedronate sodium delayed-release tablets should not be taken before breakfast."
    ],
    "tags": [
      "Bone Strengthener"
    ],
    "keywords": [
      "risedronate",
      "actonel",
      "bone",
      "strengthener"
    ]
  },
  {
    "slug": "irbesartan-hctz",
    "name": "Irbesartan + HCTZ (Avalide)",
    "class": "Antihypertensive + Diuretic",
    "summary": "1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure.",
    "dose": "2 DOSAGE AND ADMINISTRATION Indication Dose Hypertension ( 2.2 ) 150 to 300 mg once daily Diabetic Nephropathy ( 2.3 ) 300 mg once daily 2.1 General Considerations Irbesartan tablets may be administered with other antihypertensive agents and with or without food. 2.2 Hypertension The recommended initial dose of irbesartan tablets is 150 mg once daily.",
    "renal": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death [see Clinical Considerations] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Pregnancy Advise female patients of childbearing age about the consequences of exposure to irbesartan tablets during pregnancy.",
      "Discuss treatment options with women planning to become pregnant.",
      "Patients should be asked to report pregnancies to their physicians as soon as possible."
    ],
    "tags": [
      "Antihypertensive",
      "Diuretic"
    ],
    "keywords": [
      "irbesartan",
      "hctz",
      "avalide",
      "antihypertensive",
      "diuretic"
    ]
  },
  {
    "slug": "dicyclomine",
    "name": "Dicyclomine (Bentyl)",
    "class": "Antispasmodic (intestines)",
    "summary": "1 INDICATIONS AND USAGE Dicyclomine hydrochloride capsules, USP are indicated for the treatment of patients with functional bowel/irritable bowel syndrome. Dicyclomine hydrochloride capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION Dosage must be adjusted to individual patient needs. Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) .",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: use only if clearly needed (8.1) Pediatric Use: Safety and effectiveness not established (8.4) Hepatic and renal impairment: caution must be taken with patients with significantly impaired hepatic and renal function (8.6) 8.1 Pregnancy Pregnancy Category B Adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION 17.2 Use in Infants Inform parents and caregivers not to administer dicyclomine hydrochloride in infants less than 6 months of age [see Use in Specific Populations (8.4) ] .",
      "17.3 Use in Nursing Mothers Advise lactating women that dicyclomine hydrochloride should not be used while breastfeeding their infants [see Use in Specific Populations (8.3, 8.4) ] .",
      "17.4 Peripheral and Central Nervous System In the presence of a high environmental temperature, heat prostration can occur with dicyclomine hydrochloride use (fever and heat stroke due to decreased sweating)."
    ],
    "tags": [
      "Antispasmodic"
    ],
    "keywords": [
      "dicyclomine",
      "bentyl",
      "antispasmodic",
      "(intestines)"
    ]
  },
  {
    "slug": "clarithromycin",
    "name": "Clarithromycin (Biaxin)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults ( 1.1 ) Acute Maxillary Sinusitis ( 1.2 ) Community-Acquired Pneumonia ( 1.3 ) Pharyngitis/Tonsillitis ( 1.4 ) Uncomplicated Skin and Skin Structure Infections ( 1.5 ) Acute Otitis Media in Pediatric Patients ( 1.6 ) Treatment and Prophylaxis of Disseminated Mycobacterial Infections ( 1.7 ) Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults ( 1.8 ) Limitations of Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.9 ) 1.1 Acute Bacterial Exacerbation of Chronic Bronchitis Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae [see Indications and Usage ( 1.9 )] . 1.2 Acute Maxillary Sinusitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae [see Indications and Usage ( 1.9 )] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults : clarithromycin tablets 250 mg or 500 mg every 12 hours for 7 to 14 days ( 2.2 ) H. pylori eradication (in combination with lansoprazole/amoxicillin, omeprazole/amoxicillin, or omeprazole): clarithromycin tablets 500 mg every 8 or 12 hours for 10 to 14 days. See full prescribing information (FPI) for additional information. ( 2.3 ) Pediatric Patients : clarithromycin 15 mg/kg/day divided every 12 hours for 10 days ( 2.4 ) Mycobacterial Infections : clarithromycin tablets 500 mg every 12 hours; clarithromycin tablets 7.5 mg/kg up to 500 mg every 12 hours in pediatric patients ( 2.5 ) Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment ( 2.6 ) 2.1 Important Administration Instructions Clarithromycin tablets may be given with or without food.",
    "renal": "These changes in pharmacokinetics parallel known age-related decreases in renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Drug Interactions Advise patients that clarithromycin may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other medications.",
      "Diarrhea Advise patients that diarrhea is a common problem caused by antibacterials including clarithromycin which usually ends when the antibacterial is discontinued.",
      "Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "clarithromycin",
      "biaxin",
      "antibiotic"
    ]
  },
  {
    "slug": "varenicline",
    "name": "Varenicline (Chantix)",
    "class": "Smoking cessation",
    "summary": "1 INDICATIONS AND USAGE Varenicline tablets are indicated for use as an aid to smoking cessation treatment. Varenicline tablets are a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment. ( 1 and 2.1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Begin varenicline tablets dosing one week before the date set by the patient to stop smoking. Alternatively, the patient can begin varenicline tablets dosing and then quit smoking between days 8 and 35 of treatment. ( 2.1 ) Starting Week: 0.5 mg once daily on days 1 to 3 and 0.5 mg twice daily on days 4 to 7. ( 2.1 ) Continuing Weeks: 1 mg twice daily for a total of 12 weeks. ( 2.1 ) An additional 12 weeks of treatment is recommended for successful quitters to increase likelihood of long-term abstinence. ( 2.1 ) Consider a gradual approach to quitting smoking with varenicline tablets for patients who are sure that they are not able or willing to quit abruptly.",
    "renal": "Varenicline is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Alternatively, the patient can begin varenicline tablets dosing and then set a date to quit smoking between days 8 and 35 of treatment.",
      "Encourage patients to continue to attempt to quit if they have early lapses after quit day [see Dosage and Administration (2.1) ].",
      "For patients who are sure that they are not able or willing to quit abruptly, a gradual approach to quitting smoking with varenicline tablets may be considered."
    ],
    "tags": [
      "Smoking Cessation"
    ],
    "keywords": [
      "varenicline",
      "chantix",
      "smoking",
      "cessation"
    ]
  },
  {
    "slug": "raloxifene",
    "name": "Raloxifene (Evista)",
    "class": "Estrogen modulator",
    "summary": "1 INDICATIONS AND USAGE Raloxifene hydrochloride is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. ( 1.3 ) Important Limitations: Raloxifene hydrochloride tablets are not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. ( 1.3 ) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women Raloxifene hydrochloride tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1 , 14.2) ] . 1.2 Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see Clinical Studies (14.3) ] .",
    "dose": "2 DOSAGE AND ADMINISTRATION 60 mg tablet orally once daily. (2.1) 2.1 Recommended Dosing The recommended dosage is one 60 mg raloxifene hydrochloride tablet daily, which may be administered any time of day without regard to meals [see Clinical Pharmacology (12.3) ] . For the indications in risk of invasive breast cancer the optimum duration of treatment is not known [see Clinical Studies (14.3 , 14.4) ] .",
    "renal": "In rats dosed during organogenesis, retardation of fetal growth and developmental abnormalities (wavy ribs, kidney cavitation) occurred at doses ≥1 mg/kg (≥0.2 times the human dose based on surface area, mg/m 2 ).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved Medication Guide.",
      "Physicians should instruct their patients to read the Medication Guide before starting therapy with raloxifene hydrochloride and to reread it each time the prescription is renewed.",
      "17.1 Osteoporosis Recommendations, Including Calcium and Vitamin D Supplementation For osteoporosis treatment or prevention, patients should be instructed to take supplemental calcium and/or vitamin D if intake is inadequate."
    ],
    "tags": [
      "Estrogen Modulator"
    ],
    "keywords": [
      "raloxifene",
      "evista",
      "estrogen",
      "modulator"
    ]
  },
  {
    "slug": "insulin-lispro",
    "name": "Insulin Lispro (Humalog)",
    "class": "Insulin (short acting)",
    "summary": "1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important preparation and administration instructions. ( 2.1 , 2.2 , 2.3 , 2.4 ) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.2 ) Subcutaneous injection ( 2.2 ): Administer ADMELOG by subcutaneous injection into the abdominal wall, thigh, upper arm, or buttocks within 15 minutes before a meal or immediately after a meal. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis.",
    "renal": "8.6 Renal Impairment Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent ADMELOG dose adjustment and more frequent blood glucose monitoring [see Clinical Pharmacology (12.3) ] .",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Never Share an ADMELOG SoloStar Prefilled Pen or Syringe Between Patients Advise patients that they must never share an ADMELOG SoloStar pen with another person, even if the needle is changed.",
      "Advise patients using ADMELOG vials not to share needles or syringes with another person."
    ],
    "tags": [
      "Insulin"
    ],
    "keywords": [
      "insulin",
      "lispro",
      "humalog",
      "(short",
      "acting)"
    ]
  },
  {
    "slug": "insulin-degludec",
    "name": "Insulin Degludec (Tresiba)",
    "class": "Insulin (long acting)",
    "summary": "1 INDICATIONS AND USAGE XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide.",
    "dose": "2 DOSAGE AND ADMINISTRATION • Administer once-daily at same time each day with or without food. ( 2.1 ) • XULTOPHY 100/3.6 pen delivers doses from 10 to 50 units with each injection ( 2.1 , 2.2 ); each XULTOPHY 100/3.6 dosage unit contains 1 unit of insulin degludec and 0.036 mg of liraglutide. ( 2.1 ) • Maximum daily dosage is 50 units (50 units of insulin degludec and 1.8 mg of liraglutide). ( 2.1 ) • Recommended starting dosage in patients naïve to basal insulin or GLP-1 receptor agonist is 10 units (10 units of insulin degludec and 0.36 mg of liraglutide) injected subcutaneously once-daily. (2.2 ) • Discontinue therapy with liraglutide or basal insulin prior to initiation of XULTOPHY 100/3.6. ( 2.2 ) • Recommended starting dosage in patients currently on basal insulin or GLP-1 receptor agonist is 16 units (16 units of insulin degludec and 0.58 mg of liraglutide) injected subcutaneously once-daily. ( 2.2 ) • See Full Prescribing Information for titration recommendations. ( 2.3 ) • Inject XULTOPHY 100/3.6 subcutaneously into the thigh, upper arm, or abdomen. ( 2.5 ) • Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.5 ) • Do not administer intravenously or by an infusion pump. ( 2.5 ) • Do not dilute or mix with any other insulin products or solutions. ( 2.5 ) 2.1 Important Dosage Information • XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide. • Administer XULTOPHY 100/3.6 by subcutaneous injection once-daily at the same time each day with or without food. • The XULTOPHY 100/3.6 pen delivers doses from 10 to 50 units with each injection. Table 1 presents the units of insulin degludec and the milligrams of liraglutide in each dosage of XULTOPHY 100/3.6 [see Dosage and Administration ( 2.2 )]. • The maximum dosage of XULTOPHY 100/3.6 is 50 units daily (50 units of insulin degludec and 1.8 mg of liraglutide) [see Warnings and Precautions ( 5.5 )] .",
    "renal": "Fetal abnormalities and variations in kidneys and blood vessels, irregular ossification of the skull, and a more complete state of ossification occurred at all doses.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia or dyspnea) to their physician [ see Boxed Warning, Warnings and Precautions ( 5.1 )] .",
      "Acute Pancreatitis Inform patients of the potential risk for pancreatitis acute pancreatitis and its symptoms: severe abdominal pain that may radiate to the back, and which may or may not be accompanied by nausea or vomiting.",
      "Instruct patients to discontinue XULTOPHY 100/3.6 promptly and contact their physician if pancreatitis is suspected [see Warnings and Precautions ( 5.2 )]."
    ],
    "tags": [
      "Insulin"
    ],
    "keywords": [
      "insulin",
      "degludec",
      "tresiba",
      "(long",
      "acting)"
    ]
  },
  {
    "slug": "memantine",
    "name": "Memantine (Namenda)",
    "class": "Anti-Alzheimer's",
    "summary": "1 INDICATIONS AND USAGE Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily).",
    "renal": "8.6 Renal Impairment No dosage adjustment is needed in patients with mild or moderate renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) .",
      "To assure safe and effective use of memantine hydrochloride, the following information and instructions provided in the patient information section should be discussed with patients and caregivers.",
      "Patients/caregivers should be instructed to follow the dose titration schedule provided by their physician or healthcare professional for memantine hydrochloride."
    ],
    "tags": [
      "Anti-Alzheimer's"
    ],
    "keywords": [
      "memantine",
      "namenda",
      "anti-alzheimer's"
    ]
  },
  {
    "slug": "nitroglycerine",
    "name": "Nitroglycerine (NitroStat)",
    "class": "Anti-angina",
    "summary": "1 INDICATIONS AND USAGE NITROSTAT is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. INDICATIONS AND USAGE NITROSTAT is a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. Allow tablet to dissolve without swallowing.",
    "renal": "In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Anti-angina"
    ],
    "keywords": [
      "nitroglycerine",
      "nitrostat",
      "anti-angina"
    ]
  },
  {
    "slug": "insulin-aspart",
    "name": "Insulin Aspart (NovoLog)",
    "class": "Insulin",
    "summary": "1 INDICATIONS AND USAGE NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important preparation, administration, and dosage instructions ( 2.1, 2.2, 2.3, 2.4, 2.5 ). • Subcutaneous injection ( 2.2 ): o Inject subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm. o Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis. o Should generally be used in regimens with an intermediate- or long-acting insulin. • Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. o Administer by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. o Rotate the injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. o Do not mix with other insulins or diluents in the pump. • Intravenous Administration ( 2.2 ) : o Dilute NOVOLOG to concentrations from 0.05 unit/mL to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags. o NOVOLOG is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP. • Individualize and adjust the dosage of NOVOLOG based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal ( 2.4 ). • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness ( 2.4 ).",
    "renal": "8.6 Renal Impairment Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent NOVOLOG dose adjustment and more frequent blood glucose monitoring [see Warnings and Precautions ( 5.3 ) and Clinical Pharmacology ( 12.3 )].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).",
      "Advise patients using NOVOLOG vials not to share needles or syringes with another person.",
      "Sharing poses a risk for transmission of blood-borne pathogens [see Warnings and Precautions ( 5.1 )] ."
    ],
    "tags": [
      "Insulin"
    ],
    "keywords": [
      "insulin",
      "aspart",
      "novolog"
    ]
  },
  {
    "slug": "dulaglutide",
    "name": "Dulaglutide (Trulicity)",
    "class": "Antidiabetic (Increases insulin secretion from pancrease)",
    "summary": "1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.",
    "dose": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. Increase dosage to 1.5 mg once weekly for additional glycemic control.",
    "renal": "8.6 Renal Impairment TRULICITY has been studied in patients with varying degrees of renal function, including a dedicated clinical trial in patients with moderate to severe chronic kidney disease.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).",
      "Inform patients that TRULICITY causes benign and malignant thyroid C-cell tumors in rats and that the human relevance of this finding has not been determined.",
      "Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, persistent hoarseness, dysphagia, or dyspnea) to their physician [see Boxed Warning and Warnings and Precautions ( 5.1 )] ."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "dulaglutide",
      "trulicity",
      "antidiabetic",
      "(increases",
      "insulin",
      "secretion",
      "from",
      "pancrease)"
    ]
  },
  {
    "slug": "nabumetone",
    "name": "Nabumetone (Relafen)",
    "class": "Analgesic (NSAID.)",
    "summary": "INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ).",
    "dose": "DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ).",
    "renal": "Renal Insufficiency In moderate renal insufficiency patients (creatinine clearance 30 to 49 mL/min), the terminal half-life of 6MNA was increased by approximately 50% (39.2 ± 7.8 hrs, N = 12) compared to the normal subjects (26.9 ± 3.3 hrs, N = 13), and there was a 50% increase in the plasma levels of unbound 6MNA.",
    "monitoring": "WARNINGS Cardiovascular Effects Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.",
    "pearls": [
      "Information for Patients Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.",
      "Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.",
      "Nabumetone tablets, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death."
    ],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "nabumetone",
      "relafen",
      "analgesic",
      "(nsaid.)"
    ]
  },
  {
    "slug": "ropinirole",
    "name": "Ropinirole (Requip)",
    "class": "Anti-Parkinson's",
    "summary": "1 INDICATIONS AND USAGE Ropinirole Tablets are a non-ergoline dopamine agonist indicated for the treatment of Parkinson’s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS). (1.1, 1.2). 1.1 Parkinson's Disease Ropinirole tablets are indicated for the treatment of Parkinson’s disease.",
    "dose": "2 DOSAGE AND ADMINISTRATION · Ropinirole tablets can be taken with or without food. (2.1) · Retitration of ropinirole tablets may be warranted if therapy is interrupted. (2.1) Parkinson’s Disease: · The recommended starting dose is 0.25 mg taken three times daily; titrate to a maximum daily dose of 24 mg. (2.2) · Renal Impairment: The maximum recommended dose is 18 mg/day in patients with end-stage renal disease on hemodialysis. (2.2) Restless Legs Syndrome: · The recommended starting dose is 0.25 mg once daily, 1 to 3 hours before bedtime, titrate to a maximum recommended dose of 4 mg daily. (2.3) · Renal Impairment: The maximum recommended dose is 3 mg/day in patients with end-stage renal disease on hemodialysis. (2.3) 2.1 General Dosing Recommendations Ropinirole tablets can be taken with or without food [see Clinical Pharmacology (12.3)] . If a significant interruption in therapy with ropinirole tablets have occurred, retitration of therapy may be warranted.",
    "renal": "8.6 Renal Impairment No dose adjustment is necessary in patients with moderate renal impairment (creatinine clearance of 30 to 50 mL/min).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
      "Dosing Instructions Instruct patients to take ropinirole tablets only as prescribed.",
      "If a dose is missed, advise patients not to double their next dose."
    ],
    "tags": [
      "Anti-Parkinson's"
    ],
    "keywords": [
      "ropinirole",
      "requip",
      "anti-parkinson's"
    ]
  },
  {
    "slug": "methocarbamol",
    "name": "Methocarbamol (Robaxin)",
    "class": "Muscle relaxer",
    "summary": "INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.",
    "dose": "DOSAGE AND ADMINISTRATION Methocarbamol tablets, USP, 500 mg – Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development.",
    "pearls": [
      "Information for patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.",
      "Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants."
    ],
    "tags": [
      "Muscle Relaxer"
    ],
    "keywords": [
      "methocarbamol",
      "robaxin",
      "muscle",
      "relaxer"
    ]
  },
  {
    "slug": "clobetasol",
    "name": "Clobetasol (Temovate)",
    "class": "Anti-inflammatory steroid",
    "summary": "INDICATIONS AND USAGE Clobetasol propionate ointment USP, 0.05% is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (HPA) axis.",
    "dose": "DOSAGE AND ADMINISTRATION Apply a thin layer of clobetasol propionate ointment to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE .) Clobetasol propionate ointment are super- high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks , and amounts greater than 50 g per week should not be used . As with other highly active corticosteroids, therapy should be discontinued when control has been achieved.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "PRECAUTIONS General: Clobetasol propionate ointment USP, 0.05% should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment.",
    "pearls": [
      "Information for Patients: Patients using topical corticosteroids should receive the following information and instructions: 1.",
      "This medication is to be used as directed by the physician.",
      "It is for external use only."
    ],
    "tags": [
      "Anti-inflammatory Steroid"
    ],
    "keywords": [
      "clobetasol",
      "temovate",
      "anti-inflammatory",
      "steroid"
    ]
  },
  {
    "slug": "tizanidine",
    "name": "Tizanidine (Zanaflex)",
    "class": "Muscle relaxer",
    "summary": "1 INDICATIONS AND USAGE Tizanidine is indicated for the treatment of spasticity in adults. Tizanidine is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved. ( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms.",
    "renal": "8.5 Geriatric Use Tizanidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Tizanidine Tablets Dosing and Administration Tell patients to take tizanidine tablets exactly as prescribed (consistently either with or without food) and not to switch between tablets and capsules [see Dosage and Administration ( 2 )].",
      "Inform patients that they should not take more tizanidine tablets than prescribed because of the risk of adverse events at single doses greater than 8 mg or total daily doses greater than 36 mg.",
      "Tell patients that they should not suddenly discontinue tizanidine tablets, because rebound hypertension and tachycardia may occur [see Warnings and Precautions ( 5.6 )]."
    ],
    "tags": [
      "Muscle Relaxer"
    ],
    "keywords": [
      "tizanidine",
      "zanaflex",
      "muscle",
      "relaxer"
    ]
  },
  {
    "slug": "bisoprolol",
    "name": "Bisoprolol (Zebeta)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Bisoprolol fumarate tablets are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.",
    "dose": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily.",
    "renal": "The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.",
    "monitoring": "WARNINGS Click here to enter Warnings Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and beta-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In general, beta-blocking agents should be avoided in patients with overt congestive failure.",
    "pearls": [
      "Information for Patients Patients, especially those with coronary artery disease, should be warned about discontinuing use of bisoprolol fumarate tablets without a physician’s supervision.",
      "Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia.",
      "Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "bisoprolol",
      "zebeta",
      "antihypertensive"
    ]
  },
  {
    "slug": "ondansetron",
    "name": "Ondansetron (Zofran)",
    "class": "Antinausea",
    "summary": "1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen (1) postoperative nausea and/or vomiting (1)",
    "dose": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. Corresponding doses of ondansetron tablets may be used interchangeably.",
    "renal": "8.7 Renal Impairment No dosage adjustment is recommended for patients with any degree of renal impairment (mild, moderate, or severe).",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Hypersensitivity Reactions Inform patients that ondansetron tablets may cause hypersensitivity reactions, some as severe as anaphylaxis and bronchospasm.",
      "Instruct patients to immediately report any signs and symptoms of hypersensitivity reactions, including fever, chills, rash, or breathing problems to their healthcare provider [see Warnings and Precautions ( 5.1 )] .",
      "QT Prolongation Inform patients that ondansetron tablets may cause serious cardiac arrhythmias, such as QT prolongation."
    ],
    "tags": [
      "Antinausea"
    ],
    "keywords": [
      "ondansetron",
      "zofran",
      "antinausea"
    ]
  },
  {
    "slug": "olanzapine",
    "name": "Olanzapine (Zyprexa)",
    "class": "Antipsychotic",
    "summary": "1 INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ).",
    "dose": "2 DOSAGE AND ADMINISTRATION Schizophrenia in adults ( 2.1 ) Oral: Start at 5 mg to 10 mg once daily; Target: 10 mg/day within several days Schizophrenia in adolescents ( 2.1 ) Oral: Start at 2.5 mg to 5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) in adults ( 2.2 ) Oral: Start at 10 mg or 15 mg once daily Bipolar I Disorder (manic or mixed episodes) in adolescents ( 2.2 ) Oral: Start at 2.5 mg to 5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults ( 2.2 ) Oral: Start at 10 mg once daily Depressive Episodes associated with Bipolar I Disorder in adults ( 2.5 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Depressive Episodes associated with Bipolar I Disorder in children and adolescents ( 2.5 ) Oral in combination with fluoxetine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily Treatment Resistant Depression in adults ( 2.6 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Lower starting dose recommended in debilitated or pharmacodynamically sensitive patients or patients with predisposition to hypotensive reactions, or with potential for slowed metabolism. ( 2.1 ) Olanzapine may be given without regard to meals. ( 2.1 ) Olanzapine and Fluoxetine in Combination: Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability. ( 2.5 , 2.6 ) Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder or treatment resistant depression. ( 2.5 , 2.6 ) Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 , 2.6 ) Safety of co-administration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17. ( 2.5 ) 2.1 Schizophrenia Adults Dose Selection — Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 mg to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient.",
    "renal": "Specific Populations Renal Impairment — Because olanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) for the oral formulations.",
      "Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking olanzapine as monotherapy or in combination with fluoxetine.",
      "If you do not think you are getting better or have any concerns about your condition while taking olanzapine, call your doctor."
    ],
    "tags": [
      "Antipsychotic"
    ],
    "keywords": [
      "olanzapine",
      "zyprexa",
      "antipsychotic"
    ]
  },
  {
    "slug": "hydralazine",
    "name": "Hydralazine (Apresoline)",
    "class": "Antihypertensive",
    "summary": "INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct.",
    "dose": "DOSAGE AND ADMINISTRATION Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week.",
    "renal": "HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.",
    "monitoring": "WARNINGS ​ In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.",
    "pearls": [],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "hydralazine",
      "apresoline",
      "antihypertensive"
    ]
  },
  {
    "slug": "moxifloxacin",
    "name": "Moxifloxacin (Avelox)",
    "class": "Antibiotic",
    "summary": "1 INDICATIONS AND USAGE Moxifloxacin tablets are a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia ( 1.1 ) Skin and Skin Structure Infections: Uncomplicated ( 1.2 ) and Complicated ( 1.3 ) Complicated Intra-Abdominal Infections ( 1.4 ) Plague ( 1.5 ) Acute Bacterial Sinusitis ( 1.6 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.7 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin tablets and other antibacterial drugs. Moxifloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.8 ) 1.1 Community Acquired Pneumonia Moxifloxacin tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]) , Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Clinical Studies (14.3) ] .",
    "dose": "2 DOSAGE AND ADMINISTRATION Type of Infection Dose Every 24 hours Duration (days) Community Acquired Pneumonia ( 1.1 ) 400 mg 7 to 14 Uncomplicated Skin and Skin Structure Infections (SSSI) ( 1.2 ) 400 mg 7 Complicated SSSI ( 1.3 ) 400 mg 7 to 21 Complicated Intra-Abdominal Infections ( 1.4 ) 400 mg 5 to 14 Plague ( 1.5 ) 400 mg 10 to 14 Acute Bacterial Sinusitis ( 1.6 ) 400 mg 10 Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.7 ) 400 mg 5 No dosage adjustment in patients with renal or hepatic impairment. ( 8.6 , 8.7 ) 2.1 Dosage in Adult Patients The dose of moxifloxacin is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.",
    "renal": "8.6 Renal Impairment The pharmacokinetic parameters of moxifloxacin are not significantly altered in mild, moderate, severe, or end-stage renal disease.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Inform patients to stop taking moxifloxacin hydrochloride immediately if they experience an adverse reaction and to call their healthcare provider.",
      "Symptoms may be irreversible.",
      "The risk of severe tendon disorder with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants."
    ],
    "tags": [
      "Antibiotic"
    ],
    "keywords": [
      "moxifloxacin",
      "avelox",
      "antibiotic"
    ]
  },
  {
    "slug": "dutasteride",
    "name": "Dutasteride (Avodart)",
    "class": "Reduces enlarged prostate",
    "summary": "1 INDICATIONS AND USAGE Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer. ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Treatment Dutasteride and tamsulosin hydrochloride capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.2 Limitations of Use Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer.",
    "dose": "2 DOSAGE AND ADMINISTRATION The recommended dosage of dutasteride and tamsulosin hydrochloride capsules is 1 capsule (0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride) taken once daily approximately 30 minutes after the same meal each day. The capsules should be swallowed whole and not chewed or opened.",
    "renal": "Reduction of fetal adrenal weights, reduction in fetal prostate weights, and increases in fetal ovarian and testis weights were observed at the highest dose tested.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [],
    "tags": [
      "Reduces Enlarged Prostate"
    ],
    "keywords": [
      "dutasteride",
      "avodart",
      "reduces",
      "enlarged",
      "prostate"
    ]
  },
  {
    "slug": "triamterene-hctz",
    "name": "Triamterene + HCTZ (Dyazide)",
    "class": "Antihypertensive (2 diuretics)",
    "summary": "INDICATIONS AND USAGE: This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.",
    "dose": "DOSAGE AND ADMINISTRATION: The usual dose of triamterene and hydrochlorothiazide tablets 37.5mg/25mg is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see WARNINGS ). The usual dose of triamterene and hydrochlorothiazide tablets 75mg/ 50 mg is one tablet daily, with appropriate monitoring of serum potassium (see WARNINGS ).",
    "renal": "It blocks the renal tubular absorption of sodium and chloride ions.",
    "monitoring": "WARNINGS: Hyperkalemia: Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-conserving diuretic combinations, including triamterene and hydrochlorothiazide. Hyperkalemia is more likely to occur in patients with renal impairment, diabetes (even without evidence of renal impairment), or elderly or severely ill patients.",
    "pearls": [
      "Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.",
      "Serum and urine electrolyte determinations are especially important and should be frequently performed when the patient is vomiting or receiving parenteral fluids.",
      "Any chloride deficit during thiazide therapy is generally mild and usually does not require any specific treatment except under extraordinary circumstances (as in liver disease or renal disease)."
    ],
    "tags": [
      "Antihypertensive"
    ],
    "keywords": [
      "triamterene",
      "hctz",
      "dyazide",
      "antihypertensive",
      "(2",
      "diuretics)"
    ]
  },
  {
    "slug": "benztropine",
    "name": "Benztropine (Cogentin)",
    "class": "Anti-Parkinson's",
    "summary": "INDICATIONS AND USAGE For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).",
    "dose": "DOSAGE AND ADMINISTRATION Benztropine mesylate tablets should be used when patients are able to take oral medication. Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five- or six-day intervals to the smallest amount necessary for optimal relief.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Safe use in pregnancy has not been established. Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.",
    "pearls": [
      "General Since benztropine mesylate has cumulative action, continued supervision is advisable.",
      "Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.",
      "Dysuria may occur, but rarely becomes a problem."
    ],
    "tags": [
      "Anti-Parkinson's"
    ],
    "keywords": [
      "benztropine",
      "cogentin",
      "anti-parkinson's"
    ]
  },
  {
    "slug": "adalimumab",
    "name": "Adalimumab (Humira)",
    "class": "Immunosuppressive (arthritis, Crohn's disease, and ulcerative colitis)",
    "summary": "1 INDICATIONS AND USAGE IDACIO is a tumor necrosis factor (TNF) blocker indicated for: • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA . • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.",
    "dose": "2 DOSAGE AND ADMINISTRATION • Administer by subcutaneous injection ( 2 ) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis ( 2.1 ): • Adults: 40 mg every other week. • Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week. Juvenile Idiopathic Arthritis ( 2.2 ): Pediatric Weight 2 Years of Age and Older Recommended Dosage 10 kg (22 lbs) to less than 15 kg (33 lbs) 10 mg every other week 15 kg (33 lbs) to less than 30 kg (66 lbs) 20 mg every other week 30 kg (66 lbs) and greater 40 mg every other week • Administer by subcutaneous injection ( 2 ) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis ( 2.1 ): • Adults: 40 mg every other week. o Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.",
    "renal": "Patients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients with hepatic or renal impairment.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).",
      "Infections Inform patients that IDACIO may lower the ability of their immune system to fight infections.",
      "Other Medical Conditions Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, neurological disease, autoimmune disorders, or cytopenias."
    ],
    "tags": [
      "Immunosuppressive (arthritis",
      "Crohn's Disease",
      "Ulcerative Colitis)"
    ],
    "keywords": [
      "adalimumab",
      "humira",
      "immunosuppressive",
      "(arthritis",
      "crohn's",
      "disease",
      "and",
      "ulcerative",
      "colitis)"
    ]
  },
  {
    "slug": "phenytoin",
    "name": "Phenytoin (Dilantin)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Parenteral Phenytoin Sodium Injection is indicated for the treatment of generalized tonic-clonic status epilepticus, and prevention and treatment of seizures occurring during neurosurgery. Intravenous phenytoin can also be substituted, as short-term use, for oral phenytoin.",
    "dose": "2 DOSAGE AND ADMINISTRATION For Status Epilepticus and Non-emergent Loading Dose: Adult loading dose is 10 to 15 mg/kg at a rate not exceeding 50 mg/min. ( 2.2 ) Pediatric loading dose is 15 to 20 mg/kg at a rate not exceeding 1 to 3 mg/kg/min or 50 mg/min, whichever is slower. ( 2.8 ) Continuous monitoring of the electrocardiogram, blood pressure, and respiratory function is essential. ( 2.2 ) Maintenance Dosing: Initial loading dose should be followed by maintenance doses of oral or intravenous Phenytoin Sodium Injection every 6 to 8 hours. ( 2.2 , 2.3 ) Intramuscular Administration: Because of erratic absorption and local toxicity, Phenytoin Sodium Injection should ordinarily not be given intramuscularly. ( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. In pediatric patients, the drug should be administered at a rate not exceeding 1 to 3 mg/kg/min or 50 mg per minute, whichever is slower.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. ( 5.11 , 8.1 ) Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. ( 8.6 ) 8.1 Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as Phenytoin Sodium Injection, during pregnancy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION W ithdrawal of Antiepileptic Drugs Advise patients not to discontinue use of phenytoin without consulting with their healthcare provider.",
      "Phenytoin should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus [see Warnings and Precautions (5.2) ] .",
      "Advise the patient that, because these signs and symptoms may signal a serious reaction, that they must report any occurrence immediately to a physician."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "phenytoin",
      "dilantin",
      "anticonvulsant"
    ]
  },
  {
    "slug": "oxybutynin",
    "name": "Oxybutynin (Ditropan)",
    "class": "Overactive bladder",
    "summary": "1 INDICATIONS AND USAGE Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).",
    "dose": "2 DOSAGE AND ADMINISTRATION Oxybutynin chloride extended-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. Oxybutynin chloride extended-release tablets may be administered with or without food.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pediatric Use: Oxybutynin chloride extended-release tablets are not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing or crushing, or in children under the age of 6 years. (8.4) Renal or Hepatic Impairment: There have been no studies conducted in patients with renal or hepatic impairment. ( 8.6 , 8.7 ) 8.1 Pregnancy Pregnancy Category B.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Patients should be informed that oxybutynin may produce angioedema that could result in life threatening airway obstruction.",
      "Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience swelling of the tongue, edema of the laryngopharynx, or difficulty breathing.",
      "Heat prostration can occur when anticholinergic medicines are administered in the presence of high environmental temperature."
    ],
    "tags": [
      "Overactive Bladder"
    ],
    "keywords": [
      "oxybutynin",
      "ditropan",
      "overactive",
      "bladder"
    ]
  },
  {
    "slug": "levetiracetam",
    "name": "Levetiracetam (Keppra)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy.",
    "dose": "2 DOSAGE AND ADMINISTRATION Use the oral solution for pediatric patients with body weight ≤ 20 kg ( 2.1 ) For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ) Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function Dose adjustment is recommended, based on the patient’s estimated creatinine clearance ( 2.5 , 8.6 ) 2.1 Important Administration Instructions Levetiracetam tablets are given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.",
    "renal": "Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Advise patients, their caregivers, and/or families to immediately report behaviors of concern to a healthcare provider [see Warnings and Precautions (5.2) ].",
      "Effects on Driving or Operating Machinery Inform patients that levetiracetam may cause dizziness and somnolence."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "levetiracetam",
      "keppra",
      "anticonvulsant"
    ]
  },
  {
    "slug": "liraglutide",
    "name": "Liraglutide (Victoza)",
    "class": "Antidiabetic (Increases insulin secretion from pancrease)",
    "summary": "1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use: Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended.",
    "dose": "2 DOSAGE AND ADMINISTRATION Adult Patients: Initiate at 0.6 mg injected subcutaneously once daily for one week then increase to 1.2 mg daily. If additional glycemic control is required, increase the dose to 1.8 mg daily after one week of treatment with the 1.2 mg daily dose. ( 2.1 ) Pediatric Patients: Initiate at 0.6 mg injected subcutaneously once daily for at least one week.",
    "renal": "Fetal abnormalities and variations in kidneys and blood vessels, irregular ossification of the skull, and a more complete state of ossification occurred at all doses.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Risk of Thyroid C-cell Tumors Inform patients that liraglutide causes benign and malignant thyroid C-cell tumors in mice and rats and that the human relevance of this finding is unknown.",
      "Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea) to their physician [see Boxed Warning, Warnings and Precautions ( 5.1 )] ."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "liraglutide",
      "victoza",
      "antidiabetic",
      "(increases",
      "insulin",
      "secretion",
      "from",
      "pancrease)"
    ]
  },
  {
    "slug": "baclofen",
    "name": "Baclofen (Lioresal)",
    "class": "Muscle relaxer",
    "summary": "INDICATIONS AND USAGE Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function.",
    "dose": "DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40-80 mg daily).",
    "renal": "Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.",
    "monitoring": "WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy.",
    "pearls": [],
    "tags": [
      "Muscle Relaxer"
    ],
    "keywords": [
      "baclofen",
      "lioresal",
      "muscle",
      "relaxer"
    ]
  },
  {
    "slug": "oxcarbazepine",
    "name": "Oxcarbazepine (Trileptal)",
    "class": "Anticonvulsant",
    "summary": "1 INDICATIONS AND USAGE Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine tablets are indicated for: • Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures • Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years ( 1 )",
    "dose": "2 DOSAGE AND ADMINISTRATION Adults : initiate with a dose of 600 mg/day, given twice a day • Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) • Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine tablets in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) • Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day ( 2.3 ) • Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance < 30 mL/min ( 2.7 ) Pediatrics : initiation with 8 to 10 mg/kg/day, given twice a day.",
    "renal": "Comparisons of creatinine clearance in young and elderly volunteers indicate that the difference was due to age-related reductions in creatinine clearance.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Administration Information Counsel patients that oxcarbazepine tablets may be taken with or without food.",
      "Hyponatremia Advise patients that oxcarbazepine tablets may reduce the serum sodium concentrations especially if they are taking other medications that can lower sodium."
    ],
    "tags": [
      "Anticonvulsant"
    ],
    "keywords": [
      "oxcarbazepine",
      "trileptal",
      "anticonvulsant"
    ]
  },
  {
    "slug": "ketoconazole",
    "name": "Ketoconazole (Nizoral)",
    "class": "Antifungal",
    "summary": "INDICATIONS & USAGE Ketoconazole shampoo, 2% is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare ) . Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs.",
    "dose": "DOSAGE & ADMINISTRATION Apply the shampoo to the damp skin of the affected area and a wide margin surrounding this area. Lather, leave in place for 5 minutes, and then rinse off with water.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "PRECAUTIONS Severe hypersensitivity reactions, including anaphylaxis, have been reported during post-marketing use of ketoconazole shampoo. If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued.",
    "pearls": [
      "INFORMATION FOR PATIENTS Patients should be advised of the following: Ketoconazole shampoo, 2% may be irritating to mucous membranes of the eyes and contact with this area should be avoided.",
      "Patients who develop allergic reactions, such as generalized rash, skin reactions, severe swelling, angioedema, or shortness of breath should discontinue ketoconazole shampoo, 2% and contact their physician immediately."
    ],
    "tags": [
      "Antifungal"
    ],
    "keywords": [
      "ketoconazole",
      "nizoral",
      "antifungal"
    ]
  },
  {
    "slug": "nortriptyline",
    "name": "Nortriptyline (Pamelor)",
    "class": "Antidepressant",
    "summary": "INDICATIONS AND USAGE Nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.",
    "dose": "DOSAGE AND ADMINISTRATION Nortriptyline hydrochloride is not recommended for children. Nortriptyline hydrochloride is administered orally in the form of capsules.",
    "renal": "No renal guidance found in the fetched label.",
    "monitoring": "WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.",
    "pearls": [],
    "tags": [
      "Antidepressant"
    ],
    "keywords": [
      "nortriptyline",
      "pamelor",
      "antidepressant"
    ]
  },
  {
    "slug": "hydroxychloroquine",
    "name": "Hydroxychloroquine (Plaquenil)",
    "class": "Arthritis/lupus",
    "summary": "1 INDICATIONS AND USAGE Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. ( 1.1 ) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. ( 1.1 ) Treatment of rheumatoid arthritis in adults. ( 1.2 ) Treatment of systemic lupus erythematosus in adults. ( 1.3 ) Treatment of chronic discoid lupus erythematosus in adults. ( 1.4 ) Limitations of Use ( 1.1 ): Hydroxychloroquine sulfate tablets are not recommended for the: Treatment of complicated malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species.",
    "dose": "2 DOSAGE AND ADMINISTRATION Malaria in Adult and Pediatric Patients ( 2.2 ): ● Prophylaxis: Begin weekly doses 2 weeks prior to travel to the endemic area, continue weekly doses while in the endemic area, and continue the weekly doses for 4 weeks after leaving the endemic area: - Adults: 400 mg once a week - Pediatric patients ≥ 31 kg: 6.5 mg/kg up to 400 mg, once a week ● Treatment of Uncomplicated Malaria: See Full Prescribing Information (FPI) for complete dosing information. Rheumatoid Arthritis in Adults ( 2.3 ): Initial dosage: 400 mg to 600 mg daily Chronic dosage: 200 mg once daily or 400 mg once daily (or in two divided doses) Systemic Lupus Erythematosus in Adults ( 2.4 ): 200 mg once daily or 400 mg once daily (or in two divided doses) Chronic Discoid Lupus Erythematosus in Adults ( 2.5 ): 200 mg once daily or 400 mg once daily (or in two divided doses) 2.1 Important Administration Instructions Administer hydroxychloroquine sulfate tablets orally with food or milk.",
    "renal": "Nevertheless, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Important Administration Instructions Advise the patient to take hydroxychloroquine sulfate tablets with food or milk and not to crush or divide the tablet.",
      "Cardiomyopathy and Ventricular Arrhythmias Inform the patient that serious cardiac effects, life-threatening and fatal cases have been reported with use of hydroxychloroquine sulfate tablets.",
      "Advise patients to seek medical attention immediately if they experience any symptoms of heart rhythm changes including fast or irregular heartbeat, lightheadedness, dizziness, or syncope [see Warnings and Precautions (5.1) ]."
    ],
    "tags": [
      "Arthritis",
      "Lupus"
    ],
    "keywords": [
      "hydroxychloroquine",
      "plaquenil",
      "arthritis",
      "lupus"
    ]
  },
  {
    "slug": "pantoprazole",
    "name": "Pantoprazole (Protonix)",
    "class": "Antiacid (PPI)",
    "summary": "1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Limitations of Use The safety and effectiveness of Pantoprazole Sodium for Injection for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients.",
    "dose": "2 DOSAGE AND ADMINISTRATION GERD and a History of EE Adults: The recommended dosage is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. ( 2.1 ) Discontinue as soon as the patient is able to receive oral treatment. Switch to an appropriate oral medication within 10 days of starting pantoprazole sodium for injection. ( 2.1 ) Pathological Hypersecretion Conditions, Including ZE Syndrome The recommended adult dosage is 80 mg every 12 hours by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes). ( 2.2 ) For information on how to adjust dosing for individual patient needs, see the full prescribing information. ( 2.2 ) When switching between intravenous to oral formulations of gastric acid inhibitors, consider the pharmacodynamic action of the drugs to ensure continuity of acid suppression. ( 2.2 ) Preparation and Administration Instructions See full prescribing information for preparation and administration instructions by indication. ( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days.",
    "renal": "There was no renal excretion of unchanged pantoprazole.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1) ] .",
      "This product’s labeling may have been updated.",
      "For the most recent prescribing information, please visit www.meithealpharma.com."
    ],
    "tags": [
      "Antiacid"
    ],
    "keywords": [
      "pantoprazole",
      "protonix",
      "antiacid",
      "(ppi)"
    ]
  },
  {
    "slug": "phenazopyridine",
    "name": "Phenazopyridine (Pyridium)",
    "class": "Analgesic (urinary)",
    "summary": "INDICATIONS AND USAGE Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions.",
    "dose": "DOSAGE AND ADMINISTRATION 100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals. 200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.",
    "renal": "Phenazopyridine HCl is rapidly excreted by the kidneys, with as much as 66% of an oral dose being excreted unchanged in the urine.",
    "monitoring": "PRECAUTIONS General: A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind.",
    "pearls": [],
    "tags": [
      "Analgesic"
    ],
    "keywords": [
      "phenazopyridine",
      "pyridium",
      "analgesic",
      "(urinary)"
    ]
  },
  {
    "slug": "atomoxetine",
    "name": "Atomoxetine (Strattera)",
    "class": "ADHD (nonscheduled)",
    "summary": "1 INDICATIONS AND USAGE Atomoxetine capsule is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). ( 1.1 ) 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine capsule is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies ( 14 )].",
    "dose": "2 DOSAGE AND ADMINISTRATION Initial, Target and Maximum Daily Dose ( 2.1 ) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Total Daily Dose Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment — Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.4 , 12.3 ) 2.1 Acute Treatment Dosing of children and adolescents up to 70 kg body weight - Atomoxetine capsules should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day [see Clinical Studies ( 14 )].",
    "renal": "8 USE IN SPECIFIC POPULATIONS • Hepatic Insufficiency - Increased exposure (AUC) to atomoxetine than with normal subjects in EM subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase). ( 8.6 ) • Renal Insufficiency - Higher systemic exposure to atomoxetine than healthy subjects for EM subjects with end stage renal disease - no difference when exposure corrected for mg/kg dose. ( 8.7 ) • Patients with Concomitant Illness - Does not worsen tics in patients with ADHD and comorbid Tourette’s Disorder. ( 8.10 ) • Patients with Concomitant Illness – Does not worsen anxiety in patients with ADHD and comorbid Anxiety Disorders. ( 8.10 ) 8.1 Pregnancy: Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including atomoxetine, during pregnancy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "General Information Physicians should instruct their patients to read the Medication Guide before starting therapy with atomoxetine and to reread it each time the prescription is renewed.",
      "Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with atomoxetine and should counsel them in its appropriate use."
    ],
    "tags": [
      "ADHD"
    ],
    "keywords": [
      "atomoxetine",
      "strattera",
      "adhd",
      "(nonscheduled)"
    ]
  },
  {
    "slug": "metformin-sitagliptin",
    "name": "Metformin + Sitagliptin (Janumet)",
    "class": "Antidiabetic combination",
    "summary": "1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ZITUVIMET is not recommended in patients with type 1 diabetes mellitus. ( 1 ) ZITUVIMET has not been studied in patients with a history of pancreatitis. ( 1 ) ZITUVIMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ZITUVIMET is not recommended in patients with type 1 diabetes mellitus.",
    "dose": "2 DOSAGE AND ADMINISTRATION Take ZITUVIMET orally twice daily with meals. ( 2.1 ) Individualize the dosage of ZITUVIMET on the basis of the patient's current regimen, effectiveness, and tolerability. ( 2.1 ) The maximum recommended daily dose is 100 mg of sitagliptin and 2,000 mg of metformin HCl. ( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of ZITUVIMET is 50 mg sitagliptin and 1,000 mg metformin HCl twice daily. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) ○ Do not use in patients with eGFR below 30 mL/min/1.73 m 2 ○ ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 .",
    "renal": "8 USE IN SPECIFIC POPULATIONS Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. ( 8.3 ) Geriatric Use: Assess renal function more frequently. ( 8.5 ) Hepatic Impairment: Avoid use in patients with hepatic impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Available data with ZITUVIMET and sitagliptin use in pregnant women are not sufficient to inform a ZITUVIMET-associated or sitagliptin-associated risk for major birth defects and miscarriage.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Lactic Acidosis Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development.",
      "Advise patients to discontinue ZITUVIMET immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur."
    ],
    "tags": [
      "Antidiabetic Combination"
    ],
    "keywords": [
      "metformin",
      "sitagliptin",
      "janumet",
      "antidiabetic",
      "combination"
    ]
  },
  {
    "slug": "empagliflozin",
    "name": "Empagliflozin (Jardiance)",
    "class": "Antidiabetic",
    "summary": "1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .",
    "dose": "2 DOSAGE AND ADMINISTRATION Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) Individualize the starting dosage based on the patient's current regimen and renal function. ( 2.2 , 2.3 , 2.4 ) The maximum recommended dosage is 25 mg/day of empagliflozin and 2,000 mg/day of metformin HCl. ( 2.2 , 2.3 ) Initiation of SYNJARDY or SYNJARDY XR is not recommended in patients with an eGFR less than 45 mL/min/1.73 m 2 , due to the metformin HCl component. ( 2.4 ) SYNJARDY: take orally twice daily with meals, with gradual dosage escalation to reduce the gastrointestinal adverse reactions due to metformin HCl. ( 2.2 , 2.3 ) SYNJARDY XR: take orally once daily with a meal in the morning, with gradual dosage escalation to reduce the gastrointestinal adverse reactions due to metformin HCl.",
    "renal": "8 USE IN SPECIFIC POPULATIONS Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. ( 8.1 ) Lactation: Not recommended when breastfeeding. ( 8.2 ) Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. ( 8.3 ) Geriatric Patients: Higher incidence of adverse reactions related to volume depletion and reduced renal function. ( 8.5 ) Renal Impairment: Higher incidence of adverse reactions related to reduced renal function. ( 8.6 ) Hepatic Impairment: Avoid use in patients with hepatic impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Based on animal data showing adverse renal effects from empagliflozin, SYNJARDY and SYNJARDY XR are not recommended during the second and third trimesters of pregnancy.",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Lactic Acidosis Inform patients of the risks of lactic acidosis due to metformin, its symptoms, and conditions that predispose to its development.",
      "Advise patients to discontinue SYNJARDY or SYNJARDY XR immediately and to notify their healthcare provider promptly if unexplained hyperventilation, malaise, myalgia, unusual somnolence, or other nonspecific symptoms occur."
    ],
    "tags": [
      "Antidiabetic"
    ],
    "keywords": [
      "empagliflozin",
      "jardiance",
      "antidiabetic"
    ]
  },
  {
    "slug": "ticagrelor",
    "name": "Ticagrelor (Brilinta)",
    "class": "Blood thinner / anticoagulant",
    "summary": "1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel.",
    "dose": "2 DOSAGE AND ADMINISTRATION ACS or History of MI Initiate treatment with 180 mg oral loading dose of ticagrelor tablets. Then administer 90 mg twice daily during the first year.",
    "renal": "8.7 Renal Impairment No dosage adjustment is needed in patients with renal impairment [see Clinical Pharmacology ( 12.3 )].",
    "monitoring": "Monitor per standard of care when initiating or adjusting therapy.",
    "pearls": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide).",
      "Advise patients daily doses of aspirin should not exceed 100 mg and to avoid taking any other medications that contain aspirin.",
      "Advise patients that they: • Will bleed and bruise more easily • Will take longer than usual to stop bleeding • Should report any unanticipated, prolonged or excessive bleeding, or blood in their stool or urine."
    ],
    "tags": [
      "Blood Thinner",
      "Anticoagulant"
    ],
    "keywords": [
      "ticagrelor",
      "brilinta",
      "blood",
      "thinner",
      "anticoagulant"
    ]
  }
]